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Abstract
Prostate cancer is an heterogeneous disease that arises through the acquisition of key 
malignant hallmarks. At the molecular level, prostate tumours are dependent upon the 
androgen receptor pathway, which affects cell function, growth and behaviour through 
downstream androgen regulated genes. Prostate cancers require this activity and 
manipulate the AR pathway to maintain signalling. For example, mutation of the AR 
(to bind ligands other than androgens) or amplification/duplication of the AR allows 
signalling to continue in castration levels of testosterone. Around 50% of prostate 
cancers have a gene fusion between the androgen regulated TMPRSS2 gene and a 
transcription factor of the ETS family, in particular ERG. This results in aberrant androgen 
stimulated tumor growth and survival. Current research is using molecular knowledge 
to identify biomarkers and develop new therapies for castration resistant disease, such 
as enzalutamide and abiraterone acetate. Along with the advances in next generation 
sequencing technologies, the complex landscape of genomic abnormalities and novel 
genetic phenomena like chromothripsis and hypermutation in prostate cancer have 
been revealed.
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I. Molecular basis of cancer
The functional unit of life is the cell and the genetic information is transferred to daughter 
cells via its DNA. This is also true in tumours, which derive from an abnormal cell by 
accumulated DNA mutations, transferring these mutations to progeny cells. Cancer is 
a disease of DNA and RNA. Each human cell contains about two times 3.2 billion base 
pairs, divided over the 22 chromosome pairs and two X chromosomes in females or X, 
Y in males. About 30,000 known genes encoded by the human genome are responsible 
for the various cellular functions, mainly executed by the proteins encoded by the 
~21,000 protein coding genes (1). More than 40% of the genome consists of genes, but 
only ~1.8% of the genome (the exons) will be transcribed to mRNAs and subsequently 
translated to proteins. It is unlikely that a random single change in a base pair will have 
an effect on the properties of the host cell. The chance of effective mutations in the 
right combination of genes needed for tumour initiation is extremely small. However, 
with a life-long accumulation of DNA damage and 10-50 billion cells in our body, in the 
long term the development of a tumour seems inevitable.
There are various types of DNA changes (mutations) that affect the function or 
expression of genes:
-  Deletion. Loss of one copy of the DNA (in one copy of a chromosome pair) is referred 
to as loss of heterozygosity (heterozygosity is the presence of two different copies of 
a genomic region in the two chromosomes). Complete loss of two copies of a specific 
chromosomal region is called a homozygous deletion.
-  Amplifications. This can vary between short or long duplications of a chromosomal 
region to tens of additional copies (high level amplification).
-  Translocations refer to exchange of DNA fragments within or between chromosomes. 
-  Insertions. Additional base pairs can be inserted due to replication mistakes, but also 
viral DNA or genomic integration of amplified DNA are covered by this term.
-  Base pair changes are defined when one or more bases are different without loss 
or gain. If the same base pair change is observed in >1% among normal healthy 
individuals, it is called a common variant single nucleotide polymorphism (SNP). If it is 
less frequent it is named a rare variant. The change is called a mutation if it is unique 
for the genome of a tumour, and not present in the DNA from healthy cells of the same 
individual. 
The type of DNA change can have specific effects on the properties of the mutated 
genes. The genes that cause cancer are classically divided into two types:
-  Oncogenes are genes generally encoding tumour growth stimulating proteins. A single 
mutation in one gene copy is enough to activate its oncogenic function. Amplifications 
are typically associated with oncogenes, but also base pair changes and translocations 
can cause activated oncogenes or oncogenic fusion genes.
-  Tumour suppressor genes generally encode proteins that inhibit tumour growth. 
In order to stop full activity of inhibitory functions, it is almost always necessary to 
11
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inactivate both gene copies. The type of DNA change typical for tumour suppressor 
genes is DNA deletion. Often, one copy is lost by deletion while the second copy might 
be inactivated by base pair changes. Genetic alterations that predispose to tumour 
development are found in some hereditary cancer syndromes such as Li-Fraumeni 
syndrome (TP53 mutations), Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/2 
mutations), Cowden disease (PTEN mutations), and Von Hippel-Lindau disease (VHL 
mutations). In these syndromes, one copy of an inactivated tumour suppressor gene is 
present in the genome of all cells (germline) and therefore inherited, greatly increasing 
the chance of developing cancer.
The DNA changes described above are permanent alterations. However, also chemical 
base pair modification can occur and although reversible, can be quite stable and copied 
from parent to daughter cell (known as epigenetic alterations). An important epigenetic 
modification associated with cancer is DNA methylation. The frequent addition of a 
methyl group to cytosine in cytosine-guanine rich regions (referred to as CpG islands) 
located in promoter regions, will typically inhibit transcription of these genes (2, 3). 
DNA methylation is therefore an alternative mechanism to turn off tumour suppressor 
genes.
II. Hallmarks of cancer
Overcoming a series of cellular and bodily processes is thought to be necessary for 
the progression from a normal cell to a cancer cell. These may arise through genetic 
(mutation etc.) or epigenetic (e.g. DNA methylation, histone modification) means and 
include: (4)
- Self-sufficiency in growth signals
- Insensitivity to anti-growth signals
- Resistance to cell death
- Tissue invasion and metastases
- Limitless potential to replicate
- Inducing angiogenesis
- Evading the immune system
Late stage tumours have acquired all of these hallmarks. The methods used to acquire 
each hallmark will vary between cancers and in individuals, and reflects inherited or 
acquired pro-carcinogenic, events and individual features for each cancer. The pathway 
of acquiring these hallmarks is often called the Vogelstein model, after one of the first 
proponents (5) (Figure 1). 
Almost all cells in our body are fully differentiated, and specialised to perform a limited 
number of tasks. These terminally differentiated cells have usually lost their potential to 
grow and so are unlikely to be the cells from which tumours develop.  Tissue stem cells 
and precursor cells (to the differentiated mature cells) possess the capacity to divide 
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and may be the origin of cancer. Except for the sporadic stem cells, all other cell types 
can only divide about 10-30 times when activated. During each DNA replication cycle, 
the chromosome ends (telomeres) are shortened. Only stem cells and cancer cells can 
repair this by expressing the enzyme telomerase.
In the absence of support factors, normal cells will stop dividing and become dormant 
(often by a process referred to as senescence) before they eventually die, in response 
to shortening telomeres. Many processes in the cell including the cell cycle, DNA 
damage response, protein expression, and energy metabolism include checkpoints 
to monitor potential harmful changes. Upon a challenge (e.g. DNA damage, too many 
incorrectly folded proteins), normal cells halt ongoing processes (stop dividing, stop 
transcription and translation, etc.), start repair mechanisms, and if repair is impossible, 
initiate a programmed cell death programme (apoptosis). Through random mutation 
and selection, cancer cells have typically mutated genes involved in these checkpoints 
to circumvent senescence and avoid apoptosis. 
 
In prostate cancer (PCa), many common gene mutations are directly linked to adaptation 
of the hallmarks (Figure 1). The androgen receptor (AR) pathway becomes and remains 
the major growth stimulatory and anti-apoptotic cascade, partly by regulating the 
Figure 1: Evolution of prostate cancer. The development of high-grade prostatic intraepithelial neoplasia 
(HGPIN) and subsequent organ-confined prostate cancer is driven by genomic mutations. The presence 
of germline risk alleles such as BRCA1/2 and gene polymorphisms increase the chance of developing 
prostate cancer. One of the first genomic events observed in the cancer cells is the fusion between 
TMPRSS2 and ERG in about 50% of all tumours. Subsequent mutations include the loss of one PTEN 
allele and amplification of c-MYC on chromosome 8q24. In late stage tumours, the second PTEN allele 
is lost and TP53 mutations are observed. After hormone therapy, androgen receptor (AR) amplification 
and mutations are observed in castration-resistant prostate cancer (CRPC). Recently, sequencing efforts 
identified SPOP as a mutated gene in late stage cancers.
13
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TMPRSS2-ERG fusion gene (see below). Self-sufficient growth and resistance to cell 
death is further accomplished by loss of the tumour suppressor PTEN and amplification 
of the c-MYC oncogene. The tumour suppressor TP53 can be altered to eliminate cell 
cycle arrest and prevent apoptosis (6).
III. Clinical aspects of prostate cancer
In Europe, PCa is the most common solid cancer among men. So far, age, ethnicity and 
heredity are the well-established risk factors for developing PCa (7). From the clinical 
point of view, one could subdivide interventions in three phases: the prevention phase, 
the detection and curative phase and the hormone, chemo and immunotherapy phase. 
Regarding the prevention phase, several studies were perform to test whether nutritional 
supplementation as well as chemoprevention are valid prevention strategies for PCa 
(8). From the different trials performed so far, including the SELECT trial (selenium 
and vitamin E) and the PRP-1 trial (selenium, vitamin E and soy), the dietary intake 
of these supplements was either not recommendable or conferred no measurable 
improvement (9, 10). For chemoprevention, the most promising studies have tested the 
role of 5α-reductase inhibitors (finasteride and dutasteride) that block the conversion of 
testosterone (T) into 5α-dihydrotestosterone (DHT). Despite a reduction in the relative 
risk of PCa of about 25%, the occurrence of side-effects or even high-grade PCa in the 
group treated with these compounds revealed that population-based chemoprevention 
is not yet a feasible option (11, 12). 
Of all PCa cases, only a minority is linked to inherited mutations in BRCA2 (13) 
and although overall exogenous factors such as alcohol consumption and chronic 
inflammation might be involved in the development of PCa the evidence is not strong 
enough to recommend lifestyle changes (14). 
In the early detection and curative phase, the main tools to diagnose PCa include the 
measurement of PSA (prostate specific antigen; KLK3) levels and digital rectal examination 
(DRE) (15). Higher levels of serum PSA are associated with an increased likelihood of 
PCa (16). Trials to use PSA levels to detect PCa in population-based screening programs 
failed in showing a clear benefit of screening for reducing PCa-related mortality that 
would outweigh side-effects including unnecessary biopsies and overtreatment (17). 
In the current diagnostic practice the need for a transrectal ultrasound (TRUS)-guided 
biopsy should not only be determined on the basis of the PSA level (7). PSA and DRE are 
neither sensitive enough to detect all relevant PCa cases nor specific enough to prevent 
unnecessary biopsies in case of prostatitis and benign prostatic hyperplasia (BPH) (18). 
There is still an urgent clinical need for more and better diagnostic PCa markers before 
biopsies are taken.
The diagnosis of PCa is based on histologic examination (19). From this point on, 
a decision is made regarding the primary local treatment of PCa. Patients with low-
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risk and low-volume PCa can be advised for active surveillance. Patients with low- and 
intermediate- risk PCa and a life expectancy greater than 10 years have indication 
for radical prostatectomy (RP) or radiation therapy and low-dose-rate brachytherapy. 
Patients with the same risk but with a life expectancy less than 10 years can be advised 
towards watchful waiting.  With respect to patients with high-risk clinically localized 
PCa there is no consensus on the optimal treatment but RP is often the first step. 
Alternatives include adjuvant external-beam radiation therapy (EBRT) and radiation 
therapy together with androgen deprivation therapy (ADT) (7). 
In the hormone, chemo and immunotherapy phase, there is usually no curable endpoint. 
The objective is to slow any further progression of the disease or provide relief of 
disease symptoms through palliative care. The first-line treatment relies on androgen 
suppression by either bilateral orchiectomy or LHRH agonist/antagonist (20). When 
patients develop castration resistance, continuation of androgen suppression as well as 
further hormone and chemotherapies are the next step. In recent years, second- and 
third-line hormonal therapies have been successfully implemented including novel anti-
androgens (such as enzalutamide) and CYP17 inhibitors (such as abiraterone acetate).
PCa, as a clinical entity, encompasses major needs in terms of better diagnostic and 
prognostic tools as well as novel treatment options. An adequate risk stratification of 
patients with newly diagnosed PCa will certainly provide a better support for treatment 
decisions. Also, the discovery of new relevant molecular targets for novel therapies can 
provide alternative treatment options to the individual patient.
IV. Major signalling pathways affected in prostate cancer
Major pathways targeted by mutations in PCa
In recent years the knowledge of molecular mechanisms of PCa growth and the role 
of individual genes and signalling pathways in this process, has rapidly increased. This 
knowledge is crucial for improvement of diagnosis and prognosis, and to offer patients 
more specific therapies. Like other cancers, PCa development and progressive growth 
is driven by an accumulation of variable numbers of genetic alterations in the cancer 
cell genome (Figure 1) (21). Moreover, it is becoming increasingly clear that epigenetic 
events, including the microenvironment of tumours, contribute substantially to 
regulation of tumour growth. 
Approximately 5% of PCa cases have a familial history. Until recently, it was hardly 
possible to identify the hereditary alterations in the DNA, which are associated with 
tumour development. However, novel molecular technologies can now be instrumental 
to investigate this problem (see below). Genetically, sporadic PCa shows a characteristic 
pattern of chromosomal alterations. Most frequent changes are loss of the complete, or 
part of the short arm of chromosome 8 (8p), and losses of large regions of chromosome 
arms 6q, 13q and 16q. Additionally, in late stage PCa amplification of 8q is frequently 
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observed. In the affected chromosomal regions many candidate tumour suppressor 
genes and oncogenes are located. In most cases it is difficult to pinpoint exactly which 
of the genes or combination of genes are most important in tumour development, but 
it is well established that overexpression of c-MYC oncogene on 8q is involved in a large 
percentage of late stage prostate cancers. 
Additional to large chromosomal regions, three small genomic regions on 10q, 21q and 
Xq, respectively, are frequently altered in PCa. Here, the genes important in PCa can 
easily be identified. These are the tumour suppressor gene PTEN, the TMPRSS2-ERG 
fusion gene and the AR. 
In early stage PCa, one copy of PTEN is frequently lost; in late stage cancer both copies 
of the gene can be inactivated. PTEN is a phospholipid phosphatase that counteracts 
phosphoinositol-3-kinase (PI3K) (22). PI3K is activated by receptor tyrosine kinases, and 
following PI3K activation the phospholipid PIP2 can be modified to PIP3. PTEN catalyses 
the opposite conversion, PIP3 to PIP2. High concentrations of PIP3 in the cell lead to 
activation of the kinase AKT. Activation of this important PI3K/AKT signalling pathway 
affects many molecular and biological processes in the cell, including protein synthesis, 
cell proliferation, apoptosis, polarity and metabolism. The PI3K/AKT pathway can not only 
be activated by PTEN inactivation, but also by direct activation of PI3K or AKT. Remarkably, 
although occurring frequently in other tumour types, these alterations are rare in PCa 
(Figure 2).
The AR pathway in prostate cancer
DHT is essential for development, maintenance of the structure and function of the 
prostate. DHT is synthesized in the prostate by metabolism of testosterone by the 
enzyme 5-alpha-reductase. DHT mediates its function by activation of the AR, a member 
of the family of nuclear receptors, which are ligand-dependent transcription factors. 
Upon binding of DHT, the AR translocates from the cytoplasm to the nucleus. There it 
modulates gene expression by binding to specific DNA sequences, androgen response 
elements, in the promoter/enhancer regions of target genes (Figure 2).
In the normal prostate, AR expression is high in the luminal epithelial cells and absent 
in the basal epithelial cells. In stromal cells the level of AR expression is variable. It 
is generally accepted that AR in stromal cells is most important during prostate 
development, and AR in luminal cells for prostate function. Hundreds or even thousands 
of genes in the prostate are regulated by the activated AR. PSA, which is exclusively 
expressed in the luminal epithelial cells, is considered as the prototype of a tightly 
androgen-regulated gene. Castration has a dramatic effect on the normal prostate and 
results not only in modified gene expression, but also in enhanced apoptosis.
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The TMPRSS2-ERG gene fusions in prostate cancer
The AR is vital for the development and function of the normal prostate and for growth 
of PCa. For a long time it was unknown which AR regulated genes were involved in 
tumour growth. In 2005, Tomlins et al. showed the presence of unique recurrent gene 
fusions between the TMPRSS2 gene and ETS family members ERG and ETV1 in PCa. Due 
to the gene fusion, the androgen-regulated TMPRSS2 now controls the expression of 
the ERG or ETV1 oncogene, having a large impact on androgen-dependent growth and 
survival of PCa (23). 
TMPRSS2 and ERG are located on chromosome 21 approximately 3 Mb apart and have 
the same gene orientation. Mostly, TMPRSS2-ERG fusions are frequently accompanied 
by loss of the entire chromosome 21 sequence between TMPRSS2 and ERG genes 
(interstitial deletion) (24). TMPRSS2-ERG has been found as the most common type 
of ETS gene fusion in PCa, with a frequency of approximately 50% across more than 
1500 organ-confined PCa samples (25). In the PCa precursor lesion, high-grade prostatic 
intraepithelial neoplasia (HGPIN), the frequency was approx. 20% (26, 27). Additional 
Figure 2: The PTEN/PI3K/AKT and AR pathways. PCa development and progression is driven by many 
different pathways of which two play a dominant role. The AR is activated by the androgens testosterone 
and dihydrotestosterone (DHT) after which the AR binds as a dimer to promoter and enhancer regions 
of target genes. One of the target genes is TMPRSS2, which is frequently fused to ERG in PCa, thereby 
regulating the ERG oncogene in an androgen-dependent manner. The PTEN/PI3K/AKT pathway is 
activated by various growth factors. At the inner cell membrane, activated PI3K eventually results in 
phosphorylation and activation of AKT (p-AKT). Loss of PTEN results in an increased and persistent 
activation of AKT. Both cascades support cell survival and cell growth and mutations (frequent PTEN 
loss, rare PI3K and AKT mutations, AR amplification and mutations, TMPRSS2-ERG fusion) affect these 
pathways frequently.
17
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ETS gene fusions have subsequently been identified involving not only ERG and ETV1 
but also ETV4 (28), ETV5 (29), and FLI1 (30). The frequency of these variants is much 
lower compared to ERG rearrangements but still accounts for 2-5% of all ETS gene 
fusions found in PCa.
In the normal situation, members of the ETS transcription factor family bind specific 
DNA sequences regulating the expression of nearby genes. They are believed to play a 
role in self-renewal-associated proliferation and normal morphogenesis (31, 32). The 
presence of ETS gene rearrangements in precursor lesions such as HGPIN suggests that 
ETS gene fusions have a causal role in the initial steps of PCa development (33). Still, 
it is not yet understood how ETS gene rearrangements are indeed capable of initiating 
prostate tumorigenesis whereas its role in mediating progression towards more 
aggressive disease is well accepted (34, 35).
Mismatch repair in prostate cancer
The DNA mismatch repair (MMR) system is a conserved mechanism that assists in 
maintaining genomic stability by correcting DNA mismatched base-pairs during the 
replication process (36). Defects in this repair mechanism are associated with mutations 
in microsatellite repeat sequences, which consist of tandemly repeated motifs of one 
(mono) to six (hexa) nucleotides (37) (38). The repetitive nature of these sequences 
makes them highly prone to insertion/deletion mutations caused by DNA polymerase 
slippage thereby altering the length of the microsatellite (39). The mismatch repair 
heterodimers MSH2/MSH6 and MSH2/MSH3 detect replication errors and recruit the 
MLH1/PMS2 complex which in turn degrades and resynthesizes the mutated stretch 
(40). 
As a result, cells with a defective MMR system can have mutation rates 100-1000 fold 
higher than normal cells and frequently display microsatellite instability (MSI) (41). 
Several studies have shown that instability of microsatellites is present in PCa (42, 43). 
The frequency of microsatellite instability detected in PCa is variable between different 
studies and ranges from 8% to 35% (44, 45). Recently, an hypermutated phenotype 
has been observed in advanced prostate cancer patients which also displayed MSI and 
mutations in MMR genes (46).  The expression of PMS2 also seems to be elevated in 
PCa patients and correlated with recurrence (47). It remains to be determined how 
frequently do rearrangements of MMR occur in PCa and whether defects in this pathway 
facilitate the transition of tumors to castration resistant disease. 
Therapeutic targeting the AR pathway
More than 70 years ago, the beneficial effect of androgen ablation by castration on advanced 
PCa was described (48). Medical or surgical castration, aiming at inhibition of T and DHT 
production, has been the treatment of choice of metastatic PCa. Additional to castration, 
antiandrogens, e.g. flutamide and bicalutamide, which compete with DHT for AR binding, 
but do not activate AR, were added to the large panel of different endocrine treatments. 
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After a few years, essentially all tumours become refractory to endocrine therapy, and 
a resistant tumour emerges (castration-resistant prostate cancer (CRPC)). It turned out 
that CRPC still shows high expression of AR and AR target genes, including TMPSS2-ERG, 
indicating that AR is still important in this stage of the disease. However, the molecular 
mechanism of CRPC is complex, and might additionally to ERG, include a spectrum of 
many more genes for which the AR regulation has been altered (49).
During the last decades, a wide variety of mechanisms of escape from endocrine 
therapy have been described (50).  It is now well established that in a proportion of 
CRPC (estimated 30%) AR on Xq is amplified, resulting in overexpression of AR mRNA 
and protein. Overexpressed AR can still be activated by low concentrations of androgens, 
or by androgens with low affinity for AR produced by the adrenal gland.  In addition, 
there is evidence that overexpressed AR can function independent of an agonistic steroid 
ligand. Another way of AR activation in CRPC is by AR mutation. The best known mutation 
in AR is the threonine to alanine substitution in the AR ligand-binding domain, which 
allows the antagonist OH-Flutamide to display agonistic activity. More recently it was 
postulated that in CRPC constitutive active AR variants lacking the ligand-binding domain 
are present and can modify AR regulated gene expression. Moreover, evidence was 
provided that CRPC cells itself are able to synthesize T and DHT or are able to convert 
adrenal androgens to DHT.
During the last years, two novel endocrine therapies have been approved for CRPC 
treatment (51). One of the compounds recently marketed, enzalutamide or MDV3100, is 
related to more classical antiandrogens. Like other antiandrogens, it blocks AR function 
by competing with DHT for AR binding. However, enzalutamide also delays nuclear 
transport of AR. Although enzalutamide has been approved for treatment of CRPC 
patients following chemotherapy with docetaxel, at the moment there is no reason to 
believe that it is not effective in earlier stages of PCa. The second novel therapeutic 
compound is abiraterone acetate. This molecule inhibits the function of CYP17A1, a key 
enzyme of the DHT synthesis pathway.  Abiraterone acetate not only inhibits T synthesis 
in the testis but also the synthesis of adrenal androgens. Abiraterone acetate is beneficial 
in late stage PCa patients resistant to docetaxel therapy.  Abiraterone acetate is given in 
combination with prednisone to reduce its side effects, which seem more severe than 
for enzalutamide. 
V. Technology developments and emerging markers
Increasing knowledge of the molecular biology of PCa and breakthroughs in various 
technologies, form the basis of the discovery of novel markers and therapy targets. 
The technologies advanced tremendously in the ability to measure more of the 
DNA, RNA and protein content of each individual tumour (high-content) and allow 
analysis of more samples at the same time (high-throughput). These type of studies are 
referred to as ‘-omics’; for DNA, RNA and protein analyses, genomics, transcriptomics 
and proteomics, respectively.
19
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Genomics and Transcriptomics
Miniaturization of assays has been the main driving force for the high-content detection 
of RNA and DNA using array technologies and next generation sequencing (NGS). 
Microarrays can be used as a read-out system for gene expression by hybridizing 
processed RNAs or for changes in DNA copy number by hybridizing genomic DNA, 
referred to as array CGH (comparative genomic hybridization) (52). Only recently, massive 
parallel sequencing techniques have become affordable and a more comprehensive 
alternative to array-based analyses. Sequencing of RNA not only identifies changes in 
gene expression, but also mutations, alternative splicing and gene fusion events. At the 
DNA level, sequencing of all 3.2 billion base pairs in human samples at high coverage 
is still challenging with respect to costs, data handling and processing (53). However, 
since the sequencing technologies are progressing rapidly, it is expected that within 
the next decade, whole genome sequencing can be performed in a few days for a 
thousand pounds. If so, the implementation of NGS in the clinic for mutation analysis of 
PCa will likely become reality. Using NGS, individual prostate samples can be screened 
for diagnostic and prognostic markers and therapy targets to determine on a personal 
basis, the significance of the disease, the treatments to which the patient will respond 
and the optimal order of therapies (54, 55). 
Proteomics
Large scale research on proteins is much more complex than genomics and 
transcriptomics. Instead of the four bases, proteins are build-up by 20 different 
amino acids that can also be modified in many different ways (e.g. phosphorylation, 
glycosylation). Proteins cannot be amplified like RNA and DNA using the polymerase 
chain reaction (PCR) and protein detection technologies, mainly based on antibodies, 
often lack sensitivity and specificity. The breakthrough in protein detection came with 
the advancements of mass spectrometry (MS). This technology can accurately measure 
the mass of proteins and protein fragments and also allows for determining the amino 
acid sequence of a selected protein fragment (56). With some effort, hundreds to 
thousands of different proteins can be identified in tissue extracts or body fluids such 
as serum or urine. However, low abundant proteins in complex mixtures are typically 
difficult to detect using MS and in general, blood-based cancer markers such as PSA are 
present in low quantities. The implementation of MS technologies for marker research 
has not resulted in a wide range of novel clinically useful protein markers. Reasons are 
the limitations of MS to detect low abundant proteins and the huge variability in protein 
composition of body fluids between individuals. MS technology is nowadays slowly 
improving the detection of low abundant proteins and high-throughput measurements 
and eventually, MS is expected to become a technique operational in a clinical setting 
for the detection of protein biomarkers.  
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Current and new markers and targets based on our knowledge of 
prostate cancer biology
For the diagnosis of PCa, a limited number of markers are commonly in use. These 
include family history, serum PSA, DRE and imaging technologies (e.g. MRI) that 
provide an indication of prostate abnormalities including cancer. The final diagnosis is 
established by histopathological examination of prostate needle biopsies. The biopsies 
provide information for prognosis which includes an estimate of the extent of the 
cancer (number of positive cores and % cancer area in each core) and particularly the 
differentiation state of the cancer cells, which is graded using the Gleason score. Both 
the diagnosis and prognosis of PCa are far from perfect and there is a strong clinical 
need for additional markers.
Since ETS gene fusions are the most frequent genetic abnormalities found in PCa, there 
is considerable interest in using ETS fusion transcripts as diagnostic and prognostic 
markers [18]. ETS fusion events are unique to cancer and their detection has high 
diagnostic value. Molecular tests to measure TMPRSS2-ERG transcripts in urine after 
DRE have been developed and are in the final stages of clinical testing. With respect 
to their prognostic value, conflicting studies report that ERG fusions are associated 
with both favourable and unfavourable clinical outcomes [21]. It is unlikely that ERG 
overexpression by itself will be a useful prognostic marker.
Diagnostic RNA markers
Besides TMPRSS2-ERG, other transcript markers are making their way into the clinic. 
PCA3, a long noncoding RNA was discovered in 1999 as a prostate-specific molecule, 
upregulated in PCa (57).  A commercial test has been developed (Progensa) to measure 
PCA3 and PSA mRNA levels in whole urine after DRE. The PCA3 score is calculated as the 
ratio of PCA3/PSA mRNA x 1000. The diagnostic role of PCA3 has been studied in the 
setting of predicting biopsy outcome, mainly to prevent unnecessary repeat biopsies of 
men with previous negative biopsies but persisting elevated PSA levels. It was shown 
that PCA3 scored better than PSA alone and complements established PCa risk factors 
such as age, PSA, DRE and prostate volume, making PCA3 a strong candidate to add to 
existing risk calculators (58). 
As a prognostic marker, PCA3 has been limited in its ability to predict PCa stage and 
aggressiveness beyond established markers (58).  Since PCa is a very heterogeneous and 
often multifocal disease, combining different cancer markers, such as TMPRSS2-ERG 
and PCA3, is expected to improve diagnostic accuracy. Overall, combining new urine 
biomarkers that are in the pipeline with the PCA3 score might significantly improve 
predictability of biopsy outcome (58).
21
1
General Introduction and scope of the thesis
Predictive markers
In PCa, little progress has been made in developing predictive markers to aid in therapy 
decision. With the AR as the major target regarding PCa treatment, recent studies 
have shown promising results regarding the presence of AR variants and response to 
treatment (59). Resistance to abiraterone and enzalutamide has been associated with 
an increase in expression of certain AR variants that render the receptor constitutively 
active (60). With the development of compounds that target the N-terminal portion of 
the AR, such as EPI-001, detection of AR variants can be coupled with a change in the 
treatment regimen (59, 61). 
Targeting DNA repair mechanisms in cancer treatment has been widely used in the 
clinic for years as a way to circumvent acquired chemo- and radio-resistance (62). In 
PCa, PARP-1 inhibitors were shown to cooperate with castration therapy enhancing the 
therapeutic response (63). Also in vitro, the use of PARP-1 inhibitors was capable of 
suppressing CRPC cell growth. Further research is required to confirm the therapeutic 
improvement of using PARP-1 inhibitors in PCa patients with BRCA1/2 mutations.  
Prognostic RNA markers
Many initiatives are being undertaken to identify and validate prognostic RNA markers. 
Based on knowledge of changes in cell cycle genes in cancer, a cell cycle progression 
(CCP) score, created from expression levels of 31 transcripts was tested and validated 
(64). This profile requires RNA extracted from cancer tissue and should be performed on 
positive biopsies. Expression profiling of RNA isolated from whole blood has also been 
shown to separate men with CRPC in groups with long versus short median survival (65, 
66). These whole blood profiles most likely reflect changes in blood cells and not in the 
rare circulating tumour cells (CTCs) or tumour-derived RNAs. Whether the prognostic 
power of any of these mRNA profiles persist in large independent validation cohorts still 
needs to be determined.
Another type of RNA that received much attention for its regulatory role in cancer are 
short (~22 nt) RNAs referred to as microRNAs (miRNAs). These miRNAs are rather stable 
and resistant to sample treatments (e.g. fixation, long term storage) and therefore 
attractive candidate markers. Several recent studies have successfully indicated miRNAs 
as diagnostic and prognostic markers in tissue and blood (67, 68). Like for mRNAs 
mentioned above, a tissue profile of 4 miRNAs ((miR-96 x miR-183)/(miR-145 x miR-
221)) was shown to improve accuracy and outperform PSA-based diagnosis and predict 
PCa aggressiveness (69).
Emerging markers from –omics studies
Recent large scale NGS projects provided an overview of mutations in PCa (70-72). 
As expected, most frequently detected mutated genes were known as part of the 
AR pathway, PTEN/AKT axis or cell cycle regulatory genes. However, tens of novel 
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mutated genes were identified that have a very low occurrence rate (1-3%) in PCa and 
a few new mutated genes that are more commonly affected (4-15%). One previously 
unknown common mutated gene is SPOP, encoding a protein that is involved in protein 
degradation and may modulate transcriptional repression. For many of these newly 
discovered mutated genes, the research on their role as markers and therapy targets 
has now been initiated.
Gene fusions/mutations
The emerging number of next generation sequencing studies extended our knowledge 
of the genomic landscape in PCa. In 2011, the first whole genome sequencing report 
in PCa identified several rearrangements involving the PTEN gene and mutations 
in genes involved in chromatin modifications and heat shock protein pathways (73). 
Exome sequencing identified novel mutations associated with PCa, in particular, SPOP 
was found mutated in 6-15% of tumours that lacked ETS gene rearrangements (71). 
Additional exome sequencing studies focused in CRPC disease detected frequent copy 
number losses in CHD1 that defined a novel subtype of ETS negative PCa (72). Also 
mutations have been detected to a certain extend in FOXA1, a known AR co-regulator 
(71, 72). The nuclear receptor coactivator NCOA2 was found amplified in ~11% of 
tumors (74). Several novel gene fusions have been detected in PCa, but mostly these are 
individual to each patient. Gene rearrangements involving genes of the RAF pathway 
were detectable in 1–2% of prostate cancers (75).
Together, the recent next generation sequencing studies have highlighted heterogeneity 
as the most dominant feature in PCa. Common genetic abnormalities like ETS gene fusions 
and PTEN loss co-occur with many other alterations that appear to be patient specific. 
Exosomes
As described above, on protein level, candidate markers have been discovered in 
PCa tissue, urine and serum using mass spectrometry (76). Thorough independent 
validation of almost all of these candidate markers still needs to be performed. One of 
the interesting findings from MS experiments on proteins secreted by cancer cells, is 
the finding that many of these proteins are secreted via small vesicles, often referred to 
as exosomes (77, 78). This exosomal secretory pathway is completely different from the 
well-known endoplasmic reticulum-Golgi route that proteins such as PSA follow to be 
released from cells (Figure 3). 
Exosomes are small (50-100 nm) vesicles which are formed by inward budding 
of cytoplasmic endosomes (79). An endosome containing exosomes is called a 
multivesicular body (MVB) and when the MVB fuses with the cellular membrane the 
exosomes are secreted. Exosomes are secreted by most cell types and also the normal 
prostate produces large quantities of exosome-like vesicles called prostasomes (80). 
Exosomes contain the proteins and RNAs from the cytoplasm of the cell of origin 
(81, 82). This provides the unique opportunity to study the presence and molecular 
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properties of cancer cells by analyzing the protein and RNA content of cancer-derived 
exosomes. Like for PSA, the presence of prostasomes in blood is a marker for PCa (83). 
Also in urine, extracellular vesicles from the prostate can be measured and the signal 
of the exosomal markers CD9 and CD63 are significantly higher in men with PCa (84).
Genome-wide association studies and genetic variation
 
It is known for a long time that approx. 5% of prostate cancers are clearly linked to 
a family history. Typically, genome-wide association studies (GWAS) are used to 
identify the presence of common variants (single nucleotide polymorphisms - SNPs) in 
chromosomal regions and genes that influence complex diseases. In PCa, 78 published 
loci (Table 1) have been associated with prostate cancer (P < 5 × 10–8) but this only 
explains 31% of the PCa heritability (85-86). The number of genes identified by GWAS 
that are likely causally linked to hereditary PCa is limited. Besides these common variants, 
rare germline variants have been identified within families, explaining another part of 
hereditary PCa. Mutations in the BRCA2 gene that is very important in hereditary breast 
cancer, are associated with a very small percentage of hereditary PCa (87). Recently 
however, it has been discovered that a specific mutation in HOXB13 (HOXB13-G84E) 
is associated with approx. 5% of hereditary PCa (88).  The mutation is also present in 
less than 1% of PCa patients without a known family history. The mutation is approx. 
10-fold more common in PCa patients than in normal controls.  Importantly, now that 
rapid and affordable whole genome sequencing is possible, more common genomic 
polymorphisms such as SNPs, deletions and insertions will be identified and possibly 
Figure 3: Overview of different secretion mechanisms. Proteins with an N-terminal signal peptide are 
translated at the rough endoplasmic reticulum and transported via the Golgi apparatus to the cell 
membrane for secretion into the milieu.
24
linked to hereditary PCa. Hopefully, this will lead to the identification of novel genes 
that at low- or high-penetrance, predispose to the development of high risk PCa.
Table 1: List of the published loci associated with prostate cancer risk
SNP Locus Candidate gene Risk allele 
frequency
Odds ratio Reference
rs1218582 1q21 KCNN3 0.45 1.06 Eeles et al, 2013
rs4245739 1q32 MDM4–PIK3C2B 0.25 0.91 Eeles et al, 2013
rs10187424 2p11 GGCX—VAMP8 0.41 0.92 Kote-Jarai et al, 2011
rs721048 2p15 EHBP1 0.19 1.15 Gudmundsson et al, 2010
rs6545977 2p15 OTX1—RPL27P5 NR NR Eeles et al, 2013
rs1465618 2p21 THADA 0.23 1.08 Eeles et al, 2013
rs13385191 2p24 C2orf43 0.4 1.15 Takata et al, 2010
rs11902236 2p24 TAF1B:GRHL1 0.27 1.07 Eeles et al, 2013
rs12621278 2q31 ITGA6 0.06 0.75 Eeles et al, 2013
rs3771570 2q37 FARP2 0.15 1.12 Eeles et al, 2013
rs7584330 2q37 COL6A3 - MLPH 0.22 1.06 Kote-Jarai et al, 2011
rs7629490 3p11 VGLL3 - 
CHMP2B
NR 1.06 Schumacher et al, 2011
rs9284813 3p12 VGLL3 - 
CHMP2B
NR NR Takata et al, 2010
rs2660753 3p12 0.11 1.18 Kote-Jarai et al, 2011
rs7611694 3q13 SIDT1 0.41 0.91 Eeles et al, 2013
rs10934853 3q21 GATA2 0.4513 1.12 Gudmundsson et al, 2010
rs4857841 3q21 EEFSEC 0.3 1.13 Lindstrom et al, 2012
rs9311171 3p22 CTDSPL 0.1997 NR Murabito et al, 2007
rs6763931 3q23 ZBTB38 0.45 1.04 Kote-Jarai et al, 2011
rs345013 3q24 PLOD2 0.1102 NR Murabito et al, 2007
rs1894292 4q13 AFM,RASSF6 0.48 0.91 Eeles et al, 2013
rs17021918 4q22 PDLIM5 0.34 0.9 Eeles et al, 2013
rs12500426 4q22 PDLIM5 0.46 1.08 Eeles et al, 2013
rs7679673 4q24 RPL6P14–TET2 0.45 0.91 Eeles et al, 2013
rs2121875 5p12 FGF10 0.34 1.05 Kote-Jarai et al, 2011
rs2242652 5p15 TERT 0.19 0.87 Kote-Jarai et al, 2011
rs12653946 5p15 IRX4 - IRX2 0.5 1.31 Takata et al, 2010
rs4466137 5q14 HAPLN1 NR NR Murabito et al, 2007
rs2242652 5q15 LPCAT1 0.1768 1.15 Kote-Jarai et al, 2011
rs6869841 5q35 FAM44B (BOD1) 0.21 1.07 Eeles et al, 2013
rs2273669 6p21 ARMC2,SESN1 0.15 1.07 Eeles et al, 2013
rs1983891 6p21 FOXP4 0.41 1.15 Takata et al, 2010
rs130067 6p21 CCHCR1 0.21 1.05 Kote-Jarai et al, 2011
rs339331 6q22 GPRC6A;RFX6 0.31 1.28 Takata et al, 2010
rs1933488 6q25 RSG17 0.41 0.89 Eeles et al, 2013
rs651164 6q25 LOC100289162 NR 0.87 Schumacher et al, 2011
rs9364554 6q25 SLC22A3 0.29 1.17 Eeles et al, 2013
rs12155172 7p15 RPS26P30–
ASS1P11-SP8
0.2 1.05 Eeles et al, 2013
rs10486567 7p15 JAZF1 0.77 0.74 Thomas et al, 2008
rs6465657 7q21 LMTK2 0.46 1.12 Eeles et al, 2013
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rs2928679 8p21 SLC25A37 
NKX3-1
0.42 1.05 Eeles et al, 2013
rs1512268 8p21 SLC25A37 - 
NKX3-1
0.45 1.18 Eeles et al, 2013
rs11135910 8p21 EBF2 0.16 1.11 Eeles et al, 2013
rs10086908 8q24 POU5F1B, MYC 0.3 0.87 Eeles et al, 2013
rs12543663 8q24 LOC727677, 
MYC
0.33 1.08 Al Olama AA et al, 2009
rs13252298 8q24 FAM84B - 
SRRM1P1
NR 0.89 Schumacher et al, 2011
rs445114 8q24 SRRM1P1 - 
POU5F1B
0.36 1.14 Gudmundsson et al, 2010
rs16902094 8q24 SRRM1P1 - 
POU5F1B
0.15 1.21 Gudmundsson et al, 2010
rs817826 9q31 RAD23B-KLF4 0.1 1.43 Xu et al, 2010
rs1571801 9q33 DAB2IP 0.25 1.27 Duggan et al, 2007
rs10933994 10q11 MSMB - NCOA4 0.4 1.25 19 or 30
rs2252004 10q26 NR 0.23 1.16 Akamatsu et al, 2012
rs11199874 10q26 RPL19P16-
FGFR2
0.29 2.9 Nam et al, 2006
rs4962416 10q26 CTBP2 0.27 1.2 Thomas et al, 2008
rs7127900 11p15 IGF2-INS 0.2 1.22 Eeles et al, 2013
rs1938781 11q12 FAM111A 0.3 1.16 Akamatsu et al, 2012
rs11228565 11q13 TPCN2 - MYEOV 0.2 1.23 Gudmundsson et al, 2010
rs11568818 11q22 MMP7 0.44 0.91 Eeles et al, 2013
rs731236 12q13 VDR 0.264 NR Bonilla et al,2011
rs10875943 12q13 TUBA1C-PRPH 0.31 1.07 Kote-Jarai et al, 2011
rs12827748 12q21 PAWR 0.312 NR Bonilla et al, 2011
rs1270884 12q24 TBX5 0.49 1.07 Eeles et al, 2013
rs1529276 13q33 SLC10A2-
RPL7P45
NR NR Murabito et al, 2007
rs8008270 14q22 FERMT2 0.18 0.89 Eeles et al, 2013
rs7141529 14q24 RAD51B 0.5 1.09 Eeles et al, 2013
rs4775302 15q21 SQRDL 0.4293 1.41 Nam et al, 2011
rs684232 17q13 VPS53 0.4881 1.1 Eeles et al, 2013
rs11650494 17q21 GNGT2, ABI3, 
PHB, SPOP, 
HOXB13
0.08 1.15 Eeles et al, 2013
rs7241993 18q23 SALL3 0.3 0.92 Eeles et al, 2013
rs8102476 19q13 DPF1 - 
PPP1R14A
0.46 1.12 Gudmundsson et al, 2010
rs103294 19q13 LILRA3 0.3 1.28 Xu et al, 2010
rs2427345 20q13 GATAS, 
CABLES2
0.37 0.94 Eeles et al, 2013
rs6062509 20q13 ZGPAT 0.3 0.89 Eeles et al, 2013
rs9623117 22q13 TNRC6B 0.3058 1.18 Sun et al, 2009
rs742134 22q13 BIK NR 1.16 Schumacher et al, 2011
rs5759167 22q13 RPS25P10-BIK 0.47 0.86 Eeles et al, 2013
rs5945619 Xp11 NUDT11 0.36 1.19 Eeles et al, 2013
rs5919432 Xq12 AR 0.19 0.94 Eeles et al, 2013
Table 1: Continued
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VI. Scope of the thesis
Prostate cancer is one of the most common cancers among men. Despite relatively low 
morbidity, this disease represents a major burden in the current western society. In PCa, 
gene fusions are among the most frequently observed genetic alterations. Therefore, 
the aim of this thesis was to identify novel DNA and RNA gene fusions in PCa that, 
just as TMPRSS2-ERG could provide novel insight into the initiation and/or progression 
pathways of PCa.
 
In chapter 2 we combined DNA and RNA array data of several PCa samples as a first 
attempt to detect frequent unique gene fusions in PCa. The rationale was to select the 
intragenic deletions and amplifications that coincided with altered expression patterns. 
We were able to identify a novel gene fusion between the genes GPS2 and MPP2 
that resulted in an in-frame chimeric protein. If this gene fusion conferred a selective 
advantage regarding PCa progression, we expected GPS2-MPP2 to contribute to the 
proliferation or apoptosis of the cancer cells, which we later confirmed. Since we were 
not able to detect this particular gene fusion in any of the other PCa samples and the 
validation process of gene fusions using the DNA and RNA arrays was complex, we next 
utilized DNA and RNA sequencing data for fusion detection. In chapter 3, a catalogue 
all the gene fusions present in the PCa cell line PC346C and the PCa patient sample 
G089 was generated using whole genome sequencing data. We detected another gene 
fusion involving a membrane palmitoylated protein, in this case, MPP5. MPP5 was fused 
to FAM71D, which was overexpressed in the cancer cells harbouring the gene fusion. 
Also MPP5-FAM71D showed to be relevant for the proliferation capacity of the cells and 
despite the uniqueness of this gene fusion we did find overexpression of FAM71D in a 
subset of PCa samples. 
Mismatch repair (MMR) deficiency has been described in PCa but the exact role the 
MMR system plays in PCa, is not well established. In order to determine whether 
the deficiency in the MMR system might cause advantageous gene mutations in the 
context of PCa we analysed, in chapter 4, the genome of the PCa MMR-deficient cell 
line PC346C. Although mutations in the MMR system are so far relatively rare in PCa, 
they might represent a different subgroup of cancers and therefore be of relevance in 
patient stratification. We predicted that nucleotide repeat sequences would be more 
frequently hit by mutations in a MMR-deficient background. With this approach we 
found 14 candidate genes, of which PRRT2 was frequently mutated in microsatellite 
unstable colorectal and endometrial cancer patients, but not in PCa. Although the PRRT2 
mutation in the context of PCa has so far only been observed in the PC346C cell line, 
knock-down of the truncated PRRT2 protein did decrease proliferation of these cells. 
In light of the new discoveries regarding the mechanisms that generate genetic diversity, 
in particular chromothripsis, we hypothesized in chapter 5 that such a mechanism could 
also play a role in PCa. After analysis of all the structural rearrangements present in the 
sequenced PCa samples, we found VCaP to have chromothripsis in the chromosome 5q 
arm. Focusing once again on gene fusions we questioned whether the occurrence of 
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chromothripsis would originate in a high number of functional gene fusion events and 
therefore be a selective advantage to the cancer cell. Compared to the total number 
of rearrangements present in the chromotripic arm, only a minor fraction resulted in 
in-frame gene fusions. We concluded that chromothripsis is unlikely responsible for the 
generation of relevant gene fusions in PCa. 
In an attempt to broaden our knowledge of PCa biology we have discovered novel 
genetic alterations in genes and pathways not previously linked to PCa. We have 
also shown that chromothripsis occurs in PCa. In chapter 6 we discuss the relevance 
of the new findings in the context of our basic understanding and clinical aspect of 
this disease.
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Abstract
Prostate cancer is a frequently diagnosed disease and the sixth leading cause of 
cancer-related death in men worldwide. It is a heterogeneous disease, both at the 
morphological and molecular level. Gene fusions are a frequent class of somatic 
alterations observed in these solid tumours with the TMPRSS2-ERG gene fusion being 
present in approximately 50% of all prostate cancer cases. In this study we have used 
SNP (single nucleotide polymorphism) and exon array data as well as RNA sequencing 
to identify novel gene fusions in prostate cancer. By combining these methods, the gene 
fusion GPS2-MPP2 was detected in the LNCaP cell line. The GPS2-MPP2 gene fusion 
causes the expression of a chimeric protein containing part of the coiled-coil domain 
of GPS2 encoded by the first exon of the gene, that is fused to the complete MPP2 
protein coding sequence except for the 1st L27 domain which is only partially encoded 
by the fusion gene (exon 2 and onwards). The specific knockdown of this chimeric 
protein resulted in a clear decrease of proliferation rate in LNCaP cells. Furthermore, 
knockdown also induced apoptosis with higher caspase 3/7 activation levels in LNCaP 
cells as compared to control cells. Live-cell imaging of LNCaP cells showed that the 
cellular localization of the GPS2-MPP2 fusion encompasses both the speckle-like and 
membrane-patch distribution of GPS2 and MPP2, respectively. 
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Introduction
Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide 
(1). While many of these men will have an indolent form of the disease, others will 
develop an aggressive, life threatening condition (2). To date, PCa remains the sixth 
leading cause of cancer-related death among men. The spectrum of genetic alterations 
in PCa is wide and although a few genes are known to be frequently mutated in this 
disease, many have now been identified with low recurrence rate (3). 
Gene fusions are a frequent class of somatic alterations in PCa (4). The overexpression 
of the ERG oncogene due to the TMPRSS2-ERG gene fusion is one of the earliest genetic 
alterations and occurs in approximately 50% of PCa cases (5). ERG is a member of the 
ETS family of transcription factors of which other members are also found to be fused 
in PCa, typically with prostate-specific and androgen-regulated fusion partners (6). 
Advances in high-throughput technologies have extended the number of gene fusions 
detected in prostate cancer (4, 7). 
Novel rare gene fusions have been identified in PCa involving genes encoding members 
of the MAPK pathway KRAS, RAF1 and BRAF (8-10). In addition to being frequently 
overexpressed in PCa, cMYC is reported to be fused in frame with the gene partner 
C15orf21 (11). Also the tumour suppressor gene FH and members of the Rho guanine 
nucleotide exchange factor (GEF) family have been detected in gene fusions present in 
primary PCa as well as in lymph node metastases (11, 12). 
The identification of novel gene fusions in PCa, generated limited insight into novel 
high frequency events, but it provided valuable information regarding individual 
tumour genomes (13). This is particularly important in the case of PCa due to its clinical 
and biological heterogeneity (4). In the end, these private gene fusions might aid in 
providing a distinct line of treatment for the patient such as the rearrangements in the 
RAF pathway or pinpoint to common molecular pathways to different rearrangements 
(14). 
In this study we have used SNP and exon array data of a wide set of prostate cancer cell 
lines, xenografts and clinical PCa samples to detect novel gene fusions. We identified the 
in-frame gene fusion GPS2-MPP2 in the LNCaP cell line. The LNCaP PCa cell line is one of 
the most studied cell lines. It is derived from a biopsy of a supraclavicular lymph node of 
a patient with rapidly progressing PCa (15, 16). GPS2-MPP2 increases the proliferation 
capacity of LNCaP cells and protects against apoptosis. The cellular localization of GPS2-
MPP2 mimicked both the cellular localization of GPS2 and MPP2 alone.  
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Table 1: List of the top 3 candidate genes from the combined analysis of DNA and RNA data for detection 
of novel gene fusions. The event sample represents the sample in which the DNA break location 
corresponds to a shift in expression pattern. MPP2 and NRXN3 were successfully validated by 5´ race 
PCR. Chr, chromosome; ex, exon.
Gene Chr Break 
location 
(DNA)
Break 
location 
(RNA)
Event 
sample
Validated Fusion 
partner
In frame
MPP2 17 39,334,282 ex 2-3 LNCaP yes GPS2 yes
NRXN3 14 78,246,877 ex 5-6 G295 yes TSHR no
YES1 18 779,852 ex 1-2 LAPC4 no - -
Results
Identification of novel gene fusions in prostate cancer
To identify novel DNA and RNA fusions in PCa, we used Illumina 1M SNP microarray 
data of 66 PCa samples and 131 normal control samples together with Affymetrix exon 
array data of 203 clinical PCa samples, 11 xenografts and 6 cell lines (see materials & 
methods). The SNP array data was processed with the Nexus software to list all the 
detectable DNA breaks. A total of 13,150 DNA breaks were identified in all the 66 PCa 
samples (Supplementary Table 1, see supplementary data. From all the breaks identified, 
4589 overlapped with genes. Using the exon array data we were able to select which of 
the 4589 genes with breaks also showed abnormal expression. 
To determine irregular expression patterns the transcript cluster probesets located 
on the left and right side of the DNA breakpoint were selected. For each sample, the 
FIRMA scores of these probesets were calculated and compared using Wilcoxon-testing 
to determine the significance of the differential expression of these genes. With the 
algorithm AltSplice Mapper we were able to visualize the probeset distribution of each 
abnormally expressed gene. For each sample, individual probesets were normalized to 
the expression of the whole transcript and to the corresponding probeset in all PCa 
samples. 
A list with all the genes with DNA breaks and abnormal gene expression was generated 
(Supplementary Table 2, see supplementary data. We selected 3 candidates with the 
most prominent indication for abnormalities both at the DNA and RNA level. These 
3 genes showed lower expression and a break in the beginning of the gene and were 
checked for possible gene partners by 5’ gene RACE PCR (Rapid Amplification of cDNA 
Ends PCR) (Table 1). 
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Validation of novel gene fusions in prostate cancer
We were able to identify and validate a fusion partner for 2 out of the 3 genes. First, we 
identified TSHR (thyroid stimulating hormone receptor) by 5’ RACE as a fusion partner 
of NRXN3 (neurexin 3) in the G295 patient sample (Figure 1A and 1B). We validated the 
TSHR-NRXN3 gene fusion by cDNA Sanger sequencing of RNA extracted from the G295 
patient sample. This gene fusion was not in-frame and since it would not result in a 
chimeric protein, it was excluded from further analysis. We identified GPS2 (G protein 
pathway suppressor 2) as a fusion partner of MPP2 (membrane protein, palmitoylated 2 
(MAGUK p55 subfamily member 2) in the LNCaP cell line (Figure 1C and 1D). By Sanger 
sequencing we validated the GPS2-MPP2 fusion in LNCaP. This fusion was predicted to 
Figure 1: DNA and RNA breaks in the NRXN3 and MPP2 genes. The distribution of SNP probeset intensity 
values in the NRXN3 (+ orientation) and MPP2 (- orientation) gene are shown in (A) and (C), respectively. 
The shift between a positive and negative cluster of probeset values represents the breakpoint location 
at the genomic levels. The red arrow depicts the location of the break. The genomic region shown, 
contains all the probesets within the gene together with five extra probe locations upstream and 
downstream of the gene. The distribution of exon expression values for the NRXN3 and MPP2 transcripts 
(left is 5’; right is 3’) are shown in (B) and (D), respectively. Only core exon probeset values are displayed. 
The red arrow shows where the DNA break is in the exon array plots. In (B), the G295 sample shows a 
relative lower expression of the first as compared to the last exon probesets. The expression of the first 
exon probesets is also significantly lower compared to the average expression of the same probesets 
in the other PCa samples. In (D), the distribution of the MPP2 exon probeset values is displayed. The 
expression values of the first exon probesets are lower compared to the expression values of the last 
exon probesets.
A)
C)
B)
D)
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be in-frame resulting in the expression a chimeric protein. Both GPS2 and MPP2 are 
located in chromosome 17. GPS2 is located in 17p whereas MPP2 is located in 17q. 
GPS2 encodes a protein involved in MAPK signalling cascades and MPP2 is a member 
of the membrane palmitoylated subfamily of proteins with important roles in cellular 
signal transduction. The GPS2-MPP2 fusion gene was selected to further investigate the 
potential consequences of the gene fusion.
GPS2-MPP2 gene fusion in the LNCaP cell line
The GPS2-MPP2 fusion encompasses, at the transcript level, exons 1 and 2 of GPS2 
spliced to exon 2 of MPP2 (canonical isoform) (Figure 2A). This resulted in the expression 
of a chimeric protein with part of the coil-coiled domain of GPS2 and a large part of 
MPP2, with exception of the 1st L27 domain, which is only partially present (Figure 
2B). The fusion was also observed in RNAseq data of the LNCaP cell line (data not 
shown) (17). We performed Fluorescence in situ hybridization (FISH) assays of GPS2 
and MPP2 in LNCaP, PNT2C2 and normal control metaphase spreads and confirmed the 
colocalization of GPS2 and MPP2 in LNCaP nuclei. On average, there were 4 copies of 
both GPS2 and chromosome 17 and between 5 and 10 copies of MPP2 present in LNCaP 
cells (Figure 2C). Regarding GPS2 and chromosome 17 this was expected given the ~4N 
ploidy of this cell line determined previously by spectral karyotyping (18). Typically, only 
one of the 4 copies co-localized, which was observed in 85% of LNCaP cells counted. In 
the immortalized normal prostate epithelial PNT2C2 cells there were between 2 and 5 
chromosome 17 centromere probe signals, 3 and 6 GPS2 probe signals and 4 and 10 
MPP2 probe signals. Approximately 10% of the nuclei showed colocalization of GPS2 
and MPP2 signals. In the control sample (normal blood cell nuclei) the majority of nuclei 
displayed only two FISH signals for GPS2, MPP2 and the centromeric probe 17. The 
percentage of co-localization of GPS2 and MPP2 signals was 2%.
RT-PCR of RNA from 201 PCa patient samples did not reveal the presence of the fusion 
transcript in any sample. Although the expression pattern of MPP2 in the PC133 and 
PC374 PCa xenografts followed the same trend as that observed in the LNCaP sample 
(Figure 1D), the presence of the GPS2-MPP2 fusion could not be confirmed at the 
RNA level. Overall expression levels of MPP2 did not show an outlier expression for 
LNCaP harbouring the GPS2-MPP2 gene fusion (Supplementary Figure 2). Therefore, 
upregulation of MPP2 expression levels does not explain the positive selection for this 
fusion in LNCaP cells as the explanation is in case of gene fusions involving ETS genes. 
Additionally, average MPP2 and GPS2 levels were significantly higher in normal samples 
as compared to PCa samples (Supplementary Figure 1 and 2). Also MPP2 levels were 
significantly lower in lymph node metastases and transurethral resections of the 
prostate (TURP) as compared to the primary tumor. So far, there is limited knowledge 
regarding the regulation of GPS2 and MPP2 expression and no reliable antibodies are 
available to study the GPS2 and MPP2 proteins. 
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Cellular localization of the GPS2-MPP2 protein differs from GPS2 
and MPP2
We investigated the cellular localization of GPS2, MPP2 and the GPS2-MPP2 chimeric 
protein, LNCaP cells were transiently transfected with a vector expressing GPS2, MPP2 
or GPS2-MPP2 fused in-frame to TurboGFP. Live cell imaging was performed for all the 
different tagged proteins (Supplementary Movie 1-4, see supplementary data . GPS2 
showed a speckle-like distribution mainly in the cytoplasm and to a lesser extend in 
the nucleus (Figure 3A). These speckles overlapped with PKH26 red labelled vesicles 
although colocalization could not be observed for all speckles in a given cell (Figure 3B). 
MPP2 displayed a faint overall cytoplasmic distribution with brighter green membrane 
patches (Figure 3C). These patches were not present in all cells. Regarding the GPS2-
MPP2 chimeric protein, we often observed a mixed distribution with cells showing a 
more speckle-like pattern or cells with membrane patches and with cells with both 
speckles and membrane patches (Figure 3D). 
Figure 2: Validation of the GPS2-MPP2 gene fusion. The GPS2-MPP2 gene fusion was sequenced in the 
LNCaP cell line (A). We confirmed the fusion of exon 2 of GPS2 to exon 2 of MPP2. The scheme of the 
GPS2-MPP2 fusion transcript and chimeric protein is depicted in (B). In (C), the distribution of FISH 
probe signals is displayed, with MPP2 and GPS2 corresponding to the red and green signal, respectively. 
The number of signals and signal colocalization was scored per nuclei. For each sample a total of 45 
nuclei were assessed. 85% of the LNCaP nuclei showed colocalization of GPS2 and MPP2 probe signals as 
opposed to 10% and 2% in PNT2C2 nuclei and normal control metaphase spreads, respectively.
A)
C)
B)
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The GPS2-MPP2 chimeric protein promotes proliferation and 
protects against apoptosis
To determine the functional consequences of the GPS2-MPP2 gene fusion, we designed 
siRNA oligonucleotides specifically targeting the MPP2 transcript and the GPS2-MPP2 
transcript. The knockdown using siRNA against MPP2 strongly affected MPP2 expression 
in all cell lines tested (Supplementary Figure 3). The siRNA directed against the GPS2-
MPP2 fusion transcript was only effective in downregulating GPS2-MPP2 expression 
without affecting the MPP2 transcript levels (Supplementary Figure 3). 
We performed a proliferation assay of LNCaP cells transfected with the siRNA 
against MPP2 alone and a scrambled control siRNA. A significant decrease in 
proliferation capacity in MPP2 knockdown cells as compared to control cells was 
observed (Figure 4A). To investigate whether this phenotype was a result of the 
downregulation of the GPS2-MPP2 gene fusion, we tested a siRNA solely targeting 
the GPS2-MPP2 fusion transcript. Again, we observed a significant decrease in 
proliferation rate of LNCaP cells, in this case due to GPS2-MPP2 knockdown, as 
compared to control cells (Figure 4B).
Figure 3: Cellular localization of GPS2, MPP2 and the GPS2-MPP2 proteins. In (A), GPS2-tGFP shows a 
speckle-like distribution across the cytoplasm with some nuclear staining. In (B), live cell imaging of 
GPS2-tGFP is combined with the red cellular membrane staining PKH26 to examine colocalization of 
the GPS2-tGFP speckles with membrane-derived vesicles. The white arrows point to colocalization. In 
(C), MPP2-tGFP shows overall cytoplasmic staining with specific locations where membrane patches 
are strongly positive. In (D), the GPS2-MPP2-tGFP protein displays a mixed cellular localization pattern 
with both speckles that coincide with membrane-derived vesicles and membrane patches (indicated by 
white arrows). 
A)
C)
B)
D)
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The same knockdown experiment was performed using the RWPE-1 immortalized 
normal prostate epithelial cell line with no effect on the proliferation capacity of these 
cells (Figure 4C). 
In addition to the effect of GPS2-MPP2 on cellular proliferation, we addressed the 
influence of this fusion on cellular apoptosis. The PNT2C2 normal prostate epithelial 
cell line was used as a control cell line instead of RWPE-1 due to the poor performance 
of this cell line in the measurement of Caspase 3/7 levels. Both PNT2C2 and LNCaP 
cells were transfected with control and GPS2-MPP2 targeting siRNAs. Caspase 
3/7 activity levels were elevated in LNCaP cells with GPS2-MPP2 knockdown as 
compared to the control PNT2C2 cells (Figure 4D). We concluded that the presence 
of the GPS2-MPP2 gene fusion induces cellular proliferation as well as a protective 
effect against apoptosis. 
Figure 4: GPS2-MPP2 promotes cell proliferation and protects against apoptosis in LNCaP cells. In (A), 
the proliferation of LNCaP cells was measured after MPP2 knockdown. The ø represents LNCaP cells 
growing under normal conditions, H2O the addition of transfection reagent, scramble the addition of 
a non-targeting small interfering RNA and siMPP2 the knockdown of the MPP2 transcript. An asterisk 
* P ≤0.02 and **P ≤ 0.002 by a two-tailed Student’s t-test. In (B), the cell proliferation of LNCaP cells 
was measured after GPS2-MPP2 knockdown. In (C), the cell proliferation of RWPE1 cells was measured 
after MPP2 knockdown. In (D), apoptosis was measured through the detection of Caspase 3/7 activity 
corrected for cell viability. This assay was performed for both LNCaP and PNT2C2 cell lines. The same 
controls of the proliferation assays were used along with an apoptosis control (drug-treated cells for 4 h).
A)
C)
B)
D)
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Discussion
Gene fusions are common genetic abnormalities found in PCa (19). So far, several gene 
fusions involving members of the ETS family of transcription factors have been identified 
(20). TMPRSS2-ERG is present in approximately 50% of all prostate cancers whereas 
fusions with other members of the ETS family are less frequent (14). In our study we 
used SNP and exon array data to identify novel gene fusions in PCa. The combination of 
DNA and RNA information allows the exclusion of DNA abnormalities that do not alter 
expression patterns. In this way, we expect to find abnormalities that will most likely 
have functional implications to the cancer cells. 
One of the validated gene fusions involved the genes NRXN3 and TSHR. NRXN3 is one of 
the three neurexin (NRXN) genes known in humans (21). Despite the clear specificity of 
this gene to neuronal-related functions, other NRXN3 gene isoforms have been shown 
to play a role in cardiac intercellular connections and in pancreatic beta cells (22, 23). 
The fusion of NRXN3 to TSHR does not result in an in-frame chimearic protein but 
could produce a shorter NRXN3 protein due to the potential use of an alternative start 
codon in the NRXN3 transcript. TSHR encodes the thyroid stimulating hormone (TSH) 
receptor and mutations in this gene have been identified in tumours of the thyroid 
gland. Although the relevance of this NRXN3 isoform in PCa cannot be discarded, the 
low expression levels of TSHR in G295 will result in low abundance of this transcript. 
LNCaP is a cell line derived from a lymph node metastasis of a PCa patient (24). With the 
SNP array data we were able to detect a break at the DNA level in the gene MPP2. The 
expression pattern of MPP2 showed lower expression of the first exon of MPP2 and a 
relative overexpression of the remaining exons consistent with the break location at the 
genomic level. Using 5’ RACE PCR we determined MPP2 to be fused to GPS2. The GPS2-
MPP2 gene fusion results in a chimeric protein containing part of the coiled-coil domain 
of GPS2 fused to part of the 1st L27 domain and remaining domains of MPP2. 
GPS2 is a suppressor of G protein-activated MAPK signalling (25). This 37 kDa protein 
possesses an N-terminal coiled-coil domain and an α-helix motif in the N-terminus 
which is responsible for the interaction with Transducin (Beta)-Like 1 (TBL1), a protein 
involved in transcription regulation (26). This sequence motif is conserved in both SMRT 
and its homolog N-COR and in all orthologues of SMRT, N-COR and GPS2 (26). GPS2 
has been indicated by several studies to play a role in transcriptional regulation (27). 
In addition, GPS2 is also involved in DNA repair (28), metabolism (29), cytoskeleton 
architecture (30), inflammation (27) and cell cycle regulation (31). Although many of 
the functions known to GPS2 focus on its transcriptional repressor capacity, this protein 
has also been found to enhance transactivation of several transcription factor such 
as p53 (32, 33). In addition, GPS2 is also found to interact with TNFR1, revealing 
cytoplasmic functions of GPS2 in the regulation of both the JNK and the TNF-α 
proinflammatory pathways (27). 
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MPP2 is a member of the MPP subfamily of the Membrane-Associated Guanylate Kinase 
(MAGUK) family of proteins (34). This family consists of ten subfamilies and a total of 22 
members with variations in both size and domain organization (35). The conserved core 
structure of this family consists of one to multiple PDZ domains, a Src homology 3 (SH3) 
and a catalytically inactive guanylate kinase (GK) domain (36) (Supplementary figure 
4). The GK domain, although catalytically inactive, still functions as a specific phospho-
peptide binding module (37). Members of the ZO 2-3 subfamily have been shown to 
transiently locate to the nucleus and interact with a number of nuclear proteins (38). 
Members of the MAGUK family of proteins, involved in synaptic regulation, are already 
considered for pharmaceutical intervention in the case of neurological diseases (39). 
Although some MPP members have already been linked to cancer, namely MPP3 in 
hepatocellular carcinoma (40), a link between MPP2 and cancer was not yet established. 
MPP2 is the human homolog of the tumour suppressor protein DLG2 in Drosophila. 
Despite being a tumour suppressor this protein has also shown oncogenic functions 
dependent of the precise cellular context (41).
The identification of a novel gene fusion between GPS2 and MPP2 expands the currently 
knowledge regarding these two proteins. MPP2 is the second MPP family member to 
be rearranged in PCa. Previously, we independently identified the functional and in-
frame MPP5-FAM71D fusion in PC346C cells (12). Regarding GPS2, only one report so 
far has described mutations in this gene in medulloblastoma (42). In the GPS2-MPP2 
gene fusion we have a chimeric protein with the first 31 aa of GPS2 fused to aa 12 
to 552 of MPP2. The first 31 aa of GPS2 contain the N-terminal TBL1-binding 
α-helix motif and aa 12 to 552 of MPP2 lack 4 aa from the first L27 domain of MPP2 
(L27N). L27 domains are common to many scaffold proteins and are involved 
in the assembly of supramolecular complexes that participate in cell polarity (43). 
Despite the membrane localization, there is no signal peptide in the N-terminal 
region of MPP2. So far, studies suggest that MAGUK proteins containing tandem 
L27 domains such as the MPP2 protein require both domains for the formation of 
ternary complexes (44). Nevertheless, the 4 aa residues missing from the L27N 
domain do not seem to be essential for the molecular organization of the L27N domain 
itself (45). 
To address the properties of this novel chimeric protein, we determined the cellular 
localization of GPS2, MPP2 and the GPS2-MPP2 fusion. The latter showed a combined 
phenotypic distribution of both GPS2 and MPP2 alone. Although it is difficult to predict 
what the consequence of this distribution pattern might be on protein function, 
we can assume that it will likely have an effect on cellular pathways regulated by 
the fusion product. Due to the fusion, MPP2 is found in vesicle-like structures as 
well as in the membrane and part of GPS2 will consequently also localize now to the 
membrane.
 
The knockdown of the GPS2-MPP2 fusion in LNCaP cells affected both proliferation 
and apoptosis. LNCaP cells showed a decreased proliferation after the knockdown 
of the fusion as compared to control cells. The knockdown of MPP2 alone in RWPE1 
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normal epithelial prostate cells did not cause any detectable alteration in proliferation 
capacity. Caspase 3/7 activation was greatly increased in LNCaP cells following 
GPS2-MPP2 knockdown. This effect was not observed in PNT2C2 normal epithelial 
prostate cells, suggesting a role of the GPS2-MPP2 gene fusion in protecting 
against apoptosis. Although members of the MAGUK family of proteins have already 
been implicated in the regulation of cell proliferation and apoptosis (46-48), so far 
no report has shown this for the MPP subfamily.
Currently, most studies use next generation sequencing (NGS) technologies to identify 
novel gene fusions. The major advantage of these technologies is the unbiased 
approach, high resolution and ability to detect more than the known spectrum 
of genes. Nevertheless, microarray technology has been widely used for the past 
20 years with the benefits that sample preparation is easier and data analysis 
tools are well established. Also, the limitations and pitfalls of microarray technologies 
are quite well known, which is not yet fully the case for NGS. Whether microarrays 
or NGS technologies are the suitable option will depend on the aims of the study. 
The detection of novel gene fusions is better facilitated by the use of NGS but microarray 
technologies remain a feasible option for validation of known fusions, especially when 
there is a considerable number of samples to be analyzed. 
In conclusion, we show in this study the presence of a novel gene fusion GPS2-MPP2 
in PCa. Although this fusion seems to be specific for LNCaP, also MPP5 was found to 
be rearranged in PCa (12). This fact suggests that molecular pathways linked to 
both these genes most likely play a role in cancer. Whether MPP2 itself also displays 
this tumour suppressor/oncogene duality remains to be proven. Regarding GPS2, 
the multiplicity of pathways and functions targeted by this protein make it a desirable 
target for mutation in cancer. Nevertheless, only in melanoma this link has been 
shown. The GPS2-MPP2 gene fusion here identified showed oncogenic potential, 
by promoting growth and suppressing apoptosis at the same time. Additional studies 
will help determine the exact pathway and mechanism, which links these genes with 
cancer. 
Materials and Methods
SNP array data
Fresh-frozen clinical samples were obtained from the tissue bank of the Erasmus 
University Medical Center. Patient sample collection was performed according to 
national legislation concerning ethical requirements. Erasmus MC Medical Ethics 
Committee according to the Medical Research Involving Human Subjects Act (MEC-
2004-261) has approved the use of these samples.
Illumina 1M SNP Array analysis from 47 PCa patients, 11 PCa xenografts, 8 PCa cell 
lines and 6 non-cancer patients were collected. Genotyping was performed using the 
Infinium Illumina Human 1M probe BeadChip containing 1,072,820 markers of which 
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206,665 are in CNV regions. The experiments were performed by ServiceXS (Leiden, The 
Netherlands) and within the group of André Uitterlinden (Erasmus MC) according to the 
manufacturer’s protocol (Illumina) (49). 
Nexus Copy Number 5.0 (BioDiscovery) was used for data analysis. The Human 1M CV 
HapMap control set provided by the manufacturer was used as a control. SNP-FASST 
Rank segmentation was the algorithm used for sample analysis. Standard settings were 
adjusted to: significant threshold - 10-7, maximum contagious probe spacing - 1000 
kb, minimal number of probes per segment - 15, high gain - 0.6, gain -0.2, loss - -0.2, 
big loss - -1, homozygous frequency threshold - 0.9, homozygous threshold - 0.85, 
heterozygosity imbalance threshold - 0.35 and minimum loss of heterozygosity (region 
with loss of heterozygosity) length - 5000 (kb). 
Affymetrix exon arrays
Exon-array data from 89 PCa patient samples, 11 PCa xenografts and 6 cell PCa cell 
lines were collected using the GeneChip Human Exon 1.0 ST Array (Affymetrix). Staining, 
washing and scanning procedures were performed according to the manufacturer’s 
protocol (Affymetrix). Processing and RMA quantile normalization of the data were 
performed using the R-package affy (http://www.bioconductor.org/packages/release/
bioc/manuals/affy/man/affy.pdf).
The list of genes with DNA breakpoint originated from the SNP microarray data was 
analyzed to determine differential expression of exons in these genes (GSE41410). On 
the GeneChip Human Exon 1.0 ST Array, 5,362,207 probes (on average 40 probesets per 
gene) are used to analyze one million exon clusters (collections of overlapping exons). 
The file containing the raw intensity values for the core probes (derived from RefSeq 
transcripts or full-length mRNAs) was used to assess exon expression profile.
Integration of Illumina SNP arrays and Affymetrix Human Exon 
Arrays to identify potentially transcribed gene fusions
For 54 SNP arrays used in this study, matching expression data from Affymetrix Human 
Exon Arrays were available (17, 49), which were normalized using the RMA implementation 
of the aroma.affymetrix R-package and further processed using the FIRMA method (50, 
CDF used: HuEx-1_0-st-v2,fullR3,A20071112,EP.CDF, see http://www.aroma-project.
org/). In short, FIRMA was designed to identify alternative splicing events from Human 
Exon Arrays by comparing the expected gene expression profile to the profiles of each 
of its exons and scoring whether systematic deviations can be found. Since gene fusions 
may cause parts of a gene to be expressed, the observed change in expression would 
mimic alternative splicing events measured by the array and therefore can be identified 
by using the same methodology.
To find breakpoints located within genes, we defined the start and end positions of 
copy number segments called by Nexus as genomic breaks (file ‘cncalldetails.txt) and 
overlapped them with the RefSeq gene annotation (build hg18 available at http://
genome.ucsc.edu/). After translating the RefSeq gene identifiers to gene symbols, 
Affymetrix transcript clusters that represented the candidate genes were defined. Next, 
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all corresponding ‘core’ and ‘extended’ probesets that were located on the left and 
right side of the DNA breakpoint were selected, respectively. For each sample, we then 
tested whether the FIRMA scores of probesets located before and after the breakpoint 
differed using a Wilcoxon-test.
Public array datasets
The prostate cancer dataset mentioned contains 48 previously published prostate 
cancer samples (GSE41408, (49)) as well as additional cancerous and control samples, 
accessible via GEO accession number GSE59745 (17). These datasets comprise samples 
from normal adjacent prostate (NAP), localized prostate cancer obtained via radical 
prostatectomy (PCa) and transurethral resection of the prostate (TURP), as well as 
metastasis in lymph node (LN PCa). 
RNA and DNA isolation
Total RNA was isolated using the RNeasy kit (Qiagen, Valencia, CA, USA) according to 
the manufacturer’s protocol. Concentration and purity of RNA were assessed using the 
NanoDrop ND1000 spectrophotometer (Nanodrop products, Wilmington, DE, USA). 
RNA was stored at -80 degrees. DNA was isolated using the QIAamp DNA Blood Midi 
Kit (Qiagen) according to the manufacturers’ instructions. Concentration and purity of 
the DNA were assessed using the NanoDrop ND 1000 spectrophotometer (Nanodrop 
products) and stored at -20 degrees.
Q-PCR
mRNA expression was analysed by quantitative PCR (qPCR). Complementary DNA 
was prepared with MMLV-RT (Invitrogen) and oligo(dT)12 primer according to 
manufacturer’s protocol. Taqman probe Hs01115789_m1 was used to detect MPP2 
expression levels. The detection of GPS2-MPP2 was done using a costum Taqman gene 
expression assay, with the 5’ GCA AGC GGC AGG CCA TGC AGC A 3’ oligonucleotide 
probe and primers 5’ GCA CAT TAT GAT GGA GCG GGA 3’ (Fw) and 5’ GAG GCA TTA 
TGG AAA GTC CCA 3’ (Rv). For detection of GAPDH the commercial taqman probe 
Hs02758331_g1 was used. 
Cell culture
RWPE-1 and PNT2C2 (kindly provided by Prof. Norman Maitland, York, U.K.) are 
normal prostate epithelium cell lines. RWPE-1 cells were cultured in keratinocyte 
medium (GIBCO), supplemented with 5 ng/ml epidermal growth factor, 1% penicillin–
streptomycin (BioWhittaker) and 50 mg/l bovine pituitary extract. LNCaP and PNT2C2 
cells were cultured in RPMI-1640 Medium (GIBCO) supplemented with 10% fetal bovine 
serum and 1% penicillin–streptomycin (BioWhittaker). All cell lines were cultured at 37 
degrees with 5% carbon dioxide.
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RNA ligase-mediated rapid amplification of cDNA ends
5’ RACE was performed using the GeneRacer kit (Invitrogen) according to the 
manufacturer’s protocol. Briefly, cDNA was amplified using the GeneRacer 5’ primer 
and a reverse gene-specific primer (MPP2 – exon 4; NRXN3 – exon 6; YES1 – exon 4). 
The PCR products were analysed on a 1% agarose gel and bands were excised, purified 
using a gel extraction kit (Qiagen) and sequenced. 
Sequencing
Purified PCR products have been sequenced bidirectionally using standard Sanger 
sequencing. Sequencing PCR was carried out using the same reverse primer as the 
primer used in the 5’ RACE PCR. The forward primer was later designed, according to 
the gene partner identified. Primer concentrations were 3 ng of primer per reaction 
in a 20 µl reaction volume. The PCR product was sequenced on an ABI Model 3730 
automated sequencer and analyzed using DNAMAN (Lynnon Corporation, Pointe-Claire, 
QC, Canada).
FISH
FISH was performed on nuclei spreads from LNCaP, PNT2C2 and normal blood cells. 
Cells were collected and incubated at 37 degrees Celsius for 18 minutes in a 0.075M KCL 
solution. Fixation was then performed using a freshly made 3:1 Methanol/ice-acetic acid 
solution (fixative). Cells were centrifuged for 5 min at 200 g. Cells were resuspended in 5 
ml of fixative and centrifuged for 5 min at 200 g. This step was performed 3 times. Cells 
were dropped onto the slide and allowed to dry for 20 min. BAC clones RP11-1099M24 
(GPS2, before the break) and RP11-290H9 (MPP2, after the break) were purchased 
from BacPac Resources (bacpac.chori.org) and SE 17 (D17Z1) centromere probe 17 
was purchased from Kreatech Diagnostics (Netherlands). BACs were labeled with 
digoxigenin-11-dUTP or biotin-16-dUTP (Roche) and visualized with anti-digoxigenin 
FITC (Roche) or streptavidin-Alexa 594 (Invitrogen). Labelling was performed according 
to the manufacturer’s protocol. FISH was performed according to standard protocols 
with minor modifications (51).
GPS2, MPP2 and GPS2-MPP2 TurboGFP constructs
The sequence validated I.M.A.G.E clones IRATp970F0313D (GPS2) and IRATp970C0650D 
(MPP2) corresponding to the BC013652 and BC030287 clone accession numbers were 
purchased from Source Bioscience, Nottingham, UK. Primers 5’ ATG CAG CCA GCA 
GGA AAG TC 3’ (Fw) and 5’ CTC CCG CTC CAT CAT AAT GT 3’ (Rv) and 5’ ATG CCT CGA 
AGG AAG ATC AG 3’ (Fw) and 5’ CTG CCT GGT CAA TAG CAA CCT 3’ (Rv) were used to 
amplify the GPS2 and MPP2 cDNA respectively and subsequently clone the fragment 
in frame into the Mammalian expression vector pTurboGFP-C (Evrogen). GPS2-MPP2 
cDNA was synthesized by GENECUST EUROPE (Luxembourg) and cloned into the pUC57 
plasmid. The GPS2-MPP2 cDNA was cut using XbaI and BamHI and subsequently ligated 
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to pTurboGFP-C. The amplified fragments were ligated to the vector using the Rapid 
DNA Ligation Kit according to the manufacturer’s protocol (Roche). JM109 competent 
bacteria (Promega) were transformed with the ligation products using the heat shock 
method and plated in Kanamycin LB agar plates. DNA isolation was performed on 
selected colonies (Qiagen) and further sequence to confirm the cloning products.
Live-cell imaging
LNCaP and RWPE1 cells were cultured in coverslips at day 0 and transiently transfected 
at day 1 with TurboGFP-GPS2, TurboGFP-MPP2 and TurboGFP-GPS2-MPP2 using Fugene 
6 (Promega) according to the manufacturer’s protocol. After 48 h cells were imaged 
using the LSM 510 NLO confocor II (Zeiss). In addition, cells transfected with TurboGFP-
GPS2 and TurboGFP-GPS2-MPP2 were also stained with the PKH26 Red Fluorescent Cell 
Linker for General Cell Membrane Labeling (Sigma) according to standard protocol. A 
time-lapse was performed for TurboGFP-GPS2 and TurboGFP-GPS2-MPP2.
 
Functional assays
The functional role of GPS2-MPP2 in the LNCaP cell line was assessed with the 
knockdown of both MPP2 and GPS2-MPP2 fusion gene. Proliferation assays were 
performed at different time points. The small interfering RNA reagent siGENOME 
SMARTpool, Human MPP2 (ThermoFisher Scientific) interacts with a part of the MPP2 
gene, which is also present in the fusion. Briefly, LNCaP and RWPE-1 (control) cells 
were plated in 96-well culture plates at a density of 2000 cells per well (100 µl) and 
plated in T25 tissue flasks. Outer wells of the culture plates were filled with phosphate-
buffered saline in order to avoid culturing artifacts in the proliferation assays. After 2 
days, cells were washed using phosphate-buffered saline and transfected with Human 
MPP2 (siGENOME SMARTpool) or the custom GPS2-MPP2 siRNA oligos (sense GGC 
AGG CCA UGC AGC AAG UdT dT and anti-sense ACU UGC UGC AUG GCC UGC CdT 
dT) (Sigma) (final concentration of 100 nM) and Dharmafect3 reagent according 
to the manufacturer’s protocol (Thermo Scientific) in medium without P/S. As negative 
controls, medium only, Dharmafect3 with water and a transfection with non-targeting 
small interfering RNA were included. Twenty-four hours after transfection the medium 
was replaced with normal medium, without P/S and cells were allowed to grow for a 
maximum of 6 days. Proliferation was assessed using the Cell Titer-Glo Luminescent 
Cell Viability Assay (Promega) according to the manufacturer’s protocol. Apoptosis 
was assessed using the ApoLive-Glo Multiplex Assay (Promega) that measures 
both the number of viable cells as a marker of cytotoxicity and caspase activation 
as a marker of apoptosis within a single assay well. The assay was performed 
according to the manufacturer’s protocol. As positive control of apoptosis an apoptosis 
inducer set (Millipore) was used. A mix containing 700x dilutions of Actinomycin D 
(10 mM), Camptothecin (2 mM), Cycloheximide (100 mM), Dexamethasone (10 mM) 
and Etoposide (10 mM) was used for 4 hours to induce apoptosis in both LNCaP and 
PNT2C2 cell lines.
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Supplementary data
Figure S1: Expression levels of GPS2 (A) and MPP2 (B) in primary prostate cancer (56 samples), 
normal adjacent prostate tissue (12 samples), prostate cancer lymph node metastasis (12 samples) 
and transurethral resections (TURP, 10 samples). Wilcoxon testing was used to determine significant 
differences in expression levels between primary tumor and normal, lymph node metastasis and TURP. 
** p-value ≤ 0.02.
Figure S2: Expression levels of MPP2 in normal prostate samples and in PCa samples. The expression 
levels of MPP2 were measured by qPCR using a Taqman gene probe. The expression levels of MPP2 
measured by qPCR were normalized to the expression levels of GAPDH mRNA in each sample. In red, the 
expression levels of two LNCaP substrains (ATCC and Rotterdam) are highlighted.
25
20
15
10
5
0
Distribution of MPP2 expression in normal and PCa samples
PCa samplesNormal
samples
N
or
m
al
iz
ed
 e
xp
re
ss
io
n 
va
lu
e
A) B)
58
Figure S3: Taqman gene expression assay for MPP2 and GPS2-MPP2. The expression level of MPP2 was 
measured two, four and six days after siRNA transfection against MPP2 and GPS2-MPP2 in LNCaP (A) 
and against MPP2 in PNT2C2 (B) and RWPE-1 (C) cell lines. In addition, the specific knock-down level 
of the GPS2-MPP2 gene fusion was measured in the LNCaP cell line (D). All values were normalized to 
the expression of the GAPDH house keeping gene. The ø represents LNCaP cells growing under normal 
conditions and Scr the addition of a non-targeting small interfering RNA.
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Figure S4: Scheme displaying the protein domain distribution in all the different classes of the MAGUK 
protein family. The L27 domain is found in the receptor targeting proteins Lin-2 and Lin-7 and is a specific 
protein-protein interaction module.  PDZ domains are structural domains of 80 to 90 amino acids and 
usually bind to short C-terminal regions of other proteins. SH3 (SRC Homology 3) domains are found 
commonly in several intracellular or membrane-associated proteins. GuK (Guanylate kinase) domain. 
CARD (caspase activation and recruitment) domains are interaction motifs found in proteins involved 
typically in apoptotic processes and they mediate the formation of large protein complexes. ZU5 is a 
domain of 90 to 110 residues that in most cases contain a C-terminal death domain. WW is a short 
conserved region that binds proline-rich polypeptides.
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Supplementary Table 1, Supplementary Table 2 and Supplementary videos 1-4 will be 
made available through the journal’s website upon publication. 
Before publication they will be available through the following links:
Supplementary Table 1 - 
https://www.dropbox.com/sh/qe2lx9obl3q4mel/AADhlj0J-Ox-B5XWUwz7c2caa?dl=0
Supplementary Table 2 - 
https://www.dropbox.com/sh/qe2lx9obl3q4mel/AADhlj0J-Ox-B5XWUwz7c2caa?dl=0
Supplementary videos 1-4 - 
https://www.dropbox.com/sh/jyih0ntzfc64zc0/AAAPTD11w1dUVNCuEDSwMbNZa?dl=0
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Abstract
Gene fusions, mainly between TMPRSS2 and ERG, are frequent early genomic 
rearrangements in prostate cancer (PCa). In order to discover novel genomic fusion 
events, we applied whole-genome paired-end sequencing to identify structural 
alterations present in a primary PCa patient (G089) and in a PCa cell line (PC346C). 
Overall, we identified over 3800 genomic rearrangements in each of the two samples 
as compared with the reference genome. Correcting these structural variations for 
polymorphisms using whole-genome sequences of 46 normal samples, the numbers 
of cancer-related rearrangements were 674 and 387 for G089 andPC346C, respectively. 
From these, 192 in G089 and 106 in PC346C affected gene structures. Exclusion of small 
intronic deletions left33 intergenic breaks in G089 and 14 in PC346C. Out of these, 12 
and 9 reassembled genes with the same orientation, capable of generating a feasible 
fusion transcript. Using PCR we validated all the reliable predicted gene fusions. Two 
gene fusions were in-frame: MPP5–FAM71D in PC346C and ARHGEF3–C8ORF38 in 
G089. Downregulation of FAM71D and MPP5–FAM71D transcripts inPC346C cells 
decreased proliferation; however, no effect was observed in the RWPE-1-immortalized 
normal prostate epithelial cells. Together, our data showed that gene rearrangements 
frequently occur in PCa genomes but result in a limited number of fusion transcripts. 
Most of these fusion transcripts do not encode in-frame fusion proteins. The unique 
in-frame MPP5–FAM71D fusion product is important for proliferation of PC346C cells. 
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Introduction
Prostate cancer (PCa) is one of the most frequently diagnosed cancers and a major 
cause of death in men in countries with a western lifestyle (1). Throughout the past two 
decades, several genetic events have been revealed that are important in development 
and progression of PCa (2). The predominant genetic abnormalities identified so far 
include the forming of ETS-fusion genes (3), loss of phosphatase and tensin homolog 
(PTEN) tumour suppressor gene (4), amplification of AR and amplification of the MYC 
oncogene (5). Most of these studies used comparative genomic hybridization/SNP 
(single nucleotide length polymorphism) arrays and performed genome-wide copy 
number variation analysis as a start to identify specific genetic alterations (6, 7). The 
use of gene expression arrays was important in the detection of genes with aberrant 
expression patterns (8). The integration of these two different sets of data, copy number 
variation and gene expression reinforced and expanded this panel of genetic alterations 
(9, 10).
Next-generation sequencing (NGS) techniques emerging over the last few years proved 
to be a major breakthrough in documenting novel genetic changes resulting in a better 
understanding of cancer cell biology (11, 12). Both RNA and DNA can be used as 
templates for NGS methods and it is possible to analyse either paired-end, mate pair, 
as short or long sequence reads depending on the platform applied (13, 14). An exome-
sequencing approach uses only 1–2% of the genomic sequences as a template through 
capture and enrichment before the sequencing process (15, 16). This allows for higher 
sequence coverage at the expense of a few disadvantages such as the uneven capture 
efficiency and the absence of unknown or yet to be annotated exons (17). Instead of 
a focused exome-sequencing approach, more challenging whole-genome sequencing 
provides the most complete view of genomic changes (18). A range of sequencing 
technologies is now available and more are becoming available soon that provide 
different approaches for library construction, clone separation and amplification, and 
nucleotide detection (19–22). The technology utilized in this study from Complete 
Genomics Inc. (Mountain View, CA, USA) makes use of array technology to separate 
amplified DNA template organized into single-strand coils, known as DNA nanoballs. 
Nucleotide read-out is based on a ligation protocol (23). 
In PCa genomics the use of NGS has allowed significant progress in cataloguing 
systematically all the DNA changes present in cancer (24). The use of RNA-seq has 
produced major insight into the identification and expression of novel long noncoding 
RNAs and novel gene fusions in PCa (25, 26). Exome sequencing of PCa samples was 
utilized for the detection of novel small mutations (27–30). In the same way, a mutational 
landscape of patients with castration-resistant PCa was described by Tomlins et al. (3) 
in 2012 (31). In addition, deep RNA sequencing is also used to identify transcription-
induced chimeras associated with human prostate adenocarcinoma such as the novel 
TMEM79-SMG5 (32, 33). However, a full overview of all structural variations (SVs) and 
mutations can only be provided by whole-genome sequencing. Many studies so far have 
applied NGS to obtain a more thorough perceptive of already known genetic alterations 
67
3
Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer
(34). The mechanism involving PTEN loss has been correlated with novel genetic 
alterations in genes located in the vicinity of PTEN (24). Moreover, the expression of 
constitutively active androgen receptor splice variants in castration resistance PCa has 
been described (35). A few studies have been published making use of whole or focused 
genome NGS technologies to discover and describe new genetic alterations in PCa. The 
study by Berger et al. (24) in 2011 provided a comprehensive approach towards both 
known and newly identified mutations and genomic rearrangements. Other studies 
have focused on either a particular genomic region such as the 10q11.2 97-kb region 
comprising the MSMB gene or in the analysis of all alterations present in a particular 
PCa sample (36, 37). This was the case for the new type of prostate adenocarcinoma 
identified that has a hybrid phenotype of both luminal and neuroendocrine cells (37, 
38). 
In this study, we applied whole-genome paired-end sequencing in two PCa samples. 
Analysis of the PC346C PCa cell line and the G089 primary PCa patient sample, which 
were selected based on the absence of ETS-fusion genes (39), generated a wide panel 
of new SV events. We focused on the detection of SVs to unravel the events leading to 
fusion genes. The potential fusion genes were validated and the genes involved were 
checked for copy number alteration in other PCa samples. The in-frame fusion found in 
PC346C was assessed for possible functional implications.
Results
SVs detected by NGS
Whole-genome paired-end sequencing (Complete Genomics Inc.) of two PCa samples, 
the G089 primary tumor and the PC346C cell line, generated data with an average 
coverage of 61x and 67x, respectively (Supplementary Table S1, Supplementary Figure 
S1). The fully aligned genome fraction for both samples was above 93% (Supplementary 
Figure S2). Data showing reads mapping at a different position/orientation than expected 
were used to perform de novo assembly and generate a list of all SVs in the two DNAs. 
In the PC346C sample, a total of 3898 SVs were detected (both interchromosomal and 
intrachromosomal) as compared with the reference genome. For the G089 sample the 
total of SVs was 3837 (Table 1). As normal DNA from these two PCa samples was not 
available, the data were curated for polymorphisms using a data set derived from 46 
normal DNA samples (Supplementary Table S2). This left us with 387 candidate cancer-
related events in PC346C and 674 in G089 (Table 1). 
Overall, 90.1% and 82.4% of all SVs detected in PC346C and G089 were also present 
in any of the 46 normal controls. Of the cancer related events the far majority did not 
occur in a gene intron or exon: only 2.7% and 5.0% of SVs were inside genes for both 
junctions in PC346C and G089, respectively (Figures 1a and b).
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Type of SV Prostate cancer samples (before correction by 46 normal samples
Total number Gene only on one side Genes on both sides
PC346C G089 PC346C G089 PC346C G089
Interchromosomal 1228 1283 249 231 36 44
Intrachromosomal 2670 2554 48 67 796 794
Total 3898 3837 297 298 832 838
46 normal samples (average per one sample)
Total number Gene only on one side Genes on both sides
Interchromosomal 120 21 4
Intrachromosomal 301 5 94
Total 421 26 98
Prostate cancer samples (after correction by 46 normal samples)
Total number Gene only on one side Genes on both sides
PC346C G089 PC346C G089 PC346C G089
Interchromosomal 86 141 25 52 5 18
Intrachromosomal 301 533 17 44 101 174
Total 387 674 42 96 106 192
Table 1: Structural variations (SVs) identified by next-generation sequencing
Figure 1: Overview of genomic abnormalities identified by NGS. Pie chart illustrating the genomic breaks 
detected by NGS in PC346C (A) and G089 (B). The percentages represent the presence of junctions in 
any of the 46 normal samples (light green) and their occurrence within genes (green and dark green). 
Next, we classify according to the overlap of junctions with different genes (light and dark purple) and 
the gene orientation (light and dark blue).
A)
B)
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Additionally, we often found the same gene IDs on both sides of the junctions, which 
corresponded to (small) intragenic rearrangements, such as deletions, duplications and 
inversions. We detected 14 SV events in PC346C and 33 in G089 where each side of the 
junction occurred within a different gene (Figure 2) (40).
From these 14 and 33 SVs, we excluded the events in which the orientation of the genes 
was head-to-head or tail-to-tail to select for gene fusion events that could generate 
fusion transcripts. In the end, nine (PC346C) and 11 (G089) SVs fusing two different 
genes in the same orientation were identified (Table 2; Supplementary Tables S3–S5).
Validation of fusion genes present in PC346C and G089
For each possible gene fusion event in PC346C and G089, we checked all the mapped 
reads, both the normal and the mispaired reads (Supplementary Figure S3). We 
observed that a number of fusion events were not supported by a convincing number 
of discordant mate pairs (Table 2). To evaluate whether the criterion of three or more 
mispaired reads was justified, all 9 + 11 fusion events were validated using (RT)–PCR 
both at the DNA and RNA levels (Supplementary Figures S4 and S5, Supplementary 
Tables S6–S9). Most of the fusion events with low mispaired read counts (≤ 5) could 
not be confirmed, showing that the cut off number of three discordant mate pairs was 
set low. 
For most gene fusions, the event was confirmed by sequencing on the RNA and/or DNA 
level. Out of these six PC346C fusion events, all were validated on the DNA level with 
Figure 2: Graphical representation of gene rearrangements in PC346C and G089. Circos plot of the 
PC346C (A) and G089 (B) samples. The outer ring depicts the chromosomes. The 14 and 33 gene 
rearrangements found in PC346Cand G089, respectively, are shown in red (interchromosomal) and 
green (intrachromosomal) lines.
A) B)
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only one that could not be verified at the transcript level (Supplementary Tables S10 
and S11). The fusion in question, ITGA10–RBM8A, comprises the downstream part of 
the 30-untranslated repeat sequence of RBM8A so it was not expected to be present 
within the fusion transcript. In G089, out of the nine reliable fusion events eight were 
validated at the DNA level and five at the RNA level. The four fusions that were validated 
only at the DNA level were assessed for the expression levels of the involving genes 
using Affymetrix Exon-array analysis (Affymetrix, Santa Clara, CA, USA) of the G089 
PCa sample. In general, we found a low expression pattern of these fusion genes. The 
OBP2A–OBP2B fusion, comprising only three mispaired reads, was verified at the RNA 
level and involved two homologous genes. The AATK–LAMA5 fusion was confirmed at 
the DNA level, although the number of discordant mate pairs was only five (Table 2).
Next, we assessed which fusion events generated an in-frame fusion protein. On the 
basis of the sequence of the fusion transcript we determined that MPP5–FAM71D in 
PC346C and ARHGEF3–C8ORF38 in G089 were in-frame and most likely produced a 
fusion protein (Table 2). The final set of validated gene fusions (Figures 3a and b) was 
assessed for discordant mate pairs on both sides of the break as well as visible copy 
number-related breakpoints using the Illumina 1M SNP array (Illumina). The presence of 
discordant mate pair reads on both sides of the break corresponds to distinct genomic 
Table 2: List of all candidate gene fusions detected by NGS and their validation on the RNA and DNA 
levels
Abbreviations: cDNA, complementary DNA; Chr, chromosome; NGS, next-generation sequencing
Sample 5' Donor 
gene
3' Acceptor 
gene
5' Chr 3' Chr Validated 
cDNA
Validated 
DNA
In 
frame
# of Discordant 
mate pairs
PC346C ATP6V0A4 PHACTR4 chr7 chr1 No No - 5
GTF2H5 SYNJ2 chr6 chr6 No No - 3
MPP5 FAM71D chr14 chr14 Yes Yes Yes 43
TSPAN4 PHRF1 chr11 chr11 Yes Yes No 62
RNF19A SNX31 chr8 chr8 Yes Yes No 16
DCAF6 MPZL1 chr1 chr1 Yes Yes No 29
PTCRA ENPP3 chr6 chr6 No No - 3
THADA MAP4K3 chr2 chr2 Yes Yes No 55
ITGA10 RBM8A chr1 chr1 No Yes - 24
G089 ARHGEF3 C8orf38 chr3 chr8 Yes Yes Yes 39
LRBA NFKB1 chr4 chr4 Yes Yes No 27
FCRL1 RASAL2 chr1 chr1 No Yes - 82
AATK LAMA5 chr17 chr20 No Yes No 5
SERF2 PDIA3 chr15 chr15 Yes No No 8
GABPB2 BNIPL chr1 chr1 Yes Yes No 15
LAMA5 AATK chr20 chr17 Yes Yes No 41
NFKB1 FAM160A1 chr4 chr4 No Yes - 58
CCNY PARD3 chr10 chr10 No Yes - 17
OBP2A OBP2B chr9 chr9 Yes No Yes 3
ZFPM1 ZNF469 chr16 chr16 No Yes - 20
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locations that were joined together. On the other hand, a break with discordant mate 
pairs on only one side will, most likely, correspond to a break with loss of DNA on 
the other side. Regarding our final set of 15 fusions we observe mainly the presence 
of discordant mate pairs on one side of the break (Figure 3b) corresponding to the 
candidate gene fusion we initially detected. 
The remaining fusions had discordant mate pairs on both sides, meaning both sides of 
the break fused to different genomic locations. That was the case for AATK–LAMA5 with 
the reciprocal LAMA5–AATK gene fusion detected, NFKB that fuses to both LRBA and 
FAM160A1 and CCNY, which fuses to PARD3 and WDFY2. The remaining C8ORF38, LRBA 
and FAM160A1 gene fragments break to ARHGEF3 and NFKB, respectively, as well as to 
additional intergenic genomic locations.
All the genes of the validated fusion events were checked for breakpoints in a 66 SNP 
array data set of 11 PCa xenografts, eight PCa cell lines and 47 PCa patient samples with 
six matching normal controls. We observed that a few genes had breakpoints at the 
SNP level in other PCa samples providing us with an impression of the frequency of the 
specific breaks (Supplementary Table S12, Supplementary Figure S6). We checked for 
the presence of the same fusion transcript (THADA–MAP4K3, ARHGEF3–C8ORF38 and 
LRBA–NFKB1) in the samples with copy number variations (CNVs), but never observed 
a positive RT–PCR using the primer pairs that proved the fusion transcripts in G089and 
PC346C (data not shown). 
Sample 5' Donor 
gene
3' Acceptor 
gene
5' Chr 3' Chr Validated 
cDNA
Validated 
DNA
In 
frame
# of Discordant 
mate pairs
PC346C ATP6V0A4 PHACTR4 chr7 chr1 No No - 5
GTF2H5 SYNJ2 chr6 chr6 No No - 3
MPP5 FAM71D chr14 chr14 Yes Yes Yes 43
TSPAN4 PHRF1 chr11 chr11 Yes Yes No 62
RNF19A SNX31 chr8 chr8 Yes Yes No 16
DCAF6 MPZL1 chr1 chr1 Yes Yes No 29
PTCRA ENPP3 chr6 chr6 No No - 3
THADA MAP4K3 chr2 chr2 Yes Yes No 55
ITGA10 RBM8A chr1 chr1 No Yes - 24
G089 ARHGEF3 C8orf38 chr3 chr8 Yes Yes Yes 39
LRBA NFKB1 chr4 chr4 Yes Yes No 27
FCRL1 RASAL2 chr1 chr1 No Yes - 82
AATK LAMA5 chr17 chr20 No Yes No 5
SERF2 PDIA3 chr15 chr15 Yes No No 8
GABPB2 BNIPL chr1 chr1 Yes Yes No 15
LAMA5 AATK chr20 chr17 Yes Yes No 41
NFKB1 FAM160A1 chr4 chr4 No Yes - 58
CCNY PARD3 chr10 chr10 No Yes - 17
OBP2A OBP2B chr9 chr9 Yes No Yes 3
ZFPM1 ZNF469 chr16 chr16 No Yes - 20
Figure 3: Validated gene fusions detected by NGS. (A) DNA representation of the gene fusions validated 
in PC346C and in G089. The oblique line in MPP5 and ZFPM1 denotes the break occurs within the exon. 
The white rectangles correspond to non-coding exons. Light green and orange squares correspond to 
the acceptor and donor genes, respectively. All the fusions represented are validated at the RNA and/or 
DNA level. The * denotes in-frame transcripts. (B) All the gene fusions were checked for the presence of 
discordant mate pairs on both sides of the break as well as for breaks visible at the SNP level.
A) B)
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MPP5–FAM71D fusion has functional implications in  
PC346Ccell line
The two in-frame gene fusions were assessed for the expression level of the 30 acceptor 
genes in the exon-array data of G089 and PC346C. We observed a clear upregulation 
of FAM71D expression from exon 4 onwards in the PC346C sample (Supplementary 
Figure S7) compared with normal controls and with G089. Regarding C8ORF38 we did 
not observe differential expression in G089 as compared with normal controls and other 
PCa samples (Supplementary Figure S8). MPP5 and ARHGEF3 do not show differential 
expression in PCa samples or in PC346C and G089. 
The MPP5–FAM71D fusion was confirmed both at the RNA and DNA levels (Figure 4a) 
and the breakpoint was sequenced (Figure 4b). Forty-three discordant mate pairs were 
detected for MPP5 and FAM71D (Table 2). The two genes are located on chromosome 14, 
~52 kb apart. In the SNP array data we did not detect any copy number alteration (deletion 
or gain) in these two genes. The fusion transcript predicted to code for a fusion protein of 
Figure 4: Discovery of the novel MPP5-FAM71D fusion in PC346C. (A) Validation of MPP5-FAM71D fusion 
transcript in RNA (cDNA) and DNA from PC346C by PCR amplification and electrophoresis. The fusion is 
only present in PC346C and not in G089. The third lane corresponds to the negative control (no cDNA 
added). (B) Validation of the MPP5-FAM71D fusion breakpoint using Sanger sequencing in cDNA from 
PC346C. (C) Scheme of the MPP5-FAM71D fusion protein. The red line corresponds to the disruption 
of the second L27 domain which retains the first 40 aa from the original 57 aa. FAM71D has no known 
structural domains. (D) The presence of the MPP5-FAM71D fusion (cDNA) was tested in the PC346P 
patient-derived xenograft from which the PC346C cell line originated. The presence of the band in both 
PC346C and PC346P shows that this fusion was already present in the xenograft.
A)
C)
B)
D)
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aa 1–217 of MPP5 (674 aa full-length protein) and aa 54–422 of FAM71D (Figure 4c). The 
expression of MPP5 is not known to be prostate-specific or androgen-regulated. Obviously, 
the expression of the 30-sequence of FAM71D was highly upregulated in PC346C, now 
being under control of the MPP5 promoter region. The PC346P patient-derived xenograft 
from which the PC346C cell line originated also shows high expression of the fusion 
gene (Figure 4d).
In order to assess the frequency of the MPP5–FAM71D fusion and FAM71D 
overexpression, we performed TaqMan gene expression assays on 201 PCa samples. 
None of these were positive for the MPP5–FAM71D fusion transcript observed in 
PC346C. In order to extend the analyses to other genomic events that would result in 
the FAM71D overexpression, we found 10 samples to have a relative high expression 
of FAM71D as compared with PC346C, normal prostate and the bulk of cancer samples 
(Supplementary Figure S9). 
Figure 5: FAM71D promotes cell proliferation in the PC346C cell line. (A) Knockdown of FAM71D 
in the PC346C cell line. The levels of FAM71D expression were still downregulated at day 6 after 
the knockdown. Data were normalized to GAPDH and represented as fold-change. (B) Cell 
proliferation assays for PC346C cells. The ø represents PC346C cells growing under normal conditions, 
dH2O the addiction of transfection reagent, scramble the addition of a non-targeting siRNA and 
siFAM71D the knockdown of the FAM71D transcript. An asterisk (*) indicates P ≤ 0.02 and (**) P ≤ 0.002 
by a two-tailed Student’s t-test. (C) Cell proliferation assays for RWPE1. Same controls as used for 
the PC346C cells. (D) Apoptosis assay through detection of Caspase 3/7 activity corrected for cell 
viability. This assay was performed for both PC346C and RWPE-1 cell lines. The same controls of the 
proliferation assays were used along with an apoptosis control (drug-treated cells for 24 h).
A)
C)
B)
D)
74
Next, we addressed the functional relevance of FAM71D overexpression in the PC346C 
cell line by the knockdown of its expression. The small interfering RNA SMARTpool of 
FAM71D successfully caused downregulation in both PC346C and the normal epithelial 
prostate RWPE-1 cell line (Figure 5a). In the case of PC346C cells we observed a 
considerable decrease in proliferation capacity at all time points tested (2, 4 and 6 
days after the knockdown). This decrease was significant when compared with all the 
transfection controls and the normal PC346C growth (Figure 5b). In contrast, RWPE-1 
cells showed a slight increase in proliferation after FAM71D knockdown, which was not 
significant when compared with the transfection controls (Figure 5c).
In order to address whether there was induction of apoptosis by FAM71D knockdown, 
we measured the caspase 3/7 activity for both transfected PC346C and RWPE-1. We 
did not detect an increase in apoptosis in PC346C or RWPE-1 due to the knockdown 
of FAM71D as compared with the transfection controls (Figure 5d). The cell growth 
effect of overexpression of FAM71D in PC346C is most likely the result of increased 
proliferation and not inhibition of apoptosis. The selective decrease in proliferation only 
in PC346C indicates a functional beneficial role for MPP5–FAM71D in these cancer cells. 
Discussion
Correction for most SV polymorphisms using a control data set of 
46 normal samples
In the present study, we report the SVs detected by whole genome paired-end 
sequencing of two PCa samples, the primary tumor G089 and the cell line PC346C. As 
described above, we detected 3898 and 3837 SVs in PC346C and G089 as compared 
with the HG18 reference genome. As most of these SVs are polymorphisms, one needs 
to separate these common variants from the cancer-related events. Optimally, the 
sequence of a normal DNA sample from the cancer patient will do so, but the normal 
control DNA of the G089 patient sample and PC346C cell line is not available. This is 
not an uncommon problem since for many cell lines, xenografts and old cancer sample 
repositories, a normal blood or tissue sample has not been stored. In order to remove 
common polymorphism, one can make use of databases of structural variants that are 
far from complete but are becoming more comprehensive rapidly (41). We decided to 
use a control dataset of 46 normal DNA samples that were sequenced on the same 
Complete Genomics platform and analyzed using the identical pipeline. This resulted 
in the exclusion of 3511 and 3163 SVs from the initial list of SVs detected in PC346C 
and G089, respectively. As expected, the majority of the SVs detected initially were 
normal occurring variation across individuals. In the end, we anticipate that most of 
these common variants will not correlate with cancer, although we cannot exclude their 
contribution to disease susceptibility (42, 43). 
The list of gene-to-gene rearrangements in the 46 normal samples was used to estimate 
a false discovery rate of cancer related gene fusions. We observed that 28% of all 
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the ‘common’ gene-to-gene SVs were present in only one of the 46 normal samples 
(Supplementary Table S6). Such a high proportion means that many gene-to-gene SVs 
are rare and therefore we can assume that of our cancer-related gene fusions described, 
some are rare polymorphisms. 
Overall, our study showed that, in the absence of normal control DNA, it is still 
possible to eliminate the majority of the normal polymorphisms. Correction for rare 
polymorphisms will improve with the use of larger sets of normal control samples 
particularly with samples of the same ethnic origin. 
G089 and PC346C PCa samples do not show positive selection for 
breaks inside genes or in-frame gene fusion transcripts
The detection of novel gene fusions in G089 and PC346C aimed at investigating the relevance 
of these events in the initiation and/or progression of PCa. As gene rearrangements often 
affect the genes involved and are therefore under selection pressure, one might expect 
these events to be more common than random nonfunctional intergenic SVs. In order 
to determine whether there is a bias towards breaks inside genes, we checked whether 
such occurrences are more prevalent than the 38.5%—the approximate percentage of our 
genome that consists of genes (introns and exons) (44). Considering that each SV consists 
of two breakpoints, out of the 774 breaks in PC346C (387 SVs, Table 1), 42 and 212 (106 SVs 
with genes on both sides of the SV) are inside a gene, which is 32.8% of all breaks observed. 
For G089, in which out of the 1348 breaks, 96 and 384 are inside a gene representing 35.6% 
of all the breaks observed. This shows there is no bias towards breaks inside genes in our 
two PCa samples. Apparently, the occurrence of DNA breaks is an arbitrary process and is 
not selective for genomic coding regions. 
Most of the gene rearrangements present in PC346C and G089 corresponded to small 
deletions, insertions or inversions within the same gene. After the exclusion of these 
SVs, we were left with a total of 20 feasible gene fusions from which 17 were successfully 
validated. The remaining three fusions had a very low number of discordant mate pairs 
and are likely false positives. 
In order to verify the presence of in-frame gene fusions, we sequenced the breakpoint 
of the fusion transcripts. We observed that three gene fusions generated an in-frame 
fusion transcript, which is less than expected by random exon splicing, and conclude 
that there is no bias towards in-frame gene fusions in PC346C and G089. We expect 
that many of the gene fusions we have identified will be passenger events and not 
genetic drivers of PCa. However, it is certainly possible that some of the fusion genes 
that are inactivated by the rearrangement have tumor suppressor activity and their 
knockout does contribute to tumor progression. We checked whether additional 
mutations were identified in the fusion genes and found that with the exception of 
a few (THADA, C8ORF38, LRBA and LAMA5) all represent novel genes with potential 
implications in cancer biology.
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Integration of NGS data with SNP and gene expression arrays is  
a powerful approach to determine the most relevant SVs in  
cancer samples
In our study, we used SNP and Exon-array data samples in conjunction with the NGS 
data to find support for the mechanism and relevance of the rearrangement using the 
copy number variation and transcript expression changes. 
Regarding the unique gene partners identified in our study, we used the gene expression 
data to exclude genes that are not expressed in either PC346C or G089. This was 
particularly important to determine the expression change of fusion gene acceptors. In 
relation to the in-frame gene fusions, we observed that FAM71D is clearly upregulated 
in PC346C as compared with other normal and PCa samples, whereas C8ORF38 is not 
differentially expressed in G089 as compared with the other samples (Supplementary 
Figures S7 and S8). Owing to the fusion, FAM71D is regulated and expressed in a higher 
manner by the MPP5 promoter, and this outlier expression is a good indication that this 
gene fusion has a functional role in PC346C (Supplementary Figure S10). 
Our final set of gene fusions comprised several candidate genes, many of which were 
not yet identified as cancer-related. The genes LRBA, KNF19A, PARD3 and THADA 
were reported previously to be involved in other genomic events in PCa and thyroid 
adenocarcinoma (THADA) (24, 32, 33, 45). LRBA was found to be rearranged with 
regions downstream of the gene FSTL5, whereas KNF19A was not directly affected since 
the breakpoint was 3 kb upstream of the coding region (24). As for PARD3 it was found 
to be fused to ARHGAP10 and THADA to noncoding regions in chr3p25 and chr7p15 
(32, 33) SNP microarray data allowed us to check whether any of the respective gene 
partners of our list of fusion genes had additional breaks visible at the SNP level in 
an additional 64 PCa samples (Supplementary Figure S11). THADA, MAP4K3, ARHGEF3 
and LRBA were found to have copy number breaks in other PCa samples, mainly PCa 
xenografts, cell lines and late stage tumors (Supplementary Table S12). The same fusions 
(THADA–MAP4K3, ARHGEF3–C8ORF38 and LRBA–NFKB1) were not present in these 
samples with the CNV, indicating that THADA, MAP4K3, ARHGEF3 and LRBA rearrange 
to diverse genomic locations, potentially different fusion partners. The CNV check using 
SNP array data will underestimate the number of samples with breaks inside these 
genes, as rearrangements without loss of DNA and small deletion or amplifications 
cannot be identified using this technology. Recurrent breaks strongly suggest a role for 
these genes in PCa progression, although further studies are needed to explore the 
exact frequency and functional consequences. 
The integration of NGS and SNP microarray data generated a few inconsistent 
observations. We expected the lack of discordant mate pair reads on both sides of the 
break to indicate loss or gain of genetic material and therefore to be detected as a copy 
number change in the SNP array. This was the case for eight of our gene fusion partners, 
in which only one side of the break revealed discordant mate pairs without CNV in 
the SNP array data. This discrepancy can be due to the lower resolution of the SNP 
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array analyses, which has difficulties in detecting small deletions and amplifications. In 
the future, small-window copy number estimate from high coverage NGS data might 
resolve the differences observed in our study.
MPP5–FAM71D is related to the proliferation capacity of PC346C
The MPP5–FAM71D fusion, identified in the PC346C cell line, was silenced by the 
knockdown of FAM71D. This resulted in decreased proliferation capacity of PC346C cells but 
had no effect on RWPE-1-immortalized normal epithelial cells. This indicates that MPP5–
FAM71D has a functional role in the growth of PC346C, although the precise mechanism 
by which this fusion exerts its function is not clear. FAM71D is located on chromosome 14 
in the vicinity of MPP5 (46) and its function is largely unknown. Recent studies in African 
trypanosomes showed Fam71 to function as a calcium-binding protein through its EF-hand 
calcium-binding domain but nothing is known on the mammalian ortholog (47). 
Although we could not detect the MPP5–FAM71D fusion in any other of the 201 PCa 
samples analyzed, we did find relative higher expression of FAM71D in 10 of these 
cancer samples. The basis of this higher expression is unclear and could be due to fusion 
events or transcriptional upregulation. We conclude that FAM71D overexpression is not 
a frequent event in PCa and that the fusion to MPP5 as observed in PC346C is patient-
specific and extremely rare. 
Nevertheless, we cannot exclude an influence of MPP5, which is disrupted by the fusion 
event. MPP5 is a member of the membrane-associated guanylate kinase family and 
contributes to the establishment of cell polarity in mammals, which is crucial for tissue 
organization and whose loss is a hallmark of cancer (48–50). So far, the loss of MPP5 
has led to defects in polarity and assembly of tight junctions (51) as well as ineffective 
delivery of E-cadherin to the cell surface (52). The importance of MPP5 in several cellular 
functions can therefore have a role in this outcome. We can infer that the fusion will 
cause a disruption of normal MPP5, which is crucial for cell polarity. However, one copy 
of MPP5 is expressed and intact (no rearrangement or mutation), which excludes a 
complete MPP5 silencing mechanism. Further functional studies should be performed as 
to determine through which mechanism this fusion is directly affecting cell proliferation.
Materials and Methods
Samples and whole-genome sequencing data analysis
The DNA of two PCa samples, the PC346C PCa cell line (53) and the G089 PCa patient 
were sequenced by Complete Genomics (Complete Genomics Inc.). For microarray 
analyses and whole-genome sequencing, freshly frozen clinical samples were obtained 
from the tissue bank of the Erasmus University Medical Center. Collection of patient 
samples has been performed according to national legislation concerning ethical 
requirements. Use of these samples has been approved by the Erasmus MC Medical 
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Ethics Committee according to the Medical Research Involving Human Subjects Act 
(MEC-2004-261). NCBI build 36 (hg18) was used as a reference genome during the 
mapping and data analysis process. Rearrangements were identified from discordant 
paired sequence reads (discordant mate pairs), which were mapping to different 
chromosomes (translocations), different positions on the same chromosome 4400 
bp apart (deletions, inversions and duplications) or in unexpected orientations (small 
inversions and tandem duplications). The events are selected based on a minimum 
threshold of three discordant mate pairs having the same event. However, potential 
rearrangements were removed if there were any supporting discordant pairs for the 
same event in a panel of additional normal genomes that had already been sequenced 
by Complete Genomics (23) (Supplementary Methods). 
Illumina 1M SNP Array analysis
 
SNP array data from 47 PCa patients, 11 PCa xenografts, eight PCa cell lines and six 
non cancer patients were collected. Genotyping was performed using the Infinium 
Illumina Human 1M probe BeadChip containing 1’072’820 markers, among which 
206 665 are in reported CNV regions. The experiments were performed according to 
the manufacturer’s protocol (Illumina) by an accredited service provider (ServiceXS). 
Data analysis was performed using Nexus Copy Number5.0 (BioDiscovery). The Human 
1M CV HapMap control set provided by the manufacturer was used as a control. The 
algorithm used for the analysis was SNP-FASST Rank segmentation. Standard settings 
were adjusted: a significant threshold of 1.0E06,max contagious probe spacing 1000 kb, 
minimal number of probes per segment 15, high gain 0.6, gain 0.2, loss -0.2, big loss 
-1, homozygous frequency threshold 0.9, homozygous threshold 0.85, heterozygosity 
imbalance threshold 0.35 and minimum loss of heterozygosity (region with loss of 
heterozygosity) length of 5000 (kb). The plotted Log R Ratio and the B Allele Frequency 
by Nexus Copy Number 5.0were used to perform CNV calling. Log R Ratio is the ratio 
between the observed and the expected probe intensity. The expected probe intensity 
is an interpolation of the mean intensities of the surrounding probe clusters. The B Allele 
Frequency is a value between 0 and 1, which represents the proportion contributed by 
one SNP allele (B) to the total copy number. 
Affymetrix exon-array analysis
Exon-array data from 89 PCa patient samples, 11 PCa xenografts and 6 cell PCa cell lines 
were collected using the GeneChip Human Exon 1.0 ST Array (Affymetrix). The staining, 
washing and scanning procedures were performed according to the manufacturers 
protocol (Affymetrix). The processing and RMA quantile normalization of the data were 
performed using the R-package affy (http://www.bioconductor.org/packages/release/
bioc/manuals/affy/man/affy.pdf). The list of genes with DNA breakpoint originated 
from the SNP microarray data was analyzed to determine differential expression of 
exons in these genes (GSE41410). On the GeneChip Human Exon 1.0 ST Array, 5’362’207 
probes (on average 40 probesets per gene) are used to analyze one million exon 
clusters (collections of overlapping exons). The microarray chip is based on a selection 
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of validated and predicted gene locations. The file containing the raw intensity values 
for the core probes (derived from RefSeq transcripts or full-length mRNAs) was used to 
assess exon expression profile.
Cell culture
The PC346C cell line was cultured in DMEM-F12 (BioWhittaker), supplemented with 2% 
(volume/volume) FCS (PAN Biotech), 1% insulintransferrin-selenium (GIBCO BRL), 0.01% 
BSA (Boehringer), 10 ng/ml epidermal growth factor (Sigma-Aldrich, Milan, Italy) and 
500U penicillin–streptomycin (BioWhittaker), 100 ng/ml bronectin (Harbor BioProducts, 
Tebu-bio, The Netherlands), 20 mg/ml fetuine (ICN Biomedicals), 0.1 nM R1881 (Sigma-
Aldrich), 50 ng/ml cholera toxin (Sigma-Aldrich), 0.1mM phosphoethanolamine (Sigma-
Aldrich), 0.6 ng/ml triodothyronine (Sigma-Aldrich) and 500 ng/ml dexamethasone 
(Sigma-Aldrich). The PC346C cell line is an androgen-sensitive PCa cell line derived from 
the PC346P xenograft. It expresses the wild-type androgen receptor and secretes high 
levels of prostate-specific antigen. RWPE-1 cells were cultured in keratinocyte medium 
(GIBCO BRL), supplemented with 5 ng/ml epidermal growth factor, 1% penicillin–
streptomycin (BioWhittaker) and 50 mg/l bovine pituitary extract. RWPE-1 is a normal 
prostate epithelium cell line that is androgen-independent and expresses both the 
androgen receptor and prostate-specific antigen. Both cell lines were cultured at 37 
degrees with 5% carbon dioxide. 
RNA and DNA isolation
Total RNA was isolated from the PC346C, RWPE-1, PC346P and G089 using the RNeasy 
kit (Qiagen) and according to the manufacturer’s protocol. RNA was eluted in 50 ml of 
RNase-free water. Concentration and purity of RNA were assessed using the NanoDrop 
ND1000 spectrophotometer (Nanodrop products) by absorption measurements at 
260 nm. RNA was stored at -80 degrees. DNA was isolated using the QIAamp DNA 
Blood Midi Kit (Qiagen) according to the manufacturers’ instructions. Cell pellets were 
resuspended in 1 ml phosphate-buffered saline (BioWhittaker) and instructions were 
followed according to the protocol used for 1ml whole blood. DNA was eluted in 200 µl 
elution buffer. Concentration and purity of the DNA were assessed using the NanoDrop 
ND 1000 spectrophotometer (Nanodrop products) by absorption measurements at 280 
nm. DNA was stored at -20 degrees.
Sequencing
Purified PCR products have been sequenced bidirectionally using standard Sanger 
sequencing. A sequencing PCR was carried out using the same forward and reverse 
primers as used during the RT–PCR except with different primer concentrations 
(3 ng of primer per reaction) in a 20 ml reaction volume. The PCR product was 
sequenced on an ABI Model 3730 automated sequencer and analyzed using DNAMAN 
(Lynnon Corporation). 
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RT–PCR 
Complementary DNA (cDNA) was synthesized using 1 mg total RNA, M-MLV reverse 
transcriptase kit (Promega) and Oligo (dT) primer (Invitrogen) according to the 
manufacturer’s protocol. Reverse transcription was performed at 37 degrees Celsius 
for 60 min and 95 degrees Celsius for 10 min. Reverse transcription PCR for multiple 
fusions was carried out by amplification of the cDNA or DNA samples with the 
HotstarTaq Kit (Qiagen). For the standard PCR reactions, 1 µl of cDNA was used in a 50 
µl reaction containing 5 ml 10x PCR Buffer, 2 µl of each primer solution (100 mM), 0.25 
µl HotstarTaq (5 units/ml), 1 ml of dNTPs (10mM) and 40.75 µl of nuclease-free water. 
An initial denaturation step of 15 min at 95 1C was used to activate the HotstarTaq, 
followed by 35 cycles consisting of a denaturation step at 95 1C for 30 s, an annealing 
step at 55 1C for 30 s and an elongation step at 72 1C for 1 min. A final elongation step 
at 72 1C for10 min was used. PCR products were checked using electrophoresis of20 
ml of product in a 1% agarose gel. Products of the expected size were extracted from 
the agarose gel using the Nucleospin Extract II Kit (Macherey-Nagel), according to the 
manufacturer’s protocol. 
Real Time–PCR 
Quantitative PCR was performed using SYBR Green dye and TaqMan gene expression 
assays on an Applied Biosystems StepOne Real Time – PCRsystem (Applied Biosystems). 
All reactions were performed with SYBR Green Master Mix (Applied Biosystems) and 
25 ng of both the forward and reverse primer using the manufacturer’s recommended 
thermocycling conditions. The TaqMan gene expression assays consisted of a 
combination of custom primers and probes targeting MPP5–FAM71D and FAM71D. 
Oligo probe MF — 5’ TCA GGT CAA CAG AAG AGG TGA 3’ - 5’FAM 3’TAMRA and primers 
5’ TCT CCA ACG CAC AAG ATC TT 3’ (F0) and 5’ CAG TTG GCT CGG TTA TGA AGG 3’ (R0) 
were designed to target the MPP5–FAM71D fusion. Oligo probe F — 5’ CTC CTG ACA 
TCT CCT CCT GC 3’ - 5’FAM 3’TAMRA and primers 5’ CTA CTG GCC CAT CTG ACA CC 3’ 
(F0) and 5’ AGG CTC ATG TTC TCC GCA T 3’ (R0) were designed to target FAM71D. The 
comparative threshold cycle (Ct) method and the quantitative standard curve method 
were used to quantify the expression of the target genes. Equal efficiencies of the 
primers were confirmed using serial dilutions of PCa cDNA. Products from the PCR were 
resolved by electrophoresis on 1%agarose gels and sequenced as described above if 
necessary. Quantitative PCR expression values for the TaqMan gene expression assays 
were normalized by the expression of the housekeeping genes GAPDH and/or PBGD. 
Functional role of FAM71D in the PC346C cell line
The functional role of FAM71D in the PC346C cell line was assessed with the knockdown 
of both FAM71D and MPP5–FAM71D fusion gene. Proliferation assays were performed 
at different time points. The small interfering RNA reagent siGENOME SMARTpool, 
Human FAM71D (ThermoFisher Scientic) interacts with a part of the FAM71D gene, 
which is also present in the fusion. Briefly, PC346C and RWPE-1 (control) cells were 
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plated in 96-well culture plates at a density of 2000 cells per well (100 ml) and plated in 
T25 tissue flasks. Outer wells of the culture plates were filled with phosphate-buffered 
saline in order to avoid culturing artifacts in the proliferation assays. After 2 days, 
cells were washed using phosphate-buffered saline and transfected using siGENOME 
SMARTpool, Human FAM71D (final concentration of 100 nM) and Dharmafect3 reagent 
according to the manufacturer’s protocol (Thermo Scientific) in medium without P/S. 
As negative controls, medium only, Dharmafect with water and a transfection with non-
targeting small interfering RNA were included. Twenty-four hours after transfection 
the medium was replaced with normal medium, without P/S and cells were allowed 
to grow for a maximum of 4 days. Proliferation was assessed using the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega) according to the manufacturer’s protocol. 
Apoptosis was assessed using the ApoLive-Glo MultiplexAssay (Promega) that measures 
both the number of viable cells as a marker of cytotoxicity and caspase activation as 
a marker of apoptosis within a single assay well. The assay was performed according 
to the manufacturer’s protocol. As positive control of apoptosis an apoptosis inducer 
set (Millipore) is used. A mix containing 700x dilutions of Actinomycin D (10mM), 
Camptothecin (2mM), Cycloheximide (100mM), Dexamethasone (10mM) and Etoposide 
(10mM) was used for 24 h to induce apoptosis in both PC346C and RWPE-1 cell lines.
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Supplementary data
CompleteID GS00241-DNA_D03 GS00241-DNA_E03 GS00241-DNA_F03
SampleID RVM2-LT G089 PC346C
Gender MALE MALE MALE
GenomeSize 2.768 2.768 2.768
Coverage 62.23265896 61.1849711 67.42052023
Gross mapping yield (Gb) 172.26 169.36 186.62
SNP Transitions/transversions 2.14 2.12455 2.19367
SNP het/hom ratio 2.14 1.11279508 1.497774806
INS het/hom ratio 1.71 1.01138642 1.645551705
DEL het/hom ratio 2.57 1.249980157 2.640563175
SUB het/hom ratio 2.42 1.362113191 1.695779779
SNP total count 3881532 2980648 3409249
INS total count 214311 178001 202800
DEL total count 225761 182105 618504
SUB total count 78182 62590 81190
SNP novel rate 14.09% 6.60% 11.29%
INS novel rate 28.88% 21.49% 35.06%
DEL novel rate 33.29% 23.05% 69.04%
SUB novel rate 40.67% 34.15% 44.94%
Fully called genome fraction 95.19% 93.85% 95.96%
Partially called genome fraction 0.91% 1.50% 0.64%
No-called genome fraction 3.89% 4.66% 3.40%
Synonymous SNP loci 11306 8118 9752
Missense SNP loci 10623 8084 10542
Nonsense SNP loci 111 83 171
Nonstop SNP loci 29 22 31
Frame-shifting INS loci 126 113 188
Frame-shifting DEL loci 142 103 458
Frame-shifting SUB loci 10 20 20
Frame-preserving INS loci 116 97 112
Frame-preserving DEL loci 121 98 135
Frame-preserving SUB loci 274 238 266
Frame-shifting/preserving ratio 0.544031311 0.545034642 1.298245614
Nonsyn/syn SNP ratio 0.939589598 0.995811776 1.081009024
Insertion/deletions ratio 0.949282648 0.977463551 0.327887936
Ins+del/SNP ratio 0.113375853 0.120814668 0.240904668
Coding insertion/deletions ratio 0.735426009 0.831325301 0.416206262
Coding SNP/all SNP ratio 0.006213268 0.006192278 0.006665984
Coding (ins+del)/all (ins+del) ratio 0.000879402 0.000844196 0.000936316
Table S1: Overview of the CGI data generated for the G089 and PC346C samples
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Figure S1: Coverage plots of all chromosomes in PC346C (A) and G089 (B)
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Table S2: Normal genome dataset sequenced by Complete Genomics Inc.
ASW:   African ancestry in Southwest USA NA19700 LWK:   Luhya in Webuye, Kenya NA19017
NA19701 NA19020
NA19703 NA19025
NA19704 NA19026
NA19834 MKK:   Maasai in Kinyawa, 
Kenya
NA21732
CEU:   Utah residents with Northern and 
Western European ancestry from 
the CEPH collection
NA06985 NA21733
NA06994 NA21737
NA07357 NA21767
NA10851 MXL:   Mexican ancestry in Los 
Angeles, California
NA19735
NA12004 NA19648
CHB:   Han Chinese in Beijing, China NA18526 NA19649
NA18537 NA19669
NA18555 NA19670
NA18558 TSI:  Toscans in Italy NA20502
GIH:   Gujarati Indian in Houston, Texas, 
USA
NA20845 NA20509
NA20846 NA20510
NA20847 NA20511
NA20850 YRI:   Yoruba in Ibadan, Nigeria NA18501
JPT:   Japanese in Tokyo, Japan NA18940 NA18502
NA18942 NA18504
NA18947 NA18505
NA18956 NA18508
NA18517
NA19129
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Figure S2: Structural variations assembled in G089 and PC346C
Table S3: Structural variations within genes on both junctions in the 2 prostate cancer samples corrected 
for SVs in control samples
Table S4: Structural variations within genes in the 46 normal samples
type of SV gene both sides same gene on both sides different gene on both sides
--> --> or <-- <-- --> <-- or <-- --> --> --> or <-- <-- --> <-- or <-- -->
 G089 PC346C G089 PC346C G089 PC346C G089 PC346C G089 PC346C
interchrom. 18 5 0 0 0 0 7 4 11 1
intrachrom. 174 101 138 82 21 10 8 9 7 0
type of SV gene both sides same gene on both sides different gene on both sides
--> --> or <-- <-- --> <-- or <-- --> --> --> or <-- <-- --> <-- or <-- -->
interchrom. 205 0 0 114 91
intrachrom. 4329 3858 429 24 18
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Table S5: Inventory of the interchromosomal SV events with genes on both sides and the intrachromosomal 
SV events with different genes on both sides in all the 46 normal samples (all the fusions reported have 
the same orientation)
LeftChr LeftPosition RightChr RightPosition Left gene Right gene Incidence DiscordantMatePair 
Alignments
chr6 24791966 chr22 31258560 ACOT13 SYN3 6 in 46 143
chr2 114423020 chrX 44717703 ACTR3 KDM6A 1 in 46 3
chr12 4613176 chr12 7243075 AKAP3 PEX5 3 in 46 7
chr2 73642308 chr7 125890311 ALMS1 GRM8 1 in 46 101
chr4 114128776 chr6 57417655 ANK2 PRIM2 1 in 46 93
chr22 34927633 chr22 34981344 APOL4 APOL1 1 in 46 4
chr3 56740660 chr7 147170604 ARHGEF3 CNTNAP2 4 in 46 133
chr7 97334171 chr8 87780406 ASNS CNGB3 4 in 46 25
chr12 55276363 chr15 37781916 BAZ2A FSIP1 1 in 46 161
chr2 60598575 chr3 14519784 BCL11A GRIP2 2 in 46 85
chr3 114462290 chr10 60051725 BOC BICC1 2 in 46 3
chr1 109452157 chr22 28493372 C1orf194 UQCR10 1 in 46 7
chr5 175666015 chr18 53532573 C5orf25 ATP8B1 1 in 46 6
chr6 121589790 chr16 87294265 C6orf170 RNF166 2 in 46 45
chr8 96334897 chr19 18696612 C8orf37 CRTC1 2 in 46 56
chr7 44260822 chr10 60738301 CAMK2B FAM13C 1 in 46 5
chr7 26219493 chr15 38641486 CBX3 C15orf57 6 in 46 40
chr7 80075314 chr8 25228569 CD36 DOCK5 1 in 46 4
chr1 1609907 chr1 1662846 CDK11B SLC35E2 1 in 46 4
chr1 16249105 chr1 16258921 CLCNKB FAM131C 3 in 46 11
chr8 88045498 chr9 117184202 CNBD1 DEC1 1 in 46 4
chr1 86171219 chr9 99715354 COL24A1 C9orf156 5 in 46 67
chr1 33896536 chr20 40323470 CSMD2 PTPRT 1 in 46 67
chr12 56506829 chr15 36538458 CTDSP2 FAM98B 5 in 46 8
chr19 46041457 chr19 46073355 CYP2A6 CYP2A7 1 in 46 3
chr1 85756077 chr1 210549248 DDAH1 PPP2R5A 1 in 46 3
chr11 108090957 chr13 20640540 DDX10 SKA3 1 in 46 14
chr11 84872658 chr17 30502225 DLG2 UNC45B 1 in 46 3070
chr11 84872657 chrX 47634658 DLG2 ZNF81 2 in 46 4
chr10 128606023 chr13 44660068 DOCK1 GTF2F2 1 in 46 4
chr2 116093152 chr9 130498485 DPP10 SET 3 in 46 15
chr2 115411737 chr17 30502225 DPP10 UNC45B 2 in 46 129
chr2 62811531 chr14 66581210 EHBP1 GPHN 2 in 46 10
chr14 66903963 chr14 66932740 EIF2S1 PLEK2 3 in 46 35
chr13 42967826 chr15 39638687 ENOX1 TYRO3 1 in 46 14
chr12 1463516 chr12 20577913 ERC1 PDE3A 2 in 46 7
chr6 133635641 chr16 46096510 EYA4 PHKB 2 in 46 5
chr2 70377092 chr2 179004389 FAM136A PRKRA 1 in 46 3
chr2 75587805 chr7 103207935 FAM176A RELN 1 in 46 4
chr4 46662762 chr22 27395456 GABRA4 TTC28 1 in 46 31
chr1 89371762 chr1 89424837 GBP7 GBP4 1 in 46 21
chr7 2748187 chr7 26189704 GNA12 NFE2L3 1 in 46 5
chr14 24146348 chr14 24171060 GZMH GZMB 1 in 46 8
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Table S5: Continued
LeftChr LeftPosition RightChr RightPosition Left gene Right gene Incidence DiscordantMatePair 
Alignments
chr1 91625370 chr7 48642900 HFM1 ABCA13 2 in 46 37
chr1 91625736 chr10 50581095 HFM1 C10orf53 1 in 46 3
chr1 91625370 chr4 108144352 HFM1 DKK2 2 in 46 4
chr1 91625736 chr11 77275449 HFM1 INTS4 1 in 46 5
chr1 91625370 chr12 84086888 HFM1 LRRIQ1 1 in 46 11
chr1 91625370 chr22 20540553 HFM1 MAPK1 2 in 46 10
chr1 91625370 chr2 159149043 HFM1 PKP4 1 in 46 50
chr1 91625370 chr4 77026210 HFM1 PPEF2 2 in 46 245
chr1 91625736 chr1 235833345 HFM1 RYR2 2 in 46 12
chr1 91625370 chr17 72669985 HFM1 SEC14L1 3 in 46 88
chr1 91625736 chr8 70764802 HFM1 SLCO5A1 1 in 46 18
chr1 91625370 chr7 104753533 HFM1 SRPK2 1 in 46 11
chr1 91625736 chr6 144733889 HFM1 UTRN 1 in 46 4
chr6 32600654 chr6 32660804 HLA-DRB5 HLA-DRB1 2 in 46 3
chr3 123981035 chr10 17752794 HSPBAP1 STAM 1 in 46 7
chr2 149355896 chr5 79983676 KIF5C DHFR 1 in 46 6
chr17 36760562 chr17 36779545 KRT33A KRT33B 2 in 46 9
chr12 51130451 chr12 51171567 KRT6B KRT6A 1 in 46 4
chr7 55414342 chr12 4814579 LANCL2 KCNA6 1 in 46 6
chr1 26610053 chr2 179030761 LIN28A DFNB59 1 in 46 3
chr6 119600390 chr19 40838511 MAN1A1 COX6B1 1 in 46 16
chr6 119600398 chr10 35350401 MAN1A1 CUL2 10 in 46 27
chr6 119600259 chr17 28173963 MAN1A1 MYO1D 5 in 46 40
chr6 119600395 chr8 69051583 MAN1A1 PREX2 5 in 46 23
chr6 74212891 chr14 70550021 MB21D1 PCNX 1 in 46 3
chr3 184515406 chr8 66742065 MCF2L2 MTFR1 1 in 46 4
chr2 227902744 chr5 149292455 MFF PDE6A 1 in 46 8
chr6 31485269 chr6 31579996 MICA MICB 1 in 46 4
chr6 43763511 chr9 33120548 MRPS18A B4GALT1 1 in 46 16
chr2 42687780 chr10 72118662 MTA3 ADAMTS14 1 in 46 4
chr11 76581513 chr19 14567841 MYO7A CLEC17A 7 in 46 14
chr3 176583069 chr7 96161255 NAALADL2 SHFM1 1 in 46 3
chr1 143391395 chr1 143665970 NBPF9 PDE4DIP 1 in 46 3
chr6 126274506 chr8 48655786 NCOA7 KIAA0146 1 in 46 28
chr6 126280035 chr20 33881165 NCOA7 PHF20 1 in 46 24
chr17 26575403 chr19 19493427 NF1 NDUFA13 1 in 46 3
chr3 175093152 chr20 40323474 NLGN1 PTPRT 1 in 46 109
chrX 6148397 chrY 15152001 NLGN4X NLGN4Y 4 in 46 7
chr1 120345451 chr6 133635756 NOTCH2 EYA4 8 in 46 27
chr1 120345412 chr16 46096541 NOTCH2 PHKB 7 in 46 33
chr1 143988802 chr6 133635754 NOTCH2NL EYA4 6 in 46 29
chr1 143988894 chr16 46096578 NOTCH2NL PHKB 8 in 46 12
chr1 198334303 chr2 23551752 NR5A2 KLHL29 2 in 46 51
chr11 47763216 chr15 73654668 NUP160 PTPN9 1 in 46 3
chr12 20595770 chr14 89411235 PDE3A EFCAB11 1 in 46 3
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Table S5: Continued
LeftChr LeftPosition RightChr RightPosition Left gene Right gene Incidence DiscordantMatePair 
Alignments
chr1 66397553 chr11 8136900 PDE4B RIC3 1 in 46 4
chr5 32141959 chr5 32203532 PDZD2 GOLPH3 1 in 46 21
chr12 7247092 chr20 40997762 PEX5 PTPRT 1 in 46 3
chr6 13299425 chr17 62067736 PHACTR1 PRKCA 1 in 46 121
chr7 621590 chr10 128606010 PRKAR1B DOCK1 1 in 46 5
chr1 212723427 chr5 115205559 PTPN14 AP3S1 2 in 46 6
chr15 73654668 chr17 62977033 PTPN9 PITPNC1 1 in 46 4
chr14 72621755 chr14 72678268 RBM25 PSEN1 5 in 46 13
chr12 55275617 chr15 37781922 RBMS2 FSIP1 1 in 46 197
chr3 124135562 chr12 48178954 SEMA5B SPATS2 3 in 46 4
chr10 82333232 chr17 8802559 SH2D4B PIK3R5 2 in 46 80
chr1 115124725 chr1 216013856 SIKE1 SPATA17 1 in 46 26
chr20 1540516 chr20 1843589 SIRPB1 SIRPA 1 in 46 6
chr14 36701360 chr14 36840980 SLC25A21 MIPOL1 1 in 46 6
chr1 9044032 chr14 92782930 SLC2A5 BTBD7 5 in 46 112
chr6 88274265 chr20 51455050 SLC35A1 TSHZ2 2 in 46 38
chr2 213879355 chr7 28346689 SPAG16 CREB5 2 in 46 6
chr2 213879333 chr6 31585828 SPAG16 MICB 1 in 46 3
chr3 137710453 chr16 14488371 STAG1 PARN 4 in 46 13
chr7 23727175 chr8 52895822 STK31 PCMTD1 1 in 46 6
chr8 133989904 chr14 50567849 TG TRIM9 1 in 46 4
chr1 15390838 chr2 227930141 TMEM51 MFF 1 in 46 8
chr2 27380758 chr3 196408092 TRIM54 C3orf21 1 in 46 5
chr15 39640800 chr15 74340792 TYRO3 ETFA 1 in 46 3
chr3 48622068 chr8 52818266 UQCRC1 PXDNL 1 in 46 11
chr1 21898605 chrX 1575602 USP48 P2RY8 1 in 46 5
chr12 94204809 chr15 38641471 VEZT C15orf57 1 in 46 5
chr5 37745606 chr7 8629826 WDR70 NXPH1 4 in 46 57
chr1 68401586 chr10 126830121 WLS CTBP2 1 in 46 3
chr7 63927371 chr19 20921389 ZNF138 ZNF85 1 in 46 5
chr12 132289429 chr20 44564610 ZNF268 ZNF334 3 in 46 6
chr10 38350357 chr10 42443852 ZNF33A ZNF33B 3 in 46 12
chr19 58628530 chr19 58665341 ZNF761 ZNF813 1 in 46 6
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Figure S3: Mapped reads of the validated gene fusions. The upper and lower part of each of the outputs 
corresponds to the PC346C and G089 sample respectively. The grey reads represent the mapped reads 
according to the reference genome. Colored reads are discordant mate pairs mapping to different 
genomic locations.
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Figure S3: Continued
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes FAM71D MPP5
chr14:66,736,867-66,738,867 chr14:66,837,512-66,839,512
chr14chr14
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes PHRF1 TSPAN4
chr11:595,684-597,684 chr11:835,636-837,636
chr11chr11
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes RNF19A SNX31
chr8:101,386,364-101,388,364 chr8:101,714,824-101,716,824
chr8chr8
94
Figure S3: Continued
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Figure S3: Continued
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Figure S3: Continued
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Figure S3: Continued
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Figure S3: Continued
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes PARD3 CCNY
chr10:35,645,801-35,647,801chr10:35,047,047-35,049,047
chr10chr10
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes OBP2B OBP2A
chr9:137,578,803-137,580,803chr9:135,070,969-135,072,969
chr9chr9
G089 Breaks
G089_Coverage
G089 _Mate_Pairs
PC346c Breaks
PC346_Coverage
PC346_Mate
_Pairs
RefSeq genes ZNF469 ZFPM1
chr16:87,081,402-87,083,402chr16:87,029,612-87,031,612
chr16chr16
99
3
Next-generation sequencing reveals novel rare fusion events with functional implication in prostate cancer
Figure S4: RT-PCR of the validated RNA fusions of PC346C and G089 (electrophoresis on a 1% 
agarose gel). 
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Figure S5: RT-PCR of the validated DNA fusions of PC346C and G089 (electrophoresis on a 1% 
agarose gel)
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Table S6: Primers for the validation of the fusions on RNA level (PC346C sample)
1 TG Fw AAGGAAGCCACCGTCATGTGCG 389
TRIM9 Rv TTCACTCCTAAACGCTCCCTGGTC
2 ATP6V0A4 AGTGGAGGGAGGCAAAGG 535
PHACTR4 CAGCAATGACAGGGTTGCTA
3 MPP5 Fw TGGTAGATTCTCAGAGCCAGGAGGA 369
FAM71D Rv ACGGTCACCCAGTTGGCTCG
4 TSPAN4 Fw AGAGCCAGGTTCAGCTGCGA 400
PHRF1 Rv GGCAAGTCCAGCCTCACAGGC
5 RNF19A Fw TTCGGGAAAGCGGCCGTCG 394
SNX31 Rv AGCCCAAGAGCTCTCGACACAGTC
6 GTF2H5 Fw CATCAGTAAATCTGTACTGCCCGAG 365
SYNJ2 Rv TCTAGAAGGTTGAGTTCTCCAGCTG
7 DCAF6 Fw AGACGCTCTGCTGTTGCCCGTA 389
MPZL1 Rv AAGGTCTCCAGCCCAGCTGATTCTG
8 PTCRA Fw CCGGTACATGGCTGCTACTT 175
ENPP3 Rv AGCCGTGGGTGATATTCTTG
9 HLA-DRB1Fw TGGTCCTGTCCTGTTCTCCAGCATG 329
HLA-DRB5 Rv CGGCGCGCCTGTCTTCCAGG
10 CTBP2 Fw CATTTTAAGGTGGCTCGGGAGCGG 282
WLS Rv TTCAGTCCACTCAGCAAACGCGT
11 THADA Fw TGCTGCGCTGACCATTTGCCAT 437
MAP4K3 Rv TTCTGGCACCATTTGGTTTCAGGG
12 CBX3 Fw GGTGTTGGCAGTTTAGGACCTGCT 197
C15orf57 Rv TTGGCTTGGGCCAGAGTTCGAA
102
Table S7) Primers for the validation of the fusions on RNA level (G089 sample)
1 ARHGEF3 Fw AACGGCAGCGGCAAAACAACTT 570
C8orf38 Rv GCAAGTGTGCTTGACTGGCAATGTC
2 LRBA Fw TTCAACTTCCCAGACCCTGCAACAG 452
NFKB1 Rv CCAAGTGCAAGGGCGTCTGGTAC
3 FCRL1 Fw ATCCCTGACCTGGTCCTCAT 335
RASAL2 Rv TGACTGGCTTTTGGTCCTCT
4 AATK Fw CGCCTTCAGCTCGCACTTCGA 377
LAMA5 Rv CAGGCTGGCATAGGCAGCGG
5 SERF2 Fw AGAGGATGGCTGACACGAAG 152
PDIA3 Rv GTCCTGAGAGGCACTGAAGC
6 GABPB2 Fw CCAGCAAGTAATGGGGAGTG 189
BNIPL Rv ATGTCTCAGGGCTGCTCCTA
7 LAMA5 Fw GAGGACCTGACGGGTCGATGC 183
AATK Rv TCGTCCCCCTCCGCATTCTCAAAC
8 DOCK1Fw GCGGCCTAGACGCGGAGTTTCC 161
GTF2F2 Rv TTTCACTGGCAGCTGGTCGGCAT
9 NFKB1 Fw ACTACGCGGTGACAGGAGAC 115
FAM160A1 Rv TGCTGGAAACCCCTAGAAGA
10 CBX3 Fw ACTGCCATCACAGCAGGTTTCCT 399
C15orf57 Rv TCGTCCTCGGCCACTGGCTT
11 CCNY Fw GGAAATCGTGCAGTGAACCT 325
PARD3 Rv TCCTGCTCATCAAACACTGC
12 OBP2A Fw CACCCTGGAGGAGGAGGATGAGG 232
OBP2B Rv AGAGTCCCTTGCGCTGCACC
13 ZFPM1 Fw GAGACATGGAGGCCAGAGAG 188
ZNF469 Rv GCACAGGTCTTGCATCTCAA
14 C15orf57 Fw CGCTGACTCTACAGCCACAA 416
CBX3 Rv AATCCCTTCCACTTCAGGAAA
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Table S8: Primers for the validation of the fusions on DNA level (PC346C sample)
1 TG Fw G TCTCCCCAAAGAGCAAAGAGGTGAT 591
TRIM9 Rv G TGTAGGTACACTGTGGTGGCCATTT
2 PHACTR4 Fw G AACACAGAAGCATGTACTGCAGGCT 481
ATP6V0A4 Rv G CCTGACAGAGCCAGGAGCAAGAAGA
3 FAM71D Fw G AGCTGATGCCCTGGGGCTCT 213
MPP5 Rv G AACAGGCACTTTTACTGGCCCACG
4 PHRF1 Fw G GAGCCGTCGCGGTGGATGATGA 409
TSPAN4 Rv G GGCTCTATGGTTCCCTCCTGCCCTT
5 RNF19A Fw G GGGAGACCCCTGAGGATAAA 395
SNX31 Rv G CATGGCTTCCTGGTAAGGAC
6 SYNJ2 Fw G TGCCTTGAGTGCTCGTGCAGC 446
GTF2H5 Rv G TTGCAAAAATCTGTGGTGCAGCTTG
7 MPZL1 Fw G GTGCAGTGGCATAAACATGG 147
DCAF6 Rv G TTTTGGAGAGAAGGATTTGGA
8 PTCRA Fw G AAATAACATTCTGGGCCAGGT 128
ENPP3 Rv G GAAACAGGGTTTTGCCATGT
9 HLA-DRB5 Fw G ACTGTCACTGTGGCTTGCAT 254
HLA-DRB1 Rv G TCTATCTGGGCATGTGTTCA
10 WLS Fw G TGTCCAATTGCTGTCTCTTGA 200
CTBP2 Rv G GGTAGGAGCCTCGAGACCA
11 MAP4K3 Fw G TCTTCGGCACCAAATATCAA 174
THADA Rv G GCCAGGAAATTCGAGTGATG
12 CBX3 Fw G GTTCAGCAAAAGCCAGGAAG 171
C15orf57 Rv G ATACTATGGCCGCAGGACAG
13 RBM8A Fw G TCAAAACAAGGCTGTGGACCAAACT 503
ITGA10 Rv G CAAGCCCTTGCGGCTGCTCA
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Table S9: Primers for the validation of the fusions on DNA level (G089 sample)
1 ARHGEF3 Fw G AGGTAAATGCCTTGTGGGTCT 154
C8orf38 Rv G ACGCAAAGAAAGGCTATGGA
2 NFKB1 Fw G GAATGAAGGTGGATGATTGCT 233
LRBA Rv G CCAGGAGGGCATTATTTTGA
3 FCRL1 Fw G CATAGCTCCCCATCACACCT 427
RASAL2 Rv G CCACACTCGAGACAGGGTTT
4 AATK Fw G TCAATCTGCAAAGGGGAGTC 369
LAMA5 Rv G GTGGGCGCCTATAATCAGTC
5 PDIA3 Fw G TGCTGCTGTGGATATAGGTG 292
SERF2 Rv G CCATGAATCAGGTTGCAGTG
6 BNIPL Fw G CAAGTGGCTGGAACCCAGCTAG 583
GABPB2 Rv G GCACACCAACCTGGGTAACAGAG
7 AATK Fw G GGTTTGCAGGGGGAGGAG 157
LAMA5 Rv G TGGGGTTTTATTTTCTTTCAACC
8 DOCK1 Fw G CTGCCTAGAGAGTGCGGTGGTG 600
GTF2F2 Rv G CATGAACAGGTCTCCCCAAAATGCAC
9 NFKB1 Fw G TCTGGGCTGGAAGCCTCAGTGTG 369
FAM160A1 Rv G CTTGGCAGCAGAAAGAAAAACCACC
10 CBX3 Fw G GTTCAGCAAAAGCCAGGAAG 171
C15orf57 Rv G ATACTATGGCCGCAGGACAG
11 PARD3 Fw G GGTGGCAGGTGCCTTAATC 559
CCNY Rv G CATGCAGGGCTAAGTGCTATC
12 OBP2B Fw G GACCCTCCTACACCCGAGAC 410
OBP2A Rv G GGGCACTGAAGACCCATCT
13 ZNF469 Fw G TCGCCGTGCCCTCGAAGTCTAA 252
ZFPM1 Rv G ATGGGCGCGATAACACAGCAGCG
14 CBX3 Fw G CGTGTGGCATCTGAAGCA 223
C15orf57 Rv G CGTGACTACCCGAACAGCTC
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* MPP5 (ENST00000261681) Exon 5 FAM71D (ENST00000311864) Exon 4
ACTGCTTTGCTGAATACTCCACATATTCAG 
-T--A--L--L--N--T--P--H--I--Q-
GTCAACAGAAGAGGTGAATCCATTTACCTT      
-V--N--R--R--G--E--S--I--Y--L-
TSPAN4 (ENST00000397406) Exon 1 PHRF1 (ENST00000264555) Exon 13
TCAGCTGCGAGGCTGCTGGTGGCTGTGGAG
..............................
GAGGCGCCTCCCTGCCGCGGTGCCAGAGCC       
--R--R--L--P--A--A--V--P--E--P
RNF19A (ENST00000341084) Exon 1 SNX31 (ENST00000311812) Exon 4
CTGCGCTGCCGCCGCTCTGAGGAGTTAAAG
..............................
TAACCATGGACCCAAACGTGTTGAGAAGTG
V--T--M--D--P--N--V--L--R--S--
RNF19A (ENST00000341084) Exon 1 SNX31 (ENST00000311812) Exon 5
CTGCGCTGCCGCCGCTCTGAGGAGTTAAAG
..............................
AATACATTTGACATCGCCACCAAGAAAGCT
-N--T--F--D--I--A--T--K--K--A-
DCAF6 (ENST00000312263) Exon 15 MPZL1 (ENST00000359523) Exon 2
TATAAAGGCCATCGCAACTCCAGGACAATG
-Y--K--G--H--R--N--S--R--T--M-
TGACAGCTGGAGTATCAGCCTTGGAAGTAT
L--T--A--G--V--S--A--L--E--V--
THADA (ENST00000405975) Exon 4 MAP4K3 (ENST00000263881) Exon 24
AAAGAATCCCTTGAAGAAAGTATTGGCAAG
--K--N--P--L--K--K--V--L--A--S
ATCAGTACTTGATATTTGGTGCCGAAGAAG
D--Q--Y--L--I--F--G--A--E--E--
* ARHGEF3 (ENST00000338458) Exon2 C8orf38 (ENST00000396124) Exon 3
CCCTCTCCTAAAGCCTGGAATTTCAGAGGG
-P--S--P--K--A--W--N--F--R--G-
GTTAAAGACTCAGTCTCTGAGAAAACAATT
-V--K--D--S--V--S--E—K--T--I-
* ARHGEF3 (ENST00000338458) Exon 2 C8orf38 (ENST00000396124) Exon 4
CCCTCTCCTAAAGCCTGGAATTTCAGAGGG
-P--S--P--K--A--W--N--F--R--G-
GCTGTTAAAAGACATAATCTGACTAAAAGA
-A--V--K--R--H--N--L--T--K--R-
LRBA (ENST00000357115) Exon 45 NFKB1 (ENST00000394820) Exon 16
TTGCCCACCAACTTCAGAGATTTGTCCAAG
-L--P--T--N--F--R--D--L--S--K-
TGTCTTACACTTAGCAATCATCCACCTTCA
--V--L--H--L--A--I--I--H--L--H
SERF2 (ENST00000381359) Exon 1 PDIA3 (ENST00000300289) Exon  4
ACCGCTCTGAAACCGATTTCTAACAGAGAG
..............................
ATGGAATTGTCAGCCACTTGAAGAAGCAGG
D--G--I--V--S--H--L--K--K--Q--
GABPB2 (ENST00000368918) Exon 7 BNIPL (ENST00000368931) Exon 2
TTATTGTAACTGTGCAAGATGGACAGCAAG
F--I--V--T--V--Q--D--G--Q--Q--
GGTCAGGGAGATTGCAGAAGCACCAGAACT
--V--R--E--I--A--E--A--P--E--L
LAMA5 (ENST00000252999) Exon 11 AATK (ENST00000326724) Exon 3
AGCAGGTGCTGCCAGCCGGCCAGATTGTGA
E--Q--V--L--P--A--G--Q--I--V--
GAGTTTGAGAATGCGGAGGGGGACGAGTAC
-E--F--E--N--A--E--G--D--E--Y-
Table S10: RNA alignment of the validated gene fusions for PC346C and G089. The sequencing data 
was used to predict the gene fusions at RNA level. The RNA sequences and the corresponding protein 
translations of the first 30 bp before and after the junctions obtained by sequencing of the PCR products 
are depicted below. * represents the fusions in frame.
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MPP5 (ENST00000261681) Exon 6 FAM71D (ENST00000311864) Intron 3-4
TGCAGCTAGAGCCCATTACAGATGAGAGAG TAGGATGGCGCTACTGCACTCCAGCCTGGA
TSPAN4 (ENST00000397397) Intron 1-2 PHRF1(ENST00000264555) Intron 12-13
AGGAGGAGGACAGACTCCCCAGCCTGGCAC CCTGGGTGCGGGCCCTCAGGCCGTGGGAG
RNF19A (ENST00000341084) Intron 1-2 SNX31 (ENST00000311812) Intron 3-4
GATAAATATTATATAACGTATTAATATAAA TAATTTTTGTATTTTTTTAGTAGAGATGGG
ATAAAAAAAGAGAACATTAAGCAGGGCATTAATATAAAAATTAATA
DCAF6 (ENST00000312263) Intron 15-16 MPZL1 (ENST00000359523) Intron 1-2
TGATTGCAAAAAATTGTC AAATATTGCCTGGGCAACATGGCAAAACTG
THADA (ENST00000405975) Intron 4-5 MAP4K3 (ENST00000263881) Intron 23-24
TGGGGCTATTAGATTGTCAGATTTTTAATA ATCAGTCAGTGAATTACTTTTATTTCAGAT
ATTTAAAAATATTTTATTT
ARHGEF3 (ENST00000338458) Intron 2-3 C8orf38 (ENST00000396124) Intron 2-3
GAGAAGGAGTCTTGCTCTGTCACCCAGGCT TTTATTCTGGAACATTTCCATAGCCTTTCT
LRBA (ENST00000357115) Intron 45-46 NFKB1 (ENST00000394820) Intron 15-16
TAGAGCCTTGCTTTCATGCCCAGTCTGACA ATTCAAAACATTTTAGGGCCAAATAAAACT
TGGTATTCGAGTAT
GABPB2 (ENST00000368918) Intron 7-8 BNIPL (ENST00000368931) Intron 1-2
AATGGGAAATAGGGCCGGGCTCAGTGGCTC TTACTGGGTCAAATCTCGGGTTCCTCAAGG
LAMA5 (ENST00000252999) Intron 11-12 AATK (ENST00000326724) Intron 2-3
TTGCTGCATCGTGGTTAGAATTGGCACACT GCCTGGCCTCACTAGGCTGCCCCTCTGGAG
TAACCT
CCNY (ENST00000374706) Intron 3-4 PARD3 (ENST00000374789) Intron 1-2
GTTCTAGGCTGCAGTGAGCCATGATTGTGC CTCAATTCAACGTATCAGTATATTGTGGGG
ZFPM1(ENST00000319555) Intron 2-3 ZNF469 (ENST00000437464) Exon 2
ATAGCCAAAAATAATAGGACTTTTATACTG TGTGACGGTGGGCTTCCCGGGAACACCCAC
AATK (ENST00000326724) Intron 2-3 LAMA5 (ENST00000370691) Intron 11-12
GGACGATGTGTGATGCTAGAGCCCAGCCTG TGAGATTTTCTTTGTTTCTAACCTAGAATG
ITGA10 (ENST00000369304) Intron 23-24 RBM8A (ENST00000330165) 3' downstream
CACTTTGGGAGGCTGAGGCGGGCGGATCAC GAGAAGACAGAAGTAGAACATGACACAGAC
FCRL1 (ENST00000368176) Intron 1-2 RASAL2 (ENST00000263528) Intron 3-4
CAGTTAAGACCATCTTAAGATGCTCTGTAT CACGCCTATAATCCCAGCACTTTGGGAGGC
NFKB1 (ENST00000394820) Intron 15-16 FAM160A1 (ENST00000340515) Intron 2-3
GCAGCCTTGGGTAGGCAGTTGGGAGGGACC ACAGATGCTGTGTGTTAAGGCAGGCTGTCA
Table S11: DNA alignment of the validated gene fusions for PC346C and G089. The DNA sequences 
corresponding to the first 30 bp before and after the junctions obtained by sequencing of the PCR 
products are depicted below. 
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Figure S6: Breakpoints at the SNP level in a dataset of 66 prostate cancer samples
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Figure S6: Continued
MAP4K3:
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ARHGEF3:
Figure S6: Continued
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LRBA:
Figure S6: Continued
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Figure S7: RMA expression of the FAM71D and MPP5 genes in a subset of prostate cancer samples and 
normal samples is plotted according to the ensemble probeset annotation. The orientation of the genes 
are given (+ or -) and the dotted line corresponds to the position of the genomic break inside the gene.
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Figure S8: RMA expression of the C8orf38 and ARHGEF3 genes in a subset of prostate cancer samples 
and normal samples is plotted according to the ensemble probeset annotation. The orientation of the 
genes are given (+ or -) and the dotted line corresponds to the position of the genomic break inside the 
gene.
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Figure S9: Expression levels of FAM71D in a cohort of 201 prostate cancer samples and 33 normal prostate 
samples. The expression levels were assessed using a custom TaqMan probe against the terminal part 
of FAM71D. This probe was tested for a positive result in the PC346C sample. All expression values were 
further normalized using the GAPDH housekeeping gene. The PC346C sample is depicted in the graph 
as a red bar. All samples with expression levels above the PC346C sample were considered to have an 
overexpression of FAM71D.
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Figure S10: FAM71D expression plot among 6 datasets. The expression outliers are depicted in green. 
References are as follows: EMC – cell lines Boormans JL, Korsten H, Ziel-van der Made AJ, van Leenders 
GJ, de Vos CV, Jenster G, Trapman J. Identification of TDRD1 as a direct target gene of ERG in primary 
prostate cancer. Int J Cancer. 2013 Jul 15;133(2):335-45; J&J – unpublished; Taylor -  GSE21034 Taylor BS 
et al, Integrative Genomic Profiling of Human Prostate Cancer, Cancer Cell, Volume 18, Issue 1, 11-22, 
24 June 2010; Heidelberg - GSE2907 Brase JC et al. TMPRSS2-ERG -specific transcriptional modulation is 
associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer 2011, 11:507; Erho (Mayo) 
- GSE46691 Erho N et al. Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts 
Early Metastasis Following Radical Prostatectomy. PLoS One. 2013 Jun 24;8(6):e66855 and GDS1439 
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Figure S11: Comparison between the data generated by SNP arrays and NGS. The PC346C and G089 
samples were assessed for clear breaks detected by the SNP arrays. This detection was based on the 
2-fold difference between the averages of 20 SNP probes on each side of the break. The breaks were 
manually curated to exclude low coverage SNP areas. The locations of these breaks were then analyzed 
in the NGS data using a range of window sizes (a). The graph represents the percentage of breaks 
detected by DNP arrays that were also reported in the NGS data. An increase in the window size (bp) 
used to search for the breaks detected by the SNP arrays resulted in a higher percentage of overlap 
between the two sets of data. The minimal overlap percentage is 52.4% whereas the maximal reaches 
up to 88.4% (b).
# of breaks confirmed by NGS within:
Sample # breaks by 
SNP arrays
1000 bp 5000 bp 10,000 bp 50,000 bp 100,000 bp
G089 43 27 30 35 38 38
PC346C 42 22 25 30 33 35
The SNP array data of PC346C and G089 samples showed distinct profiles, with more 
copy number variation events in G089 than in PC346C. This pattern was not concordant 
with the number of SVs reported for these samples as both had closely the same number 
of events (Table 1). In order to determine the overlap between these two different sets 
of data, SNP arrays and next generation sequencing (NGS), we selected the clearest 
breaks detected by SNP arrays and searched if these were also reported in the NGS data 
(a). The criteria used to select clear breaks at the SNP level was based on the difference 
in the average of 20 SNP probes before and after the break. The highest values were 
then reported and checked manually to exclude low coverage SNP regions such as the 
ones found in the Y chromosome. We used an increasing window size to search for the 
genomic locations of the SNP breaks in the NGS dataset. Both PC346C and G089 had an 
overlap of more than 80% with a window length of 100Kb (b). This significant overlap 
increased the confidence in the data provided by the NGS.
A)
B)
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Table S12: Inventory of validated genes with genomic abnormalities detected by SNP arrays in other 
prostate cancer samples
Genes Samples with SNP abnormality
THADA PC346B, PC374, PC135, PC310, MDA PCa2b, G321
MAP4K3 PC346B, PC374, PC339, G157, G321
ARHGEF3 PC135, G295
LRBA PC374, 22RV1
Supplementary methods
1. Complete Genomics data processing:
 
Paired-end sequencing for all DNA samples was performed with the Complete Genomics 
(CG) service provider using a proprietary sequencing-by-ligation technology and primary 
data analysis, including image analysis, base calling, alignment and variant calling [1]. 
Reads were mapped to the NCBI Build 36.1 reference genome and mappings were 
expanded by local de novo assembly on all regions of the genome that contain single 
nucleotide variations (SNVs) relative to the reference genome [1]. Structural variations 
(SV) reported in the junctions files do not contain SNVs, inserts and deletions (indels) 
or substitutions (subs) but include information on junctions represented by 3 or more 
discordant mate pairs. The format of the junctions in the “allJunctionsBeta” files [2] 
was transformed using the table below, which calculates start and end locations of the 
junctions.
The junctions are then filtered for normal samples with the union of the all control 
samples used as a global normal control. Duplicates were filtered out such that if the left 
and right positions and chromosomes of one junction exactly matched that of another, 
only one of the junctions was kept. The two prostate cancer samples were filtered using 
the global normal control by removing any junction in the sample that had a matched 
normal junction. A matched normal junction has a left/right position within 10 base 
pairs of the left and right positions in the sample junction. 
The remaining junctions (left and right positions) are annotated with gene features 
(exons, gene symbol) derived from UCSC genome browser [3] using the rtracklayer 
package [4] in R. The junctions located inside such regions are further categorized as 
junctions with different genes on both sides, with the same genes or junctions with 
only one gene on either the left or right side. The following table depicts how the 
single intrachromosomal structural variation events are called per junction. Note from 
personal communication with CGI: “+/+ junction may indicate a deletion or insertion, 
but our current process only detects deletions.”
Strand Left Start LeftEnd RightStart RightEnd
- Left Position Left Position +  
Left Length
Right Position – 
Right Length
Right Position
+ Left Position –  
Left Length
Left Position Right Position Right Position + 
Right Length
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Junction LeftStrand Junction Right Strand Single Event
+ + deletion
- - inversion or deletion
+ - inversion
- + inversion
2. CNV analysis of CGI prostate cancer samples data:
The algorithm CNV-Seq was used to determine copy number variation from the CGI 
data. This algorithm uses a sliding window analysis method with a window size of 
2000bp and a slide of 1000bp. CNV-Seq determines whether the coverage in each region 
is significantly different between test and reference (reference is hg18). Four or more 
consecutive regions with log2 relative coverage (essentially test coverage / reference 
coverage) greater than 0.6 classifies as a gain and lower than -0.6 classifies as a loss. The 
“output”.csv file for each chromosome in each sample contains the called ploidy which 
is determined as specific below:
 0 if cnv_log2 < -1.35
 1 if -1.35 ≤ cnv_log2 < 0
 2 if not in region of loss or gain
 3 if 0 ≤ cnv_log2 < 1.35
 4 if cnv_log2 ≥ 1.35
1.  Carnevali P, Baccash J, Halpern AL, Nazarenko I, Nilsen GB, Pant KP, Ebert JC, Brownley A, 
Morenzoni M, Karpinchyk V, Martin B, Ballinger DG, Drmanac R. Computational techniques 
for human genome resequencing using mated gapped reads. J. Comput. Biol. 2012, 3:279-
292. 
2. http://www.bx.psu.edu/~giardine/tests/tmp/DataFileFormats112.pdf
3.  Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM and Haussler D.  The human 
genome browser at UCSC. Genome Res. 2002, 12(6):996-1006. 
4.  Lawrence M, Gentleman R, Carey V. rtracklayer: an R package for interfacing with genome 
browsers. Bioinformatics. 2009, 25(14):1841-2.
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Abstract
The DNA mismatch repair (MMR) system contributes to maintaining genomic stability 
by the correction of DNA replication errors. MMR deficiency increases mutation 
frequency and predisposes to cancer. Whole genome sequencing data provides a 
complete overview of novel important targets in MMR deficiency. We have performed 
whole genome sequencing of the MMR deficient PC346C prostate cancer cell line. 
Overall, we detected 1196 mutations in PC346C. Comparison with DNA from a MMR 
proficient prostate tumor showed that frameshifts in mononucleotide repeat sequences 
were most specific for MMR deficiency. A selection of genes with mononucleotide 
frameshift mutations was further analyzed in a panel of prostate, ovarian, endometrial 
and colorectal cancer cell lines. PRRT2 and DAB2IP were identified as novel genes 
frequently mutated in cell lines and also in genomic DNA from MMR deficient colorectal 
and endometrial cancer patient samples. Functional studies showed that the mutated 
form of PRRT2 (ΔPRRT2) promoted both cellular proliferation and migration. 
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Introduction
The DNA mismatch repair (MMR) system is highly conserved and contributes to maintain 
genomic stability through the correction of mismatched base pairs occurring during 
the DNA replication process (1). Defects in this repair mechanism are associated with 
mutations in microsatellite repeat sequences (2), which consist of tandemly repeated 
motifs of one (mono) to six (hexa) nucleotides (3). The repetitive nature of these 
sequences makes them highly prone to insertion/deletion mutations caused by DNA 
polymerase slippage thereby altering the length of the microsatellite (4). The mismatch 
repair heterodimers MSH2/MSH6 and MSH2/MSH3 detect replication errors and recruit 
the MLH1/PMS2 complex which in turn degrades and resynthesizes the mutated stretch 
(5). In case the MMR system is defective, these errors will not be corrected and will lead 
to frequent microsatellite instability (MSI) (2).
The majority of microsatellite sequences are located in non-coding DNA with limited 
consequences to cell functions (6). But defects in the MMR system also give rise to 
a mutator phenotype with an increased rate of frameshift mutations in genes with 
coding microsatellites and can therefore increase cancer predisposition (7). Most of the 
gene mutations associated with MSI cancers have been observed in mononucleotide 
repeats (MNR). Affected genes are involved in signal transduction pathways (TGFβRII, 
IGFIIR and PTEN) (8-10), apoptosis (BAX and CASP5) (11, 12), DNA repair (MBD4) (13), 
and transcriptional regulation (TCF-4, EPHB2, AXIN2) (14-16). The proteins resulting 
from these frameshift mutations can contribute to tumor progression by functional 
inactivation, a dominant negative effect, or a gain of function (17-19). 
Germline mutations in MMR genes are present in over 90% of Lynch syndrome patients, 
which are characterized by MSI and an increased risk of colorectal cancer and several 
other cancer types (20). The MSI phenotype is also observed in approximately 15% 
of sporadic colorectal cancers (21), 12% of ovarian cancers (22), 20% of endometrial 
cancers (23, 24), 30% of gastric cancers (25) and less frequent in other cancer types 
(26). MMR deficiency is also frequent in in vitro growing prostate cancer cell lines. 
LNCaP cells do not express MSH2 due to gene deletion and MLH1 is mutated in DU145, 
resulting in expression of an unstable truncated MLH1 protein (27, 28). The frequency of 
MSI reported in prostate cancer patients varies considerably between different studies 
but it is conclusively lower than in other sporadic cancer types (29, 30).
So far, no whole genome sequencing study has focused on identifying novel genes 
commonly targeted by MSI in prostate cancer cell lines and patient samples. We 
performed whole genome paired-end sequencing of two prostate cancer samples, one 
with a functional MMR system (G089, a late stage prostate cancer patient) and the other 
with deficiency of the MMR system due to absence of MSH2 expression caused by point 
mutations in both gene alleles (PC346C, a prostate cancer cell line) (31).
Numerous mutations were observed in G089 and PC346C. Mutations in mononucleotide 
repeats were most specific for the MMR deficient PC346C sample. A potentially 
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interesting set of 17 PC346C-specific genes with MMR deficiency-associated mutations 
(insertions/deletions in mononucleotide repeats) was defined and further evaluated 
in a larger panel of prostate, colorectal, endometrial and ovarian cancer cell lines. We 
identified proline-rich transmembrane protein 2 (PRRT2) and DAB2 interacting protein 
(DAB2IP) to be frequently mutated in all different cancer cell line types. Further analysis 
showed that both genes were also frequently mutated in colorectal and endometrial 
cancer patient samples. Functional studies revealed PRRT2 to be implicated in cellular 
proliferation and migration with the truncated MSI-derived PRRT2 form promoting both 
processes.  
Results
Overview of microsatellite mutations in gene sequences
To identify novel gene mutations caused by MMR deficiency in prostate cancer, we 
analyzed the whole genome sequence of the MMR-deficient prostate cancer cell line 
PC346C and the MMR-proficient prostate cancer patient sample (G089). We selected 
for mutations that would likely disrupt the normal protein function (insertion/deletion 
introducing frameshifts, and mutations in the start or stop codon). The sequence 
flanking each gene mutation (10 nucleotides up and downstream) was retrieved using 
the UCSC genome browser. We selected for mutations occurring in microsatellite 
sequences present in the PC346C sample and absent in G089, thereby enriching for 
mutations that are caused by MMR deficiency. First, the type and length of repeats were 
used to attain an overview of the mutation spectrum in both prostate cancer samples 
(Figures 1A, 1B and 1C). 
We included in our studies repeats with three or more repeat units, depending 
on the repeat composition (mono-, di- or three-nucleotide repeat). Overall, we 
detected 1196 gene mutations in PC346C and 760 gene mutations in G089 (Tables 
S1 and S2, see supplementary data. From the 1196 gene mutations in PC346C, 303 
were in mononucleotide repeats (MNRs), 79 in dinucleotide repeats (DNRs) and 19 in 
trinucleotide repeats (TNRs) (6x n1 for MNR, 3x n2 for DNR and 3 x n3 for TNR) (Figure 
S1A). In G089, 47 gene mutations were in MNRs, 56 in DNRs and 19 in TNRs (6x n1 for 
MNR, 3x n2 for DNR and 3 x n3 for TNR) (Figure S1B). 
PC346C had a 1.5-fold increase in the number of mutated genes as compared to G089. 
The number of mutations found in MNR sequences of 6 nucleotides was 6-fold higher 
in PC346C. A 6-fold increase in MNR gene mutations in PC346C was also observed for 
MNRs of length n8. Since MNRs showed, compared to di- and tri-nucleotide repeats, a 
substantial higher incidence of mutations in MSI+ cancers we focused on these repeats. 
We separated the mutated genes in PC346C and G089 in A, T, C and G MNRs categories 
of different lengths (Table S3). The UCSC build hg18 was used as reference for gene 
annotation. The number of C and G MNRs in reference genes was considerable lower 
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than that of A and T repeats. As expected the mutations in C and G MNRs in PC346C and 
G089 was also much lower than that of A and T MNRs (Table S3). 
Novel target genes of microsatellite instability
The comparison between the whole genome sequence of the MMR-deficient prostate 
cancer cell line PC346C and the MMR-proficient prostate cancer sample G089 allowed 
the identification of novel candidate target genes of MMR deficiency. Our selection 
procedure aimed to identify novel gene mutations associated with MMR deficiency 
with expected functional impact. First, we filtered for mutations in MNR sequences in 
PC346C, which were 6 nucleotides or longer. We excluded LOC annotated gene symbols 
and genes already known to be associated with MMR deficiency or MSI (text mining 
software Anni 2.0, http://biosemantics.org/anni/). We identified over 35 mutated 
genes in PC346C, which were already known as targets of MSI or are associated with 
MMR deficiency including TGFβRII, PTEN, BAX, MLH3, MSH6 and MSH2. The frequent 
Figure 1: Overview of the mutation spectrum in G089 and PC346C genomic DNA. Genes with mutations 
in mononucleotide repeats (MNRs) (A), dinucleotide repeats (DNRs) (B) and trinucleotide repeats (TNRs) 
(C) were distributed according to the length of the mutated repeat sequence. The repeat unit length for 
MNRs is one nucleotide (n=1), for DNRs it is two nucleotides (n=2) and for TNRs it is three nucleotides 
(n=3). The x-axis shows the number of repeat units: 6, 8 and 10 in case of MNRs; 3x, 4x and 5x in case 
of DNRs and TNRs.
A)
C)
B)
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Table 1: List of microsatellite instability target genes in PC346C. Genes are ordered first by the frequency 
of mutation in MMR deficient prostate cancer samples and second alphabetically. The 3 MMR associated 
genes used as a positive control are depicted in red.
identification of known MMR-associated genes confirmed the validity of our approach. 
This procedure left 119 genes for further selection. Next, Ingenuity Pathway Analysis 
(IPA) was used to identify genes with functions most likely to be cancer-associated, 
like cell cycle, cellular growth, apoptosis and other important cell signaling pathways. 
Finally, we checked the expression profile of candidate genes using Affymetrix exon 
array data of 90 prostate cancer RNA samples and 17 normal controls (supplementary 
materials and methods). A final subset of 14 novel genes showing MNR mutations and 
differential expression between normal and prostate cancer samples was assessed for 
their mutation status in a larger panel of cancer cell lines (Table 1). For comparison we 
added three known MSI target genes (PHACTR4, MLL3 and CEP164).
Frequency of microsatellite instability target genes
Microsatellite status of the set of target genes was examined in three MMR-proficient 
prostate cancer cell lines and in four MMR-deficient prostate cancer cell lines (Figure 2, 
Table S4, Figure S2). None of the MMR-proficient prostate cancer cell lines showed MSI 
in the selected gene panel. Controls CEP164, PHACTR4 and MLL3 were mutated in two 
or more of the MMR-deficient cell lines. We found that CNOT1, DAB2IP and PRRT2 were 
mutated in at least three MMR-deficient cell lines (Figure 2, Table S4). 
Gene Name Length of
repeat
Mutation in
PC346C
CNOT1 CCR4-NOT transcription complex, sub 1 A13 del AA
DAB2IP DAB2 interacting protein C8 del C
PRRT2 proline-rich transmembrane protein 2 C9 ins CC
TTC3 tetratricopeptide repeat domain 3 A8 del A
CEP164 centrosomal protein 164kDa A11 del A
PHACTR4 phosphatase and actin regulator 4 A10 del A
TROVE2 TROVE domain family, member 2 A9 del A
ZFR zinc finger RNA binding protein T9 del T
MLL3 myeloid/lymphoid or mixed-lineage leukemia 3 T9 del T
ANLN anillin, actin binding protein A7 del A
ANUBL1 AN1, ubiquitin-like, homolog A7 del A
EPRS glutamyl-prolyl-tRNA synthetase T6 ins T
KCNMA1 potassium large conductance calcium-activated channel,  
subfam M, α1
T9 del T
PDS5A PDS5, regulator of cohesion maintenance,  
homolog A (S. cerevisiae)
A6 del A
SFRS12IP1 SFRS12-interacting protein T10 ins T
TSHZ2 teashirt zinc finger homeobox 2 C7 del C
USP42 ubiquitin specific peptidase 42 A8 del A
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Next, we expanded the cell line panel with ten colorectal, four endometrial and three 
ovarian cancer MMR-deficient cell lines and control MMR-proficient cell lines of each 
cancer type. As observed in the MMR-proficient prostate cancer cell lines, colorectal, 
endometrial and ovarian cancer MMR-proficient cell lines showed no mutations in the 
analyzed genes (Table 2 and Table S5). The control genes CEP164, PHACTR4 and MLL3 
displayed as expected high mutation frequencies, ranging from 30% to 80% in the MSI 
cancer cell lines (Table 2 and Table S5).
Also here we identified CNOT1, DAB2IP and PRRT2 as novel MSI target genes, in the 
MMR-deficient cancer cell lines, although with varying frequency. The genes displayed 
mostly deletions and to a lesser extend insertions (Table 2 and Table S5). The mutations 
shifted the open reading frame of the affected genes and consequently predicted to 
result in synthesis of truncated proteins due to premature termination (Table S1). CNOT1 
contains a n13 A repeat in the open reading frame located 10 nucleotides upstream 
of the stop codon. A frameshift mutation at this position might not be critical for the 
protein and no further research was conducted for this gene. The n
9
 C repeat in PRRT2 
and the n8 C repeat in DAB2IP displayed a mutation pattern reflecting both insertions 
and deletions. (Figure S3A, S3B). 
Figure 2: MNR repeat analysis of top mutated genes in prostate cancer in genomic DNA from prostate 
cancer cell lines PC346C (MMR deficient) and PC3 (MMR proficient). Fragment size analyses of PCR 
amplified fragments of CNOT1 (A), DAB2IP (B) and PRRT2 (C) containing the repeat are presented. The 
highlighted peaks represent a mutant allele. PCR primers are presented in supplementary data. WT: wild 
type; del: deletion; ins: insertion. Indicated PRRT2 PCR fragments are flanked by sequence analysis of 
the repeat.
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Frequency of PRRT2 and DA2IP repeat mutations in MSI patient 
cancer samples
Next, we checked whether the mutation frequencies of PRRT2 and DAB2IP observed 
in the cancer cell line panels could be confirmed in primary cancer samples. We tested 
a total of 80 prostate cancer patient samples, including late stage and metastasized 
cancers. None of the samples displayed the mutations in either of the genes (data not 
shown), not unexpected because MSI is not frequent in clinical prostate cancer. Further, 
we tested 24 colorectal and 24 endometrial MSI patient cancer samples. We found 
PRRT2 to be mutated in 15 out of 24 colorectal cancer patients and in 11 out of 24 
endometrial cancer patients (Figure S4, Table S6). Although the mutation frequency in 
the DAB2IP MNR was similar (11/23), only one endometrium cancer sample displayed a 
mutation in the repeat. To further evaluate the significance of the mutation frequency 
of PRRT2 and DAB2IP in clinical MSI colorectal and endometrial cancer patient samples, 
we compared their frequency to the average mutation frequency for common MSI target 
genes published in databases (SelTarbase (33)) (Table S7). Compared to other genes, 
PRRT2 displayed a very high mutation frequency in both colorectal and endometrial 
cancer and was selected for functional studies.
Table 2: Number of MSI positive (MSI) and negative (MSS) prostate, colorectal, endometrial and ovarian 
cancer cell lines with mutations in the set of MSI target genes in PC346C. The 3 control genes are 
depicted in red. Three MSS cell lines were available for prostate, colorectal and endometrial cancer 
and one MSS cell line for ovarian cancer. The number of MSI cell lines available for prostate, colorectal, 
endometrial and ovarian cancer were four, ten, four and three respectively. 
 Prostate Cancer Colorectal Cancer Endometrial Cancer Ovarian Cancer
 MSS MSI MSS MSI MSS MSI MSS MSI
CNOT1 0/3 4/4 0/3 9/10 0/3 4/4 0/2 1/3
DAB2IP 0/3 3/4 0/3 6/10 0/3 1/4 0/2 0/3
PRRT2 0/3 3/4 0/3 4/10 0/3 4/4 0/2 2/3
TTC3 0/3 2/4 0/3 5/10 0/3 1/4 0/2 0/3
CEP164 0/3 3/4 0/3 8/10 0/3 3/4 0/2 2/3
PHACTR4 0/3 3/4 0/3 7/10 0/3 3/4 0/2 1/3
TROVE2 0/3 1/4 0/3 5/10 0/3 4/4 0/2 1/3
ZFR 0/3 2/4 0/3 4/10 0/3 3/4 0/2 1/3
MLL3 0/3 2/4 0/3 8/10 0/3 3/4 0/2 1/3
ANLN 0/3 1/4 0/3 0/10 0/3 0/4 0/2 0/3
ANUBL1 0/3 1/4 0/3 2/10 0/3 0/4 0/2 0/3
EPRS 0/3 1/4 0/3 0/10 0/3 0/4 0/2 0/3
KCNMA1 0/3 1/4 0/3 6/10 0/3 1/4 0/2 1/3
PDS5A 0/3 1/4 0/3 0/10 0/3 1/4 0/2 0/3
SFRS12IP1 0/3 1/4 0/3 6/10 0/3 2/4 0/2 1/3
TSHZ2 0/3 1/4 0/3 10/10 0/3 3/4 0/2 3/3
USP42 0/3 1/4 0/3 4/10 0/3 4/4 0/2 0/3
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The PRRT2 gene
PRRT2 encodes a 340 amino acids protein that has two predicted transmembrane 
domains. This protein is poorly characterized, although recently a link between PRRT2 
mutations and a rare neurological disease, paroxysmal kinesigenic dyskinesia, was 
established (34). Whether PRRT2 has a role in cancer is unknown. Frameshifts in the 
C-repeat would result in expression of truncated proteins of 222 or 227 amino acids that 
lack the predicted transmembrane domains (Figure 3A). The PC346C prostate cancer 
cell line is the only cell line we identified, which has a mutation in both PRRT2 alleles. 
To investigate a possible role of PRRT2 in cancer we first documented PRRT2 expression 
levels by RNA sequencing in available cancer data sets (Supplementary materials and 
Figure 3: Expression pattern of PRRT2 mRNA. (A) Schematic representation of the wildtype and the 
mutant PRRT2. The insertion of C and CC in the 9C repeat of PC346C leads to a truncated protein lacking 
the predicted transmembrane and cytoplasmatic domains. The frameshift occurs within the proline-rich 
region of PRRT2. (B) Box plot analysis of PRRT2 mRNA in prostate cancer lymph node metastasis (LN-
PCa, 12 samples), transurethral resections (TURP- PCa, 10 samples), primary prostate cancer (PCa, 56 
samples) and normal adjacent prostate tissue (NAP, 12 samples). (C) Expression levels of PRRT2 in lung 
adenocarcinoma (22 samples) and normal lung tissue (22 samples). (D) Expression levels of PRRT2 in 
gastric cancer (20 samples) and normal gastric tissue (20 samples). Wilcoxon testing was used in (B), (C) 
and (D) to determine significant differences in expression levels.
A)
C)
B)
D)
PRRT2 wildtype and truncated protein PRRT2 expression in a prostate cancer 
dataset
PRRT2 expression in a lung cancer 
dataset
PRRT2 expression in a gastric cancer 
dataset
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methods). Overall, PRRT2 showed a consistent decrease in expression in cancer as 
compared to normal in prostate, lung and gastric tissue samples (Figures 3B, 3C, 3D). 
Both lung and gastric cancers have been associated with MSI. In order to exclude non-
mediated mRNA decay of the mutated PRRT2 transcript we investigated the expression 
level of PRRT2 in PC346C. The elevated expression level detected suggested that the 
stability of the PRRT2 transcript is not affected by the mutation (Figure S5). 
Biological activity of PRRT2
 
To assess whether the truncated PRRT2 (ΔPRRT2) influenced cell proliferation, we stable 
transfected the normal prostate epithelial cell line PNT2C2 with lentiviral constructs 
expressing wild type PRRT2 (PRRT2wt) or ΔPRRT2. Efficiency of transfection was assessed 
by the expression of GFP, independently transcribed under the CMV promoter. Cell 
proliferation was measured during 4 days after plating of equal numbers of control (GFP 
only), PRRT2wt and ΔPRRT2 transfected cells. 
Figure 4: PRRT2 affects cellular proliferation. (A) PNT2C2, (B) RWPE-1 and (C) HCT116 cells were stably 
transduced with lentiviral vectors expressing the truncated form of PRRT2 (ΔPRRT2), the wildtype PRRT2 
(wtPRRT2) and the control GFP vector. Cellular proliferation was measured 1, 2, 3 and 4 days after 
plating of the RWPE-1 and HCT116 cells, and 2, 4, 6 and 8 days after plating of the PNT2C2 cells. Cellular 
viability was measured by the reduction of luciferin into ocyluciferin in the presence of ATP. The y-axis 
displays the RLU (relative light units). Asterisks indicate *P≤0.02 and **P≤0.002, respectively, in a two-
tailed Student’s t-test.
A) B)
C)
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A significant increase in proliferation capacity of PNT2C2 cells expressing ΔPRRT2 
(37.5%) was observed as compared to the control cells at day 8. Conversely, the growth 
of PNT2C2 cells expressing PRRT2wt was impaired especially as compared to the PNT2C2 
cells expressing ΔPRRT2 (Figure 4A). 
The ΔPRRT2 effect on cellular proliferation was further validated in the RWPE-1 prostate 
epithelial cell line and the HCT116 colorectal cancer cell line. Both cell lines displayed 
the same growth promoting effect of ΔPRRT2. RWPE-1 cells stably expressing ΔPRRT2 
showed an increase of 20% in proliferation capacity whereas PRRT2wt did not affect 
proliferation (Figure 4B). HCT116 cells expressing ΔPRRT2 showed an increase of 41% 
in proliferation capacity as compared to the control. Similar to PNT2C2, cells expressing 
PRRT2wt showed a decrease in cellular proliferation (Figure 4C).
The influence of PRRT2 expression on apoptosis was addressed in a caspase 3/7 
activation assay in all ΔPRRT2 and PRRT2wt expressing cell lines described above. In 
none of the cases we observed a clear difference in apoptosis levels between ΔPRRT2, 
PRRT2wt and control GFP expressing cells (data not shown). 
Finally we addressed the effect of PRRT2 on cell migration. PNT2C2, RWPE-1 and HCT116 
expressing ΔPRRT2, PRRT2wt and GFP were cultured in migration chambers for 24h in 
both presence and absence of 10% FCS. We detected a significant increase in migratory 
capacity of ΔPRRT2 expressing cells as compared to the GFP controls (Figure 5A and 5B). 
Migration of PRRT2wt expressing cells was consistently lower than the GFP control cells, 
but in all cases, not significantly different. 
Figure 5: PRRT2 plays a role in cellular migration. (A) Migratory capacity of HCT116, PNT2C2 and RWPE-1 
cells was assayed by measuring the cells migrating through a 5 µm polycarbonate membrane. Migration 
was induced by 10% FCS. Cells were assayed using CyQuant® GR fluorescent dye. All samples were 
normalized to the fluorescent detection in the absence of chemo attractant (10% FCS). RFU represents the 
relative fluorescent units. **P≤0.002 was calculated using a two-tailed Student’s t-test. (B) Representative 
illustrations of migration of HCT116 cells expressing ΔPRRT2, wtPRRT2 or control GFP in the presence and 
absence of 10% FCS (see also legend to Fig. 4).
A) B)
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Discussion
Microsatellite instability in cancer
The most prominent characteristic allowing cancer cells to survive, proliferate and 
disseminate is the development of genomic instability (35). DNA repair mechanisms 
are the cell’s surveillance systems and defects in this machinery are responsible for 
accelerating the rate at which cells can accumulate favorable genotypes. The MMR 
system eliminates base-base mismatches and insertion-deletion loops that arise 
during DNA replication due to slippage of the DNA polymerase (1). Simple repetitive 
DNA sequences known as microsatellites are particularly prone to insertions and 
deletions due to defective MMR (36). As a result, cells with a defective MMR system 
might have mutation rates 100-1000 fold higher than normal cells (37). Several studies 
have shown that instability of microsatellites is present in PCa (38, 39). The frequency 
of microsatellite instability detected in PCa is variable between different studies and 
ranges from 8% (40) to 35% (41, 42). To elucidate the role of MMR in PCa we have 
sequenced the complete genome of the MMR-deficient PC346C cell line. This cell line 
was derived from a transurethral resection of a primary tumor and lacks a functional 
MSH2 protein due to point mutations in both alleles (31). 
The use of whole genome sequencing allowed an unbiased detection of all gene 
mutations and it is a powerful strategy to uncover genes implicated in the disease. Using 
this approach we identified a total of 1196 gene mutations in PC346C. Approximately 
one third of these mutations occurred in nucleotide repeat sequences (see also ref 
(43)).  The total number of gene mutations detected in G089 was 1.5 fold lower than 
in PC346C, which fits to the mutational phenotype due to MMR deficiency of PC346C. 
Mutations in MNRs were enriched by 6-fold in PC346C as compared to G089. The 
bias in MNR mutations in PC346C as compared to G089 was used to select for gene 
mutations triggered by the MMR system. Several of the downstream target genes of 
MMR deficiency have shown to be key players in proliferation and apoptosis pathways. 
Identification of novel MMR target genes in PCa
A list of 381 genes showing mutations in mononucleotide repeats in PC346C was used 
to select for novel target gene mutations caused by deficiency in the MMR system 
in PCa. Since the percentage of PCa cases with MSI was low we extended the test 
panel to include ovarian, endometrial and colorectal cancer cell lines. A final list of 
13 candidate genes was further assessed for their mutation status in cell lines with 
and without microsatellite instability. CEP164, PHACTR4 and MLL3 are genes already 
known as associated with microsatellite instability and their mutation frequencies were 
compared to those of the novel gene candidates. We have first selected for the genes 
with the highest mutation frequencies in our prostate cancer cell line panel. Although 
TSHZ2 showed the highest mutation frequencies for colorectal and ovarian cancer cell 
lines only one out of the four MSI prostate cancer cell lines was positive for the TSHZ2 
mutation. CNOT1 was mutated in all MSI prostate cancer cell lines but this was, in all 
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cases, a heterozygous mutation and occurred closed to the end of the coding region. 
Both PRRT2 and DAB2IP were mutated in three out of the four MSI prostate cancer cell 
lines. Whereas PRRT2 mutations were also frequent in both colorectal, endometrial 
and ovarian cancer cell lines DAB2IP mutations were mostly restricted to prostate and 
colorectal cancer samples. DAB2IP has recently been identified as a regulator of tumor 
growth and apoptosis. The expression of DAB2IP is often downregulated in PCa and 
this downregulation causes activation of the RAS signaling cascade and inactivation 
of the ASK1-JNK pathway leading to growth stimulation and suppression of apoptosis 
(44, 45). The observation that DAB2IP is mutated at high frequency in MMR deficient 
prostate and colorectal cell lines indicates a link between MMR and this gene. But so 
far, epigenetic suppression was suggested as the major mechanism behind DAB2IP 
downregulation (46). Truncating mutations in PRRT2 were first identified in 2011 by 
Chen WJ et al. in paroxysmal kinesigenic dyskinesia (PKD) (34).  Although PRRT2 appears 
to be an important factor in several neurological-related conditions (47) there is no 
correlation between PRRT2 and other diseases. Also, there is little functional data 
regarding the PRRT2 protein with only one protein-protein interaction known so far 
with the synaptosomal-associated protein 25 (SNAP25) (48). 
PRRT2 and mismatch repair deficiency
The mutation status of PRRT2 and DAB2IP was assessed in a cohort of 24 colorectal 
and 24 endometrial MSI patient samples. We observed a high number of patients with 
mutations in PRRT2 and to a lesser extent mutations in DAB2IP were detected. The 
finding that DAB2IP was mutated in only one endometrial cancer sample indicates tissue 
specificity for this particular gene mutation. PRRT2 was frequently mutated in both 
colorectal and endometrial cancer patients. The frequency of PRRT2 mutation in patient 
samples is only second to the frequency of TGFβRII in colorectal cancer and the highest 
in endometrial cancer of all MSI genes (Table S7) (49). Although most targets of MMR 
deficiency are considered to be tumor suppressor genes that through the frameshift 
outcome lose their function there are also studies showing activating mutations such 
as the frameshifts in the TCF4 gene (50). The two PRRT2 frameshift mutations found 
in PC346C, the insertion of one or two Cs, occur in a C9 repeat in the second coding 
exon and introduce a premature stop codon in the mRNA. As a consequence, the 
PC346C cell line lacks a wild type PRRT2 protein. Although it is claimed that the non-
sense mediated mRNA decay (NMR) mechanisms recognize premature stop codons and 
eliminate aberrant transcripts (51) we found a high level of expression of the PRRT2 
transcript in the PC346C cell line. The expression level of PRRT2 is overall lower in 
cancer as compared to normal, which would indicate it as a potential tumor suppressor 
gene. However mutations in this gene only affect one of the copies in almost all 
affected cancers, leaving a wild type PRRT2 copy intact. The PC346C prostate cancer cell 
line and patient from which the cell line is derived are the only samples with 
homozygous mutations in the 9C repeat. Despite the lower expression of PRRT2 in cancer 
versus normal tissue our data suggests a dominant negative effect of the truncated 
PRRT2 protein.
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PRRT2 in proliferation and migration
To investigate the functional role of both the wild-type (PRRT2wt) and the truncated 
PRRT2 protein (ΔPRRT2) we generated stable PRRT2wt and ΔPRRT2 expressing cell lines. 
Two normal prostate cell lines (PNT2C2 and RWPE-1) and one colorectal cancer cell 
line (HCT116) were used to assess the effect of PRRT2 in proliferation, apoptosis and 
migration. Remarkably, we observed an oncogenic effect of ΔPRRT2. Both proliferation 
and migration were enhanced by stable ΔPRRT2 expression. Conversely, PRRT2wt 
appeared to decrease the proliferation rate, being this effect more evident in the 
PNT2C2 and HCT116 cell lines as compared to RWPE-1. This decrease in proliferation 
by PRRT2wt overexpression suggests PRRT2 to participate in cell cycle regulation. The 
frameshift mutation creates a truncated PRRT2 protein that increases both proliferation 
and migration in cell lines with a wild type PRRT2 protein. Based on our findings, we 
hypothesize that wild type PRRT2 inhibits slightly proliferation, whereas truncated 
PRRT2 can stimulate, and overrules wild type PRRT2. In this way it can function as an 
oncogene by promoting both proliferation and migration. Although genes are usually 
dichotomized in either oncogenes or tumor suppressors (52) many can actually exert 
both functions such as the TP53 tumor suppressor gene which can lead to tissue 
invasion, metastasis and increased proliferation when mutated (53).
 
In conclusion, a focused genome-wide sequencing approach, followed by subsequent 
expression and functional studies indicate mutated PRRT2 as a novel dominant 
oncogene, and wtPRRT2 as a candidate tumor suppressor gene.  The finding that 
the same PRRT2 mutation detected in this study has also been documented in 
colorectal, pancreatic and stomach cancer samples (depicted as A214P in Suppl. 
Fig. 6) supports a more general role of PRRT2 in cancer biology. 
Materials and Methods
DNA samples used in whole genome and data analysis
The DNA of two prostate cancer samples, the PC346C prostate cancer cell line (32) and 
the G089 prostate cancer patient, were sequenced by Complete Genomics (Complete 
Genomics Inc, CA). Tissue sample G089 and other patient materials described below has 
been collected according to national legislation concerning ethical requirements. Use of 
the clinical samples has been approved by the Erasmus MC Medical Ethics Committee 
according to the Medical Research Involving Human Subjects Act (MEC-2004-261). NCBI 
build 36 (hg18) was used as a reference genome during the mapping and data analysis 
process. Complete Genomics Inc. pipeline generated a report with all single nucleotide 
variants present in the two samples. Further information on the Complete Genomics Inc. 
data processing is present in supplementary materials and methods. 
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DNA from additional cell lines and tissue samples
Additional genomic DNA was isolated from MMR-proficient prostate cancer cell lines 
PC3, PC135 and PC295 and MMR-deficient prostate cancer cell lines DU145, LNCaP 
and PC374. Cell pellets from thirteen colorectal, seven endometrial and three ovarian 
cancer cell lines were kindly provided by Dr. W. Dinjens, Dept Pathology, Erasmus MC, 
Rotterdam, The Netherlands. Also, genomic DNA was isolated from frozen 31 primary 
prostate cancer patient tissues, 37 transurethral resection of the prostate (TURP) samples 
and 11 lymph node prostate cancer metastasis samples. Genomic DNA from paraffin 
embedded formalin fixed tissue samples of 24 microsatellite instable colorectal cancer 
patients and 24 microsatellite instable endometrial cancer patients were kindly provided 
by Dr. W. Dinjens. 
DNA isolation
DNA isolation from prostate cancer samples was performed using the QIAamp DNA 
Blood Midi Kit (Qiagen) according to the manufacturers’ instructions. Cell pellets were 
resuspended in 1 ml PBS (BioWhittaker) and instructions were followed according to 
the protocol used for 1 ml whole blood. DNA was eluted in 200 µl elution buffer. DNA 
isolation from the colorectal, endometrial and ovarian cancer cell lines pellets was 
performed using the Gentra Puregene Cell Kit (Qiagen) (approx. 15 µg DNA from 2x106 
cells) following the manufacturer’s protocol. Concentration and purity of the DNA was 
assessed using the NanoDrop ND 1000 spectrophotometer (Nanodrop) by absorption 
measurements at 260 nm. DNA was stored at -20 degrees Celsius.
RNA isolation
Total RNA was isolated from PC346C, RWPE-1, VCaP, HCT116 and PNT2C2 using the 
RNeasy kit (Qiagen) according to the manufacturer’s protocol. RNA was eluted in 50 µl 
RNase free water. Concentration and purity of RNA was assessed using the NanoDrop 
ND 1000 spectrophotometer (Nanodrop) by absorption measurements at 260 nm. RNA 
was stored at -80 degrees Celsius.
Cell culture
The PC346C cell line was cultured in DMEM-F12 (BioWhittaker), supplemented with 
2% (V/V) FCS (PAN Biotech), 1% insulintransferrin-selenium (GIBCO BRL), 0.01% BSA 
(Boehringer-Mannheim), 10 ng/ml epidermal growth factor (Sigma-Aldrich) and 500 U 
penicillin-streptomycin (BioWhittaker), 100 ng/ml bronectin (Harbor Bio Products), 20 
mg/ml fetuine (ICN Biomedicals), 0.1 nM R1881 (Sigma-Aldrich), 50 ng/ml cholera toxin 
(Sigma-Aldrich), 0.1 mM phosphoethanolamine (Sigma-Aldrich), 0.6 ng/ml triodothyronine 
(Sigma-Aldrich), and 500 ng/ml dexamethasone (Sigma-Aldrich). The PC346C cell line 
expresses the wild-type androgen receptor and secretes high levels of PSA. RWPE-1 cells 
were cultured in keratinocyte medium (GIBCO BRL), supplemented with 5 ng/ml epidermal 
growth factor, 1% penicillin-streptomycin (BioWhittaker), and 50 mg/L bovine pituitary 
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extract. RWPE-1 is a normal prostate epithelium cell line that is androgen-independent 
and expresses both the androgen receptor and PSA. The colorectal cancer cell line HCT116 
and the normal prostate cell line PNT2C2 cells were cultured in RPMI-1640 (GIBCO BRL), 
supplemented with 10% FCS (PAN Biotech) and 1% penicillin-streptomycin (BioWhittaker). 
All cell lines were cultured at 37 degrees in a 5% CO2 atmosphere. 
Mononucleotide repeat analysis
A microsatellite instability assay was used to detect changes in the length of 
mononucleotide repeats by PCR amplification. Primers were designed using the 
Primer3Plus program. The final fragment size was set to vary between 100 and 130 bp in 
order to allow precise fragment sizing and robust amplification of all the genes tested. 
Primer sequences are described in Supplementary materials and methods. The M13 
sequence (GTAAAACGACGGCCAGT) was added at the 5’ end of each forward primer. This 
enabled the use of a M13-FAM primer to fluorescently label each PCR fragment. PCR 
reactions were performed in a total volume of 16 µl containing 12.5 ng genomic DNA, 3 
µl 10x PCR Buffer (Qiagen), 2 µl 5x Q-Solution (Qiagen), 0.9 µl 25 mM MgCl2 (Quiagen), 
0.3 µl dNTPs (10 mM), 0.5 µl forward primer (100 ng/µl), 0.5 µl M13-FAM primer (100 ng/
µl), 1 µl reverse primer (100 ng/µl), and 1 U HotStarTaq Polymerase (Qiagen). An initial 
denaturation step of 15 min at 95 degrees Celsius was used to activate the HotstarTaq, 
followed by 35 cycles denaturation at 95 degrees Celsius for 30 sec, an annealing step 
at 54 degrees Celsius for 30 sec and elongation at 72 degrees Celsius for 1 min. A final 
elongation step at 72 degrees Celsius for 10 min was used. PCR products were checked 
by electrophoresis in a 1% agarose gel.
Fragment analysis
The PCR products were separated by capillary electrophoresis using an ABI PRISM 3130 
sequencing analyzer. This method allows single base pair resolution of PCR fragments. 
A mixture of 1.5 µl of the PCR products with 9.8 µl highly-deionized formamide (HiDi) 
and 0.2 µl GeneScan-500 LIZ size standard (Applied Biosystems) was prepared. This 
mixture was heated for 2 min at 95 degrees Celsius and subsequently loaded to 
the sequence analyzer. Data was analyzed with the Peak Scanner software (Applied 
Biosystems).
Sequencing
PCR products have been sequenced bi-directionally using standard Sanger sequencing. 
The sequencing reactions were carried out using the same forward and reverse primers 
as indicated above in the PCR but at different concentrations (3 ng primer per reaction). 
The final reaction volume was 20 µl. The sequencing products were precipitated using 
isopropanol and resuspended in 20 ul formamide (Sigma-Aldrich). The PCR product was 
sequenced on an ABI Model 3730 automated sequencer and analyzed using DNAMAN 
(Lynnon Corporation).
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PRRT2 expression constructs
The sequence validated I.M.A.G.E clone IRATp970E0579D corresponding to the BC053594 
clone accession number was purchased from Source Bioscience, Nottingham, UK. This 
plasmid contains the wtPRRT2 cDNA sequence. Primers 5’ GAT CGA ATT CGT TTG CCG CTG 
TCT CT 3’ (Fw) and 5’ GAT CGC GGC CGC TCA CTT ATA CAC GCC 3’ (Rv) were used to amplify 
the wtPRRT2 cDNA and subsequently clone the fragment into the pCDH-CMV-MCS-EF1-
GFP-T2A-Puro vector (System Biosciences). Primers 5’ GAT CGA ATT CGT TTG CCG CTG TCT 
CT 3’ (Fw) and 5’ GAT CGC GGC CGC CCC TTC TCA TTC GAT 3’ (Rv) were used to generate 
a truncated PRRT2 cDNA fragment.  This fragment was integrated into the pCDH-CMV-
MCS-EF1-GFP-T2A-Puro vector (System Biosciences) for expression of ΔPRRT2 protein. 
The amplified fragments were ligated to the vector using the Rapid DNA Ligation Kit 
according to the manufacturer’s protocol (Roche). JM109 competent bacteria (Promega) 
were transformed with the ligation products using the heat shock method and plated in 
Ampicillin LB agar plates. DNA isolation was performed on selected colonies (Quiagen) and 
restriction enzyme reactions (BamH1  and Not1 ) confirmed the proper ligation of fragment 
to vector. 
Lentivirus production
HEK293T cells were co-transfected with pCDH-wtPRRT2-GFP-Puro or pCDH-ΔPRRT2-GFP-
Puro or pCDH-GFP-Puro expression vectors and pPAX2 and pMD2.G (kind gift of Prof Didier 
Trono, Switserland) using the calcium phosphate precipitation method. Virus was harvested 
from the supernatant and used for transduction of PNT2C2, RWPE-1 and HCT116 cells. 
Pools of infected cells were propagated.
Functional role of PRRT2
The functional role of PRRT2 was assessed in RWPE-1, HCT116 and PNT2C2 cell lines 
expressing the truncated form of PRRT2 (ΔPRRT2), the wildtype PRRT2 (wtPRRT2) and 
the control GFP. These cell lines were propagated in medium supplemented with 1 
µg/mL puromycin (Millipore).  Briefly, cells were plated in 96-well culture plates at a 
density of 1000 cells per well (100 µl). Proliferation was assessed using the CellTiter-
Glo Luminescent Cell Viability Assay (Promega), according to manufacturer’s protocol. 
Apoptosis was assessed using the ApoLive-Glo™ Multiplex Assay (Promega), which 
measures both the number of viable cells as a marker of cytotoxicity and caspase 
activation as a marker of apoptosis within a single assay well. The assay was performed 
according to the manufacturer’s protocol. As positive control of apoptosis an apoptosis 
inducer set (Millipore) was used. A mix containing 700x dilutions of Actinomycin D (10 
mM), Camptothecin (2 mM), Cycloheximide (100 mM), Dexamethasone (10 mM) and 
Etoposide (10 mM) was supplemented for 24h to induce apoptosis. The QCM Chemotaxis 
Cell Migration Assay, 96-well (8 μm), fluorimetric (Millipore) was performed according to 
the manufacturer’s protocol.
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Supplementary data
Figure S1: Distribution of mononucleotide (MNR), dinucleotide (DNR) and trinucleotide (TNR) repeat 
mutations of length 6 nucleotides of MNRs and DNRs and length of 9 nucleotides for TNRs in affected 
genes. (A) represents the distribution in the PC346C DNA and (B) in G089 DNA. The numbers in the 
intersection of the different categories represent genes with both NR (either MNR and DNR or DNR and 
TNR).  No genes had both MNR and TNR.
Table S3: Distribution of mutated genes in PC346C and G089 and in all UCSC hg18 genes in MNR 
categories of different type and length. The subscript number represents the total nucleotide length of 
the repeat. 
PC346C (1196 genes) G089  (760 genes) UCSC genes
n6 n7 n8 n9 n10 n12 n6 n7 n8 n9 n10 n12 n6 n7 n8 n9 n10 n12
A 96 78 54 29 19 4 13 11 7 4 4 0 15100 9501 5768 4025 3013 1880
T 84 66 44 25 15 1 12 7 5 2 2 0 14617 9690 6358 4672 3616 2359
C 68 33 15 5 1 0 10 6 4 0 0 0 8636 2106 522 225 128 44
G 55 26 8 3 1 0 12 9 5 3 2 0 7468 1630 423 157 83 24
A)
B)
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Table S4: Allele pattern of microsatellite instability gene targets in MMR-deficient and -proficient prostate 
cancer cell lines. Genes are ordered first by the frequency of mutation in MMR-deficient prostate cancer 
samples and secondly alphabetically. The three MMR associated genes used as positive controls are 
depicted in red. MSS stands for microsatellite stable and MSI for microsatellite instable. WT represents 
the wildtype allele. M1 and M2 correspond to deletion of one or two nucleotides, respectively. P1 and 
P2 correspond to insertion of one or two nucleotides.
MMR-proficient (MSS) MMR-deficient (MSI)
Gene PC3 PC295 PC135 DU145 LNCaP PC346C PC374
CNOT1 wt wt wt m1wt m1m2wt m1m2wt m1wt
DAB2IP wt wt wt wt m1wt m1wt wtp1
PRRT2 wt wt wt wtp1p2 wt p1p2 wtp1
TTC3 wt wt wt m1wt wt m1wt m1wt
CEP164 wt wt wt wt m1wt m1wt m1wt
PHACTR4 wt wt wt wt m1wt m1wt m1wtp1
TROVE2 wt wt wt wt wt m1wt m1wt
ZFR wt wt wt wt m1wt m1wt wt
MLL3 wt wt wt wt m1wt m1wt wt
ANLN wt wt wt wt wt m1wt wt
ANUBL1 wt wt wt wt wt m1wt wt
EPRS wt wt wt wt wt wtp1 wt
KCNMA1 wt wt wt wt wt m1wt wt
PDS5A wt wt wt wt wt m1wt wt
SFRS12IP1 wt wt wt wt wt wtp1 wt
TSHZ2 wt wt wt wt wt m1wt wt
USP42 wt wt wt wt wt m1wt wt
Figure S2: Western blot analysis of the MLH1 and MSH2 protein expression in the MMR deficient 
prostate cancer cell lines LNCaP, DU145 and xenograft transplant PC374 and in the MMR proficient 
prostate cell lines PC3 and TSU. Actin is displayed as a loading control.
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Figure S4) Analysis of the PRRT2 PCR fragment containing the C9 repeat sequence and repeat sequence 
analysis of MSI colorectal and endometrial cancer patient samples. (A) Chromatogram and fragment 
analysis of three colorectal cancer patients. (B) Chromatogram and fragment analysis of three 
endometrial cancer patients. The highlighted peaks (grey outline and red circle) represent mutant 
alleles. The wildtype 9 C repeat shows a prominent 107 bp fragment and a shoulder peak at length 106 
bp. The intensity of shoulder peaks are less than 32% the intensity of the highest peak. Both MH09-0462 
and MH09-0483 display peaks of equal intensity at length 106 and 107. The peak at 106 bp is therefore 
highlighted as a mutant allele in the two samples mentioned above. In (B) MH09-0095 has a lower peak 
corresponding to the wt 107 fragment. Fragments of 106 and 108 bp are also present in this sample. 
A)
B)
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Patient Type of cancer PRRT2 DAB2IP
MH09-0412 Colon wt wt
MH09-0419 Colon m1wt wt
MH09-0421 Colon wt wt
MH09-0443 Colon m1 wt
MH09-0456 Colon wt wt
MH09-0462 Colon m1wt wt
MH09-0467 Colon wt m1wt
MH09-0477 Colon wt wtp1
MH09-0483 Colon m1wt wt
MH09-0496 Colon wt wt
MH09-0503 Colon wt wt
MH09-0515 Colon wtp1 wt
MH09-0541 Colon wt wt
MH09-0543 Colon wt wt
MH09-0569 Colon wtp1 m1wt
MH09-0575 Colon wtp1 wt
MH09-0586 Colon m1wt wt
MH09-0587 Colon m1wt wt
MH09-0609 Colon m1wt wt
MH09-0648 Colon m1wt wtp1
MH10-0016 Colon m1wt wt
MH10-0017 Colon m1wt wtp1
MH10-0030 Colon m1wt wt
MH10-0122 Colon m2m1wt m1wt
MH07-0071 Uterus wtp1 wt
MH07-0120 Uterus m1wt wt
MH08-0225 Uterus wt wt
MH08-0249 Uterus wt wt
MH08-0265 Uterus wt wt
MH08-0318 Uterus wt wt
MH09-0060 Uterus wtp1 wt
MH09-0071 Uterus ND ND
MH09-0095 Uterus wtp1 wt
MH09-0099 Uterus wt wt
MH09-0109 Uterus wt wt
MH09-0203 Uterus wt ND
MH09-0204 Uterus wt ND
Table S6) Allele pattern of PRRT2 and DAB2IP in MSI colorectal and endometrial cancer patients. ND 
represents not defined. WT represents the wildtype allele. M1 and M2 correspond to deletion of one or 
two nucleotides, respectively. P1 corresponds to insertion of one nucleotide.
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Gene CRC % EC % CRCc %
TGFβR2 74.6 14.6 88.6
BAX 41.7 24.0 56.5
Caspase 5 47.6 11.4 84.6
PTEN 18.7 11.6 0.0
MSH6 24.3 15.8 37.0
IGFR2 20.0 16.0 22.7
CEP164 38.1 - -
PHACTR4 23.8 - 70.0
MLL3 47.6 - 70.0
PRRT2 62.5 45.8 40.0
DAB2IP 25.0 8.3 60.0
MH09-0308 Uterus m1wt wt
MH09-0363 Uterus wt -
MH09-0393 Uterus wtp1 wt
MH09-0437 Uterus m1wtp1 wt
MH09-0440 Uterus wt m1wt
MH09-0479 Uterus m1wt wtp1
MH09-0486 Uterus wt wt
MH09-0535 Uterus m1wt wt
MH09-0572 Uterus m1wt wt
MH09-0656 Uterus wt wt
MH09-0657 Uterus m1wt -
Table S7) Frequency of mutations in MNRs in known MSI sensitive target genes, and in PRRT2 and 
DAB2IP. CRC is colorectal cancer, EC is endometrial cancer and CRCc is colorectal cancer cell. A – means 
not determined. 
Table S6) Continued
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Figure S5: Expression of the PRRT2 transcript in PC346C, PC374 and LNCaP. (A) Raw expression values of 
the exon probes across the PRRT2 transcript. (B) RNAseq read distribution of the PRRT2 transcript. The 
reads mapping to PRRT2 are plotted bellow the coverage plot. The upper panel represents PC346C, the 
middle panel PC374 and the lower panel LNCaP. PRRT2 exons are depicted in blue at the end.
A)
B)
151
4
A mononucleotide repeat in PRRT2 is an important, frequent target of mismatch repair deficiency in cancer
Figure S6: Spectrum of somatic alterations in PRRT2. The cBIOPortal for cancer genomics [http://www.
cbioportal.org/public-portal/] was used to catalogue all the genetic alterations found in the PRRT2 
gene across several cancer datasets. (A) Diagram of all mutations catalogued in the PRRT2 gene. Red 
corresponds to truncating mutations and green to missense mutations. The A214P frameshift corresponds 
to the mutation also found in the PC346C cell line. (B) List of the samples containing the A214P mutation. 
This mutation has additionally been detected in 3 pancreatic adenocarcinoma samples, 1 colorectal 
adenocarcinoma sample, 1 stomach adenocarcinoma sample and 1 medulloblastoma sample. 
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Supplementary materials and methods
DNA sequencing
Paired-end sequencing of the G089 and PC346C DNA samples was performed with 
the Complete Genomics service provider using a proprietary sequencing-by-ligation 
technology and primary data analysis, including image analysis, base calling, alignment 
and variant calling (1). Reads were mapped to the NCBI Build 36.1 reference genome and 
mappings were expanded by local de novo assembly on all regions of the genome that 
contain single nucleotide variations (SNVs) relative to the reference genome (1). SNVs, 
insertions and deletions (indels) and substitutions are reported in the variation files. 
Additional information on the nomenclature used by Complete Genomics can be found 
in ‘http://www.completegenomics.com/FAQs/Variant-Calls-SNPs-and-Small-Indels/’.
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Public exon array datasets 
We used a publicly available dataset of Affymetrix Human Exon Arrays to determine the 
expression levels of PRRT2. The prostate cancer dataset contains 48 previously published 
prostate cancer samples (GSE41408, (2)) as well as additional cancerous and control 
samples, accessible via GEO accession number GSE59745. The datasets comprised 
samples from normal adjacent prostate (NAP), localized prostate cancer obtained via 
radical prostatectomy (PCa) and transurethral resection of the prostate (TURP), as well 
as metastasis in lymph node (LN PCa). Public datasets of lung cancer (GSE12236, (3)) 
and gastric cancer (GSE13195) were used to confirm the expression pattern of PRRT2. 
Table 1: Primer sequences for microsatellite analysis.
Gene symbol Primer Sequence: 5’ - 3’ Fragment length (bp)
PRRT2 Forward CTCACTCACCACCCTCAAAAA 107
Reverse TTCTCATTCGATCCTCCTCAAC
TSHZ2 Forward AAGCACGCTCTGTCTGACATC 130
Reverse CTGACATCCATTTCCAGCTTC
ANLN Forward GTGATTGTTCGGAAGGAAGATG 135
Reverse AAGCCCCTTTCCACAAAAGTA
CEP164 Forward AACACTATCGGAGCTTGGTGAT 126
Reverse GGGGTCTCTGTCCTTCTTGTCT
CNOT1 Forward CTGTCAAACATCGTGTTGAGAAT 128
Reverse CCATATTTGTTTGATGTCTTCCA
KCNMA1 Forward CCTCTCCTTACCTCATCAGCTT 121
Reverse CCGTCAACACTATCACCAAAAA
ANUBL1 Forward CCAGCATTTTCAGGAAGAAAAC 119
Reverse ACTACTAGAGCATGTTGAAAGGAAAA
EPRS Forward ACATCAGGGTCAAAGGAAAAGA 120
Reverse ACCCTGGGATAGAAAGACCATT
TTC3 Forward TCAGCCTAGAGAAACTAAGACTGAAA 115
Reverse TCCTCCTCCATTCTTTCTTGTG
SFRS12IP1 Forward CAGGAATAAATGAAGAAGAGGAAA 134
Reverse CTCATAGGCCTGCTTTGTTTTT
SFR Forward TGAAGCAAAATGTTTCCTTTTTA 125
Reverse GCTGGTATTTTGTGAGGCTTTC
DAB2IP Forward GCGCAGTTGTTAGAAGACGAG 124
Reverse CCAGGGTCCAGTTTTACCTTTT
PHACTR4 Forward AAGAGCAAGTTCTCAGGCTTTG 117
Reverse CCCTTAATATCTCACCTTCTGAAGTC
MLL3 Forward TCAGTGTGTATCTGTTGAACCAAA 133
Reverse ACTTCCGTTTTTACCTCATTGG
PDS5A Forward CAATGCAGATTCACCAAAGGAC 94
Reverse TGTGGTAGGAAAAATGAGAGGAA
TROVE2 Forward TTTGCCTTTTTGTTAGGTTTCC 166
Reverse AGAACCGGTGTAGTCGATTCAT
USP42 Forward CTGACCTCCACAGACACAAAAA 116
ACCCTGGGTAAGTGCAGTTCT
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1.  Carnevali P, et al., Computational Techniques for Human Genome Resequencing Using Mated 
Gapped Reads. Journal of Computational Biology, 2012. 19(3): p. 279-292.
2.  Boormans JL, et al., Identification of TDRD1 as a direct target gene of ERG in primary prostate 
cancer, Int J Cancer. 2013; 133(2):335–345
3.  Xi L, et al., Whole genome exon arrays identify differential expression of alternatively spliced, 
cancer-related genes in lung cancer. Nucleic Acids Res. 2008; 36(20):6535–6547
Supplementary Table 1 and Supplementary Table 2 will be made available through the 
journal’s website upon publication. 
Before publication they will be available through the following links:
Supplementary Table 1 -
https://www.dropbox.com/sh/qe2lx9obl3q4mel/AADhlj0J-Ox-B5XWUwz7c2caa?dl=0
Supplementary Table 2 - 
https://www.dropbox.com/sh/qe2lx9obl3q4mel/AADhlj0J-Ox-B5XWUwz7c2caa?dl=0

5Chapter 5
Gene fusions by 
chromothripsis of 
chromosome 5q in 
the VCaP prostate  
cancer cell line
I. Teles Alves1,2
Saskia Hiltemann3
Thomas Hartjes1
Peter van der Spek3 
Andrew Stubbs3
J. Trapman2
G. Jenster1
Departments of Urology1, Pathology2 and 
Bioinformatics3, Erasmus MC, Rotterdam, 
The Netherlands
Human Genetics, 2013, 132(6):709-13 

157
5
Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line
Abstract
The VCaP cell line is widely used in prostate cancer research as it is a unique model 
to study castrate resistant disease expressing high levels of the wild type androgen 
receptor (AR) and the TMPRSS2-ERG fusion transcript. Using next generation sequencing 
we assembled the structural variations in VCaP genomic DNA and observed a massive 
number of genomic rearrangements along the q arm of chromosome 5, characteristic 
of chromothripsis. Chromothripsis is a recently recognized phenomenon characterized 
by extensive chromosomal shattering in a single catastrophe event, mainly detected in 
cancer cells. Various structural events identified on chromosome 5q of VCaP resulted 
in gene fusions. Out of the 18 gene fusion candidates tested, 15 were confirmed on 
genomic level. In our set of gene fusions only rarely we observe microhomology flanking 
the breakpoints. On RNA level, only 5 transcripts were detected and NDUFAF2-MAST4 
was the only resulting in an in-frame fusion transcript. Our data indicate that, although 
a marker of genomic instability, chromothripsis might lead to only a limited number of 
functionally relevant fusion genes.
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Advances in DNA sequencing technologies have allowed the detailed analysis of 
genomic aberrations in cancer. Stephens et al. (2011) described massive genomic 
rearrangements, designated ‘chromothripsis’, in a subgroup of chronic lymphocytic 
leukemia (1). Subsequently, chromothripsis has been observed in several cancer cell 
lines, including lung, sarcoma, esophageal, renal, thyroid cells and in a few patient 
samples of multiple myeloma, colorectal cancer, medulloblastoma and neuroblastoma 
(2-5). 
The process of chromothripsis involves the shattering of one or a few chromosomes that 
is followed by fragment reassembly into derivative chromosomes (6). It is defined on 
the basis of three main features: the occurrence of numerous genomic rearrangements 
in localized chromosomal regions, several copy number changes alternating between 
only one, two, or occasionally three, different copy number states and the alternation 
between regions where heterozigosity is preserved with regions displaying loss of 
heterozigosity (6). The localized pattern observed for chromothripsis differs from that of 
other types of genomic instability where rearrangements tend to be dispersed genome-
wide (11-12) and suggests chromothripsis will likely occur when chromosomes are 
largely condensed. Moreover, the alternation between few copy number states strongly 
implies that the chromosomal rearrangements occurred in a short time scale, probably 
in one single mutational event (1, 13). 
Several mechanisms have been proposed to induce the massive number of genomic 
rearrangements observed in chromothripsis. Overall, the clustering pattern of 
rearrangements observed in chromothripsis is readily explained by assuming a 
condensed configuration of the chromosome by the time chromothripsis was triggered. 
Moreover, one can also consider, although less reasonably, that a chromosomal region is 
exposed to localized high-energy ionizing radiation (7). Along with telomere erosion and 
breakage–fusion–bridge cycles also abortive apoptosis after extensive chromosomal 
fragmentation and replication stress have been proposed as potential initiating triggers 
of chromothripsis (8). Currently, the most attractive model for chromothripsis combines 
both replication stress and mitotic errors with the formation of micronuclei containing 
missegregated anaphase chromosome(s) that undergo defective DNA replication. 
The fragmentation created by this first stage of chromothripsis is further repaired 
by one of the several DNA repair mechanism (9). So far, both non-replicative repair 
pathways such as non-homologous end joining (NHEJ) and replication-associated repair 
pathways such as microhomology-mediated break-induced replication (MMBIR) have 
been implicated in the reassembly process of pulverized chromosome(s) (10). In case of 
limited sequence overlap, non-homologous end joining has been suggested as the most 
probable molecular mechanism involved in reconnecting the shattered DNA fragments 
(4). 
In this study, whole-genome paired-end sequencing was performed on DNA from the 
prostate cancer cell line VCaP (14). This cell line is widely used as a model for research 
on castration-resistant prostate cancer (CRPC). It is derived from a vertebral metastatic 
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lesion, grows androgen-dependently and has an amplified androgen receptor (AR) 
gene and the common TMPRSS2-ERG fusion gene (15). The genome was sequenced 
at an average coverage of 113x and an average fully called genome fraction of 97.6% 
(Supplementary methods). Overall, we detected 2414 high confidence structural 
variation (SV) breakpoint events of which less than 4% juxtaposed portions of gene 
sequences on both sides (Figure 1a). By far the highest number (573; 24%) mapped on 
chromosome 5q (Figure 1b, Table S1).
The pattern of rearrangements observed in 5q strongly resembles the chromothripsis 
phenomenon recently described in cancer cells (16). First, we observed a large number 
of rearrangements in a localized chromosome location (5q). Second, the copy number 
distribution in 5q varied predominantly between two copy number states with sporadic 
regions of three (Figure 2, Figure S1). The regions with lower copy number have retained 
heterozygosity (Figure 2, Figure S1). The rare presence of loss of heterozigosity regions 
correlates with the fact that the VCaP cell line has a near-triploid genome, in which, 
most likely the chromothripsis event happened after the duplication. In addition, the 
breakpoints in 5q were remarkably clustered in smaller regions, with six rearrangements 
involving a 7 kb region between 81.121 Mb and 81.128 Mb (Table S1) although the 
normal distance between the two joined fragments is normally of tens of megabases. 
Out of the 573 SV breakpoints involving 5q, only four were interchromosomal, 
involving hence rearrangements between chromosome 5 and other chromosomes 
Figure 1: Circos plots showing structural and copy number variation across the whole genome (A) and 
chromosome 5 (B) of VCaP. Each chromosome is represented in the outer ring. The outer data ring 
corresponds to copy number variation, with regions of gain depicted in green and loss in red. The inner 
data ring represents B-allele frequency. The intra and interchromosomal rearrangements are on the 
inside and depicted in black and red lines, respectively.
A) B)
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(Table S1). Remarkably, sequencing of the breakpoint junctions of these SV 
breakpoints revealed frequent insertions of novel sequences (186/573) (Table 
S2). In the gene fusions resulting from complex chromothripsis rearrangements in 
5q, these insertions of up to 255 bp corresponded to fragments of chromosome 
5 located within 7 to 53 Mb distance of the adjacent fusion partner. We rarely observe 
microhomology flanking the breakpoints in our set of gene fusions and, in a few cases, 
we could detect repeats flanking both sides of the breakpoint junction (Table S3).
Forty-three out of the 573 SV breakpoint events on 5q were in different genes at both 
sides, with 18 of these involving genes in the same orientation capable of originating 
functional gene fusions (Table 1, Figure S2).
In order to confirm the 18 candidate gene fusions detected by sequencing we have 
designed PCR reactions spanning sequences on both genes. We could validate 15 
Figure 2: Clustered rearrangements on chromosome 5q of VCaP. Copy number across chromosome 5 
oscillates between a copy number of 2, 3 and 4. Copy number 2 corresponds to segments of SNP probes 
bellow the zero line, copy number 2 to segments of SNP probes in the zero line and copy number 4 to 
segments of SNP probes above the zero line. The B-allele frequency plot is displayed bellow the copy 
number plot.  
1
0.8
0.6.
0.4
0.2
0
1
0.8
0.6.
0.4
0.2
0
1.5
1
0.5
0
-0.5
-1
-1.5
1.5
1
0.5
0
-0.5
-1
-1.5
0 Mb 20 Mb 40 Mb 60 Mb 80 Mb 100 Mb 120 Mb 140 Mb 160 Mb
70 Mb 75 Mb 80 Mb 85 Mb 90 Mb
180 Mb
A)
B)
161
5
Gene fusions by chromothripsis of chromosome 5q in the VCaP prostate cancer cell line
5' Donor 
gene
3' Acceptor 
gene
5' Chr 3' Chr Validated 
cDNA
Validated 
DNA
In frame # of 
Discordant 
mate pairs
PDE4D C5orf47 5 5 yes yes no 218
CPLX2 UBXD8(FAF2) 5 5 no yes no 55
EBF1 FBXL17 5 5 no yes no 74
KCNN2 EBF1 5 5 no yes yes 509
RASGRF2 RNF145 5 5 no yes no 71
JMY DMGDH 5 5 yes yes no 102
TRIM40 FBXO38 6 5 no yes no 89
LMAN2 AP3S1 5 5 yes yes no 191
EFNA5 PCDHB7 5 5 no yes no 11
YTHDC2 PPP2R2B 5 5 no yes no 8
PDE8B UIMC1 5 5 no yes no 63
ZFP62 RGNEF 5 5 no yes no 225
NDUFAF2 MAST4 5 5 yes yes yes 197
ADAMTS12 PXDNL 8 5 no no no 3
EBF1 FEM1C 5 5 no yes no 11
PDE4D FAM172A 5 5 yes yes no 119
PDE4D PPP2R2B 5 5 no no no 12
PPP2R2B FAM172A 5 5 no no yes 7
Table 1: List of gene fusions involving chromosome 5 of VCaP. The column 5’ Chr refers to the 
chromosome number of the 5’ donor gene and the column 3’ Chr refers to the chromosome number of 
the 3’ acceptor gene. The column # of discordant mate pairs displays the number of mate pair reads that 
are discordant in relation to the reference genome build and concordant with the respective reported 
SV event (gene fusion).
candidate gene fusions at the DNA level (Figure S3) whereas only one third were 
detected on mRNA level suggesting downregulation of gene expression or instability 
of the fusion transcripts (1). The two non-validated gene fusions PDE4D-PPP2R2B 
and PPP2R2B-FAM172A represent by-products of the PDE4D-FAM172A gene fusion 
in which a small fragment of PPP2R2B sequence is inserted in-between the PDE4D 
and FAM172A genes. Conversely, the ADAMTS12-PXDNL candidate gene fusion had 
a very low number of confirming DNA reads and hence is most likely a sequencing 
artifact (Table 1). Chromothripsis, being a seemingly random process, originates 
highly derivative chromosomes with numerous mutations and rearrangements. The 
formation of gene fusions as a consequence of the chromothripsis event does not 
seem to be preferential over rearrangements occurring outside genes (43 versus 
573). Moreover, we did not observe positive selection for in-frame fusion transcripts 
since only one out of the five expressed fusion transcripts resulted in a feasible 
fusion protein. The role of this fusion between NDUFAF2 and MAST4 remains to 
be determined (Figure S4, Table S4). Using PCR, we observed that all 15 fusions 
detected in VCaP were also present in the DuCaP cell line, which is derived from a 
dura mater metastasis from the same patient that gave rise to VCaP (17)), indicating 
that chromothripsis occurred in the cells that resulted in both VCaP and DuCaP 
metastases (Figure S3 and S4) (data not shown). The confirmation that both VCaP 
and DuCaP harbor the gene rearrangements identified in chromosome 5 supports 
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the assumption that these were present in the precursor prostate adenocarcinoma 
lesion rather than being cell line cultivation artifacts. 
In our whole genome study of VCaP cells we also detected a fairly complex rearrangement 
involving the TMPRSS2 and ERG genes on chromosome 21q. The TMPRSS2-ERG fusion in 
VCaP results from the assembly of the ERG and TMPRSS2 breakpoints with the insertion 
of two fragments of TMPRSS2 (Table S5). This did not disrupt the transcript and open 
reading frame of the final fusion product (18). 
Recently, an association between TP53 mutations and chromothripsis has been 
observed for acute myeloid leukemia and pediatric medulloblastoma (4). In order to 
determine the mutational status of TP53 in the VCaP cell line we have examined all 
the single nucleotide variants (SNVs) detected by next-generation sequencing in the 
TP53 gene (Table S6). We observed two homozygous missense SNVs present in the TP53 
coding DNA sequence (CDS): c.742C>T and c215C>G. The c.742C>T (p.R248W) is a well 
known hotspot TP53 mutant with no residual activity whereas the c215C>G (p.R72P) is 
a natural occurring variation in exon 4 of TP53. As a result of the c.742C>T SNV the VCaP 
cell line has no wild type functional p53, a key player in the maintenance of genomic 
stability. In addition, we have also examined whether there were SNVs present in DNA 
repair genes previously shown to be altered in prostate cancer (19) (Table S7).
 
Interestingly, we found the genes ATM, MLH1, PRKDC and ERCC5 to have missense 
SNVs in the respective CDS. The only SNVs described to be mutational were present 
both in the ATM gene (COSMIC mutation ID number 21826 and 21827) (20). An SNV 
present in the intron 7 acceptor splicing site of the XRCC4 gene (rs1805377) has shown 
to be significantly associated with increased prostate cancer risk (21). The homozygous 
missense c.655A>G SNV present in the MLH1 gene (p.I219V) has been associated with 
increased risk of colorectal cancer (22). Deficiencies in the DNA mismatch repair system 
are commonly observed in colorectal cancer and to a less extend in prostate cancer. 
The influence of the c.655A>G (p.I219V) missense SNV in the development of prostate 
cancer remains undetermined.
Here we report the structural variations detected in VCaP and show that the q arm of 
chromosome 5 has undergone chromothripsis. Chromosome 5 appears to be frequently 
affected by chromothripsis with studies showing the same pattern in a renal cancer 
cell line (1) and a neuroblastoma patient (5). It remains undetermined, however, 
whether chromosome-dependent properties or the nonrandom radial localization 
of chromosomes in distinct territories play a role in the preferential target of certain 
chromosomes by chromothripsis. Whether the catastrophic events on 5q in VCaP, 
and the related cell line DuCaP, have been playing and still play an important role in 
tumorigenesis remains to be determined. 
The massive number of genomic breaks occurring in chromosome 5q hampers the 
formulation of a definitive model for the generation of chromothripsis.  The copy number 
variation and B-allele frequency of chromosome 5q in VCaP is a repetition of regions 
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with n2 (AB), n3 (AAB) and n4 (AAAB) (Figure S1). Based on chromosome painting, 
VCaP is an overall near-triploid cell line with 4 copies of chromosome 5 that vary in 
size (23). We hypothesize that this pattern is explained by two normal chromosome 
copies (n2 (AB)) and two copies of A with chromothripsis (n4 (A*A*AB)) of which one 
of the two copies has undergone additional rearrangements resulting in n3 (A*AB). The 
sequence of events that would lead to this pattern is a duplication of A and B (AABB) 
and subsequent loss of one B allele (AAB). One of the A alleles would have undergone 
chromothripsis (A*AB) and duplication (A*A*AB). Additional rearrangements (deletions 
or even a second chromothripsis event) would explain the observed 5q regions of n3 
A*AB (Figure S5). Our study has shown that research on genes located on and transcripts 
derived from chromosome 5q, need to take the chromothripsis into account. Besides 
being a widely used model for research on AR, ERG and CRPC, VCaP might prove a highly 
relevant model for research on chromothripsis.  
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 Supplementary data:
Figure S1: Copy number and B-allele frequency distribution across a region on chromosome 5q. Each 
blue dot represents a SNP detected on the 1M SNP Illumina array. Chromosome 5 is depicted on top 
with the red box corresponding to the zoomed-in region. The copy number variation plotted varies from 
copy number state 2 to 4.
Figure S2: Circos plots of the 43 gene rearrangements present on chromosome 5q of VCaP. (A) represents 
25 rearrangements between genes of different orientations and (B) represents 18 rearrangements 
between genes with the same orientation.
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Figure S3: RT-PCR of the validated DNA fusions (electrophoresis on a 1% agarose gel). The gene fusion 
name and sample is displayed on top of the corresponding wells. We have used VCaP and DuCaP as 
our test samples and LNCaP as a control for specificity. LNCaP is a cell line derived from a lymph node 
carcinoma of the prostate. It is nearly-tetraploid and displays a stable karyotype [1-2]. The positive 
control consists of primers within the NCAPD2 gene.
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Figure S3: Continued
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Table S2: DNA alignment of the validated gene fusions. The DNA sequences corresponding to the first 30 
bp before and after the junctions obtained by sequencing of the PCR products. The red nucleotide here 
present represent a difference in relation to the reference genome. The transition sequence found in the 
junction is depicted in red in an additional row and the red nucleotides in the 30bp sequences represent 
variation found in the sequencing of the PCR products to the reference genome. 
PDE4D [ENST00000405755] Intron 5-6 - C5orf47 [ENST00000522195] Intron 1-2
AATGACAGTAATTGGAAGCAGTGTAGAAAG TCTCTGTTTTCCTGGTATGTTCCTGCAGTA
C
CPLX2 [ENST00000359546] Intron 2-3 - UBXD8 [ENST00000261942] Intron 10-11
CAGGAGAATCGCTTGAACCTGGGAGGCGGA GCTTGTGGTGAGCTGAGATGGCGCCATTGC
FBXL17 [ENST00000359660] Intron 5-6 - EBF1 [ENST00000313708] Intron 11-12
TATTTAACATACAAATAGTAACATCATCAA TGGTATGCCTTCTTCATTAACTGCTCATAA
KCNN2 [ENST00000264773] Intron 5-6 - EBF1 [ENST00000313708] Intron 11-12
TCAAGAGACAAAATCACCTGCAGGAGAGAA TTCAAGACAGAGTCATATATGTCACCAATA
RASGRF2 [ENST00000265080] Intron 2-3 - RNF145 [ENST00000274542] Intron 2-3
ACTGTATTCATTTTCTATTCTGTAACAAAT GGGAAAGTTCCTTTATGTTGCAAAACACTG
DMGDH [ENST00000255189] Intron 7-8 - JMY [ENST00000396137] Intron 2-3
GCCCTTCTGTGTTCCAGGAAATAGTTGCCC CGTAATTAGTCGATTGTACCTAAAACCTTA
FBXO38 [ENST00000340253] Intron 12-13 - TRIM40 [ENST00000383610] Intron 2-3
TGGGTGGTGATGCCCCTGGGCTAGTGAAGA AAATTTAACGTGGAGTTATCCTTCACACAA
AP3S1 [ENST00000316788] Intron 1-2 - LMAN2 [ENST00000303127] Exon 2
GTCTCTACTAAAAATACAAAAATAGCTGGG AGACGTACGTACTGGCTCGTGAGCATAGTG
AGTGAGATAGCAGGGTAAGGTTAACCCTCACCTCCCCAGCACAGAAAGGACTG
CAGAAAGCCCCGAGAGCCTCAGGCTGCCTCCACCTCTGTCTCTGCAGTGCCTTT
EFNA5 [ENST00000333274] Intron 1-2 - PCDHB7 [ENST00000231137] Exon 1
GGTTCCTGCCAGTGGGTATGCGACAGGAAG GCTGCAGAATGGCTCCGCGCCCTGCACCGA
YTHDC2 [ENST00000161863] Intron 2-3 - PPP2R2B [ENST00000394413] Intron 5-6
CTTACTCTATGTCCCCGCAAAGGACATGAA TTGAAGCCCAGAGAGTGAAGTGGAGCATGG
AATTTGATTGTGCTGTGGTCTGAGAGAGTGGTTGTTGTAATATCAATTCTTT
TGCATTTGCTGAGCAAAGTTTTGTATTTGATTATATAATCAGTTTTAGAGTA
PDE8B [ENST00000264917] Intron 1-2 - UIMC1 [ENST00000274827] Intron 10-11
CTTTTTTTGGTTGCTCCAGAGAAATTGTGA CAGAATGAATACTGGTAACACTCCAACTTG
NDUFAF2 [ENST00000296597] Intron 1-2 - MAST4 [ENST00000403625] Intron 2-3
AAGGCTGCCCAAATATCTCTCCTGGCCTGT TGTGCAGGGTTGAATAACAATGGTTCTTAA
FEM1C [ENST00000274457] Intron 2-3 - EBF1 [ENST00000313708] Intron 6-7
GTAACAAGACAACTCACAAAAGACTACATA ACATTGCTCTATGACTGCCACTTACTAATC
GGGACATGAACATCAGAATGACTTGATAACATTGCTTGTTTTGAGCTTTTCCTTCAAAT
TTTAGCCCCTGATGTGGTTTGTTTACGGTAACAACAACAGGAATACTCACTGAGCCACT
ACTACATACAGGCACTTTGCTCAGTGCTGGAAATACAGCAGTGATCCATGGACCAAAA
TCCCTGTTCTAGTGCAGATGACATTCTTTCTAATGAGGTGAGAAAGATAATAAGCAACA
CAAATAATAAATAAGTAAGT
PDE4D [ENST00000405755] Intron 1-2 - FAM172A [ENST00000265139] Intron 9-10
ATTTATGTGCTATGTACTGTGTAATCCACC AGAATTGTCAGCCACTAAGTTTATCAAGCT
CAGCATGCTTCAGTGGTACCACTATGAGTCTTTAGACCTGGGGAAACTACACCTT
170
Table S3: List of repeats flanking both sides of the junction
Figure S4: RT-PCR of the validated RNA fusions 
(electrophoresis on a 1% agarose gel). The gene fusion 
name and sample is displayed on top of the corresponding 
wells. We have used VCaP and DuCaP as our test samples 
and LNCaP as a control for specificity. BL represents the 
blank control (no cDNA). The positive control consists of 
primers within the GAPDH gene. 
5' Donor 
gene
3' Acceptor 
gene
5' Chr 3' Chr LeftRepeat  Classification RightRepeat 
Classification
PDE4D C5orf47 5 5 L1PB1:LINE:L1
CPLX2 UBXD8 5 5 AluY:SINE:Alu AluY:SINE:Alu;Self chain
EBF1 FBXL17 5 5
KCNN2 EBF1 5 5 MER20:DNA:   MER1_type
RASGRF2 RNF145 5 5 MLT1E2:LTR:MaLR
JMY DMGDH 5 5
TRIM40 FBXO38 6 5
LMAN2 AP3S1 5 5 L2:LINE:L2 L1PA8:LINE:L1
EFNA5 PCDHB7 5 5 AluSc:SINE:Alu;Self chain Self chain
YTHDC2 PPP2R2B 5 5 SegDup;Self chain
PDE8B UIMC1 5 5 AluSx:SINE:Alu; Self chain
ZFP62 RGNEF 5 5
NDUFAF2 MAST4 5 5 LTR71A:LTR:ERV1
EBF1 FEM1C 5 5 L1MB8:LINE:L1
PDE4D FAM172A 5 5
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Table S4: RNA alignment of the validated gene fusions. The sequencing data was used to predict the 
gene fusions at RNA level. The RNA sequences and the corresponding protein translations of the first 
30 bp before and after the junctions obtained by sequencing of the PCR products are depicted below. * 
represents the fusions in frame.
Table S5: List of junction related to the event generating the TMPRSS2-ERG gene fusion in VCaP. The 
scheme bellow represents the three junctions with matching position numbers and leading to the 
TMPRSS2-ERG fusion. 
PDE4D [ENST00000405755] Exon 5 - C5orf47 [ENST00000522195] Exon 2
AACCATCCATCAACAAAGCCACCATAACAG GCAGCAAGCCAATCACTGAGGTGATGCGTT
Q--P--S--I--N--K--A--T--I--T-- ..............................
       
JMY [ENST00000396137] Exon 2 - DMGDH [ENST00000255189] Exon 8
CTTGCCATGCTACGAAGACAGCAGATCAAG ATATGGCATAATCCACGCTGGTGGGGTAGG
-L--A--M--L--R--R--Q--Q--I--K- --Y--G--I--I--H--A--G--G--V--G
       
LMAN2 [ENST00000303127] Exon 1 - AP3S1 [ENST00000316788] Exon 2
GGGAGCATTCGCTCATTAAGCCCTACCAAG AGTGAAGATACACAACAGCAAATCATCAGG
R--E--H--S--L--I-=K=-P--Y--Q-- -S--E--D--T--Q--Q--Q--I--I--R-
       
* NDUFAF2 [ENST00000296597] Exon 1 - MAST4 [ENST00000403625] Exon 3
ACTACATCCCGCAGTACAAGAACTGGAGAG GGAGGTACCTTCTTCCAAACCCGGTGGCGG
Y--Y--I--P--Q--Y--K--N--W--R-- G--R--Y--L--L--P--N--P--V--A--
       
PDE4D [ENST00000405755] Exon 1 - FAM172A [ENST00000265139] Exon 10
GATTGCTATCACTTCTGCAGAATCCAGTGG GCACCGACCGTCACGAGCTAACTTCCTGGA
--I--A--I--T--S--A--E--S--S--G G--T--D--R--H--E--L--T--S--W--
Left gene Chr Position seqO Righ Gene Chr Position seqO Mate pairs
TMPRSS2 chr21 41779386 - TMPRSS2 chr21 41793822 + 307
\ chr16 66265351 - ERG chr21 38798283 + 12
TMPRSS2 chr21 41775625 - TMPRSS2 chr21 41786403 - 13
C16orf70 chr16 65702685 - TMPRSS2 chr21 41775590 - 49
ERG chr21 38798223 + TMPRSS2 chr21 41779892 - 474
C16orf70 chr16 65702689 + \ chr16 66265338 - 294
172
Figure S5: Hypothesis on the chain of events leading to copy number variation and B- allele frequency 
profile of VCaP. As can be observed in figure S1, the most likely sequence of events explaining VCaP’s copy 
number and B-allele frequency will be a duplication of the two normal chromosome copies followed by 
the loss of one B allele (although the duplication of only A cannot be excluded). Next, one of the A alleles 
undergoes chromothripsis and is duplicated. Now, with two copies of A*, one wild type copy of A and 
one wild type copy of B there are two possible situations: 1. One of the A* suffers additional deletions, 
or 2. One of the A* undergoes another chromothripsis event.
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Table S6) Single nucleotide variations (SNVs) detected by next-generation sequencing in the TP53 gene 
of the VCaP cell line. All except intronic SNVs are shown. The column type refers to the variation type 
(snp – single nucleotide polymorphism; sub – substitution; del – deletion). The reference is the base 
present at that position in the reference genome and the call is the base present at that position in 
the VCaP sample. Haplotype discriminates between heterozygous (het) and homozygous (hom) SNVs. 
Component refers to the component of the gene that is affected (CDS – coding DNA sequence; TSS-
UPSTREAM – transcription start site-upstream). Protein Pos is the aminoacid position that is modified 
by the SNV, Ref Seq is the aminoacid present in the reference protein sequence and Sample Seq the 
aminoacid present in the VCaP protein sequence.
Chr Position Type Reference Call Haplotype Component Protein 
Pos 
Ref 
Seq 
Sample 
Seq 
chr17 7518263 snp G A hom CDS 247 R W 
chr17 7520196 snp G C hom CDS 71 P R 
chr17 7532892 snp C G hom TSS-
UPSTREAM 
chr17 7534043 snp T C hom TSS-
UPSTREAM 
chr17 7534564 snp A G hom TSS-
UPSTREAM 
chr17 7535187 snp G T hom TSS-
UPSTREAM 
chr17 7535209 snp T C hom TSS-
UPSTREAM 
chr17 7535252 del AAACAAA 
CAAACAA AC 
hom TSS-
UPSTREAM 
chr17 7535434 sub G TT hom TSS-
UPSTREAM 
chr17 7535500 snp C T hom TSS-
UPSTREAM 
chr17 7535712 snp A G hom TSS-
UPSTREAM 
chr17 7536162 snp A G hom TSS-
UPSTREAM 
Table S7: Single nucleotide variations (SNVs) detected by next-generation sequencing in the selected 
DNA repair genes in the VCaP cell line. All except intronic and TSS (transcription start site) SNVs are 
shown. The column type refers to the variation type (snp – single nucleotide polymorphism; ins – 
insertion; del – deletion). The reference is the base present at that position in the reference genome 
and the call is the base present at that position in the VCaP sample. Haplotype discriminates between 
heterozygous (het) and homozygous (hom) SNVs. Component refers to the component of the gene that 
is affected (CDS – coding DNA sequence; UTR3 – untranslated region 3’; UTR5 – untranslated region 5’; 
acceptor – acceptor splicing site and donor – donor splicing site). Protein Pos is the aminoacid position 
that is modified by the SNV, Ref Seq is the aminoacid present in the reference protein sequence and 
Sample Seq the aminoacid present in the VCaP protein sequence. 
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Chr Position Type Reference Call Haplotype Component Protein 
Pos 
Ref Seq Sample Seq 
ATM 107599042 snp G A het UTR5
ATM 107643212 snp T C het CDS 857 F L
ATM 107648665 snp C G het CDS 1053 P R
ATM 107656917 ins A het ACCEPTOR 1134 TAATTTCTTTTT 
AAG
TAAATTTCTTTTT 
AAG
ATM 107663343 snp T C het UTR5
ATM 107688376 snp A G hom CDS 1982 N S
ATM 107741992 snp G T het UTR3
ATM 107743048 snp C T het UTR3
ATM 107744837 snp G T het UTR3
BRCA1 38449933 snp G A hom UTR3
BRCA1 38450347 del TT het UTR3
BRCA1 38450799 snp C A hom UTR3
BRCA1 38476619 snp T C hom CDS 1612 S G
BRCA1 38487995 snp A G hom CDS 1435 S S
BRCA1 38497525 snp T C hom CDS 1182 K R
BRCA1 38497960 snp T C hom CDS 1037 E G
BRCA1 38498461 snp G A hom CDS 870 P L
BRCA1 38498762 snp A G hom CDS 770 L L
BRCA1 38498991 snp G A hom CDS 693 S S
BRCA2 31787791 snp A G het UTR5
BRCA2 31810298 snp T C het CDS 1268 V V
BRCA2 31811054 snp A G hom CDS 1520 L L
BRCA2 31813004 snp G C hom CDS 2170 V V
BRCA2 31827386 snp T C hom CDS 2465 V A
BRCA2 31834645 snp T C het ACCEPTOR 2601 CTTTTATTTGTT 
CAG
CCTTTATTTGTT 
CAG
BRCA2 31871011 snp A C het UTR3
BRCA2 31871275 snp A G het UTR3
ERCC2 50560148 snp T G het CDS 155 R R
ERCC4 13933507 snp G A hom ACCEPTOR 324 AACTTTTCGTAT 
TAG
AACTTTTCATAT 
TAG
ERCC5 102296198 snp A G hom UTR5
ERCC5 102296375 snp T C het UTR5
ERCC5 102302517 snp T C hom CDS 45 H H
ERCC5 102312459 snp C T het CDS 319 D D
ERCC5 102318565 snp A G het CDS 878 N S
ERCC5 102325849 snp G C hom CDS 1052 G R
ERCC5 102325930 snp G C hom CDS 1079 G R
ERCC5 102326337 snp G A het UTR3
MLH1 37028571 snp A G hom CDS 218 I V
PRKDC 48901857 snp G A het CDS 2898 R C
PRKDC 48903465 ins A het ACCEPTOR 2798 TTGAATTTTTTA 
CAG
TTGAATTTTTTTA 
CAG
PRKDC 48968369 ins G hom CDS 1243 F L
PRKDC 49009071 snp T C het DONOR 541 GTAACA GTAACG
RAD50 131920877 snp G A hom UTR5
XRCC4 82684698 snp G A het ACCEPTOR 297 TGATTTTCTTTT 
CAG
TGATTTTCTTTT 
CAA
XRCC4 82684732 snp T G het CDS 308 S S
XRCC4 82685222 snp T C het UTR3
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Chr Position Type Reference Call Haplotype Component Protein 
Pos 
Ref Seq Sample Seq 
ATM 107599042 snp G A het UTR5
ATM 107643212 snp T C het CDS 857 F L
ATM 107648665 snp C G het CDS 1053 P R
ATM 107656917 ins A het ACCEPTOR 1134 TAATTTCTTTTT 
AAG
TAAATTTCTTTTT 
AAG
ATM 107663343 snp T C het UTR5
ATM 107688376 snp A G hom CDS 1982 N S
ATM 107741992 snp G T het UTR3
ATM 107743048 snp C T het UTR3
ATM 107744837 snp G T het UTR3
BRCA1 38449933 snp G A hom UTR3
BRCA1 38450347 del TT het UTR3
BRCA1 38450799 snp C A hom UTR3
BRCA1 38476619 snp T C hom CDS 1612 S G
BRCA1 38487995 snp A G hom CDS 1435 S S
BRCA1 38497525 snp T C hom CDS 1182 K R
BRCA1 38497960 snp T C hom CDS 1037 E G
BRCA1 38498461 snp G A hom CDS 870 P L
BRCA1 38498762 snp A G hom CDS 770 L L
BRCA1 38498991 snp G A hom CDS 693 S S
BRCA2 31787791 snp A G het UTR5
BRCA2 31810298 snp T C het CDS 1268 V V
BRCA2 31811054 snp A G hom CDS 1520 L L
BRCA2 31813004 snp G C hom CDS 2170 V V
BRCA2 31827386 snp T C hom CDS 2465 V A
BRCA2 31834645 snp T C het ACCEPTOR 2601 CTTTTATTTGTT 
CAG
CCTTTATTTGTT 
CAG
BRCA2 31871011 snp A C het UTR3
BRCA2 31871275 snp A G het UTR3
ERCC2 50560148 snp T G het CDS 155 R R
ERCC4 13933507 snp G A hom ACCEPTOR 324 AACTTTTCGTAT 
TAG
AACTTTTCATAT 
TAG
ERCC5 102296198 snp A G hom UTR5
ERCC5 102296375 snp T C het UTR5
ERCC5 102302517 snp T C hom CDS 45 H H
ERCC5 102312459 snp C T het CDS 319 D D
ERCC5 102318565 snp A G het CDS 878 N S
ERCC5 102325849 snp G C hom CDS 1052 G R
ERCC5 102325930 snp G C hom CDS 1079 G R
ERCC5 102326337 snp G A het UTR3
MLH1 37028571 snp A G hom CDS 218 I V
PRKDC 48901857 snp G A het CDS 2898 R C
PRKDC 48903465 ins A het ACCEPTOR 2798 TTGAATTTTTTA 
CAG
TTGAATTTTTTTA 
CAG
PRKDC 48968369 ins G hom CDS 1243 F L
PRKDC 49009071 snp T C het DONOR 541 GTAACA GTAACG
RAD50 131920877 snp G A hom UTR5
XRCC4 82684698 snp G A het ACCEPTOR 297 TGATTTTCTTTT 
CAG
TGATTTTCTTTT 
CAA
XRCC4 82684732 snp T G het CDS 308 S S
XRCC4 82685222 snp T C het UTR3
Table S8: Primers for the validation of the fusions on DNA level. 
1 PDE4D Fw DNA TCAGGGGACTGGGAACAGTA 340
C5orf47 Rv DNA GGCAAGTAGCAGGCAGGACT
2 CPLX2 Fw DNA CAACGTAACGCAATTCATGC 541
UBXD8 Rv DNA CCACAACTTGGCTCTCAAAA
3 FBXL17 Fw DNA TGAAATCCAGAGAAGAAGATGGA 248
EBF1 Rv DNA AATGGGGCATTAATGGTTTG
4 KCNN2 Fw DNA AACCTTGGCACTCGTGACTT 327
EBF1 Rv DNA TCTCCCACATAAAGCCCAAG
5 RASGRF2 Fw DNA GTGATCGTAGCCTCGTGACA 272
RNF145 Rv DNA AAGCCAAGTACCCAGTTGTTC
6 DMGDH Fw DNA ATGCAAAGAGAAAGCTCCAG 516
JMY Rv DNA TGTGATTTGCACTCTCAAACCT
7 FBXO38 Fw DNA ATGGTGCCTTTGGGCTAGT 244
TRIM40 Rv DNA TGAGTGTGCTGCTCTGTTTT
8 AP3S1 Fw DNA TAAAGCCAAGGATTGGGTCA 319
LMAN2 Rv DNA TGGCCTCTTAGCACCTGTCT
9 EFNA5 Fw DNA ACATGACCTCGCCATAAAGG 317
PCDHB7 Rv DNA ACCACCAGGTAGACGGTGAG
10 YTHDC2 Fw DNA CTTTCCCCCTAATCCCTGAC 261
PPP2R2B Rv DNA CTGAAAGGTGAGGCTTCTGC
11 PDE8B Fw DNA ATGTGCTGAACGCTATACTTTGC 606
UIMC1 Rv DNA GGTCAAGTTGGAGTGTTACCAG
12 RGNEF Fw DNA CCCTTAGAAGCCACCATGTC 254
ZFP62 Rv DNA GGAAAACTAAGGGCCTCCAA
13 NDUFAF2 Fw DNA AGCTCGTGTCAGGTTTGCTTAT 474
MAST4 Rv DNA GGAACTGTGTAACCTGCTCTCC
14 FEM1C Fw DNA CAACCCAATAATGCCACTCC 395
EBF1 Rv DNA TGTTCCGGAATCAAGCAGATA
15 PDE4D Fw DNA CCTCTTCCCCCATAAAACG 398
FAM172A Rv DNA AAGCAGACTGGTGCCAAAA
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Table S9: Primers for the validation of the fusions on RNA level 
1 PDE4D Fw cDNA ATCCGACAGCGATTATGACC 160
C5orf47 Rv cDNA TCAGGTTTGTTCTCCCGTCT
2 CPLX2 Fw cDNA ATCTGCTCTGCTCAGCGACT 127
UBXD8 Rv cDNA TGGGAAAATTGGCTTCAATC
3 EBF1 Fw cDNA AGGGGACAATTTCTTTGATGG 325
FBXL17 Rv cDNA CGTAGGTCCAAGCTGGAAAG
4 KCNN2 Fw cDNA TAATTGCCGCATGGACTGT 623
EBF1 Rv cDNA GCTCGTGGTGACGGAGTTAT
5 RASGFR2 Fw cDNA CTGCAGCTGCGAACGAAC 382
RNF145 Rv cDNA AAGGCTGTGGTAAACCGATTC
6 JMY Fw cDNA GCCTTGCAGAAGCTACAACC 206
DMGDH Rv cDNA CATTTGCCATAGCGATTAGGA
7 TRIM40 Fw cDNA AACCACCAGAAGAGGGTGTG 375
FBXO38 Rv cDNA AACGCCGAGTACCGTTCTTA
8 LMAN2 Fw cDNA TTTTGTTGTTGGGGTCTGTG 210
APS3S1 Rv cDNA CAGTTTGTTGTCAGATCCTCCA
9 EFNA5 Fw cDNA CTGGTGCTCTGGATGTGTGT 263
PCDHB7 Rv cDNA ACCACCAGGTAGACGGTGAG
10 YTHDC2 Fw cDNA ATTCGCATTGATGAGGAGGT 257
PPP2R2B Rv cDNA ACACGAAGGTGTTGCAATGA
11 PDE8B Fw cDNA GTGATCTACTGCCGGGACTC 350
UIMC1 Rv cDNA TGTCCCACTGTCACTCTTGG
12 ZFP62 Fw cDNA CTGTCTTCATGGTTTCATAGCC 333
RGNEF Rv cDNA GTGCTGTCCCTTCGACATTT
13 NDUFAF2 Fw cDNA TTGTGGAGATCGCTGTCAAG 301
MAST4 Rv cDNA GTGACTGCCCATTGCCTATT
14 EBF1 Fw cDNA TGAAGGCCAAGACAAGAACC 392
FEM1C Rv cDNA GTATTTCAAAGCCCCAAGCA
15 PDE4D Fw cDNA GAACATTCAACGACCAACCA 289
FAM172A Rv cDNA CTCGACACAAGCAGTGAGGA
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Supplementary methods:
Paired-end sequencing of the VCaP DNA sample was performed with the Complete 
Genomics service provider using a proprietary sequencing-by-ligation technology and 
primary data analysis, including image analysis, base calling, alignment and variant 
calling (1). Reads were mapped to the NCBI Build 36.1 reference genome and mappings 
were expanded by local de novo assembly on all regions of the genome that contain 
single nucleotide variations (SNVs) relative to the reference genome (1).  Structural 
variations (SV) reported in the junctions files do not contain SNVs, inserts and deletions 
(indels) or substitutions (subs) but include information on junctions represented by 3 or 
more discordant mate pairs. The “HighConfidenceJunctionBeta” files contain all 
junctions which have been filtered for their absence from a set of v2.0 baseline genomes 
(as provided at the website of Complete Genomics (B36baseline-junctions.tsv)) (2).  The 
junctions (left and right positions) are annotated with gene features (exons, gene 
symbol) derived from UCSC genome browser (3) using the rtracklayer package (4) in R 
(3-4). The junctions located inside such exons are further categorized as junctions with 
different genes on both sides, with the same genes or junctions with only one gene on 
either the left or right side. The following table depicts how the single intrachromosomal 
structural variation events are called per junction. Note from personal communication 
with CGI: “+/+ junction may indicate a deletion or insertion, but our current process 
only detects deletions.” 
Data analysis was performed on Hg18 annotated genome of VCaP. CGA tools were used 
to analyze the data (http://cgatools.sourceforge.net/docs/1.3.0/) (5). 
The data here obtained will be deposited in the Sanger Institute Catalogue Of Somatic 
Mutations In Cancer (COSMIC). 
Copy number variation and B-allele frequency was obtained using Infinium Illumina 
Human 1M probe BeadChip microarrays. We have used the values of ≤ -0.2 for copy 
number loss and ≥ 0.2 for copy number gain. 
DNA and RNA isolation were performed using the RNeasy kit (Qiagen) and the QIAamp 
DNA Blood Midi Kit (Qiagen) according to the manufacturers protocol. Concentration and 
purity of DNA and RNA was assessed using the NanoDrop ND 1000 spectrophotometer 
(Nanodrop products) by absorption measurements at 280 nm and 260 nm, respectively. 
RNA was stored at -80˚C. DNA was stored at -20˚C.
Junction Left Strand Junction Right Strand Single Event
+ + deletion
- - inversion or deletion
+ - inversion
- + inversion
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VCaP was cultured in RPMI-1640 (Lonza) with 10% FCS (PAN Biotech) and 1% penicillin-
streptomycin (BioWhittaker). LNCaP and DuCaP were cultured in DMEM (BioWhittaker) 
with 5% FCS (PAN Biotech) and 1% penicillin-streptomycin (BioWhittaker). All cell lines 
were cultured at 37˚C with 5% CO2. 
cDNA was synthesized using 1 µg total RNA, M-MLV reverse transcriptase kit (Promega), 
and Oligo (dT) primer (Invitrogen) according to manufacturer’s protocol. Reverse 
transcription was performed at 37˚C for 60 minutes and 95˚C for 10 minutes. The PCR 
for multiple fusions was carried out by amplification of the cDNA or DNA samples with 
the HotstarTaq Kit (Qiagen). For the standard PCR reactions, 1 µL of cDNA was used 
in a 50 µL reaction containing 5 µL 10x PCR Buffer, 2 µL of each primer solution (100 
µM), 0.25 µL HotstarTaq (5 units/µL), 1 µL of dNTPs (10 mM), and 40.75 µL of nuclease 
free water. An initial denaturation step of 15 minutes at 95˚C was used to activate 
the HotstarTaq, followed by 35 cycles consisting of a denaturation step at 95˚C for 30 
seconds, an annealing step at 55˚C for 30 seconds and an elongation step at 72˚C for 
1 minute. A final elongation step at 72˚C for 10 minutes was used. PCR products were 
checked by electrophoresis of 20 uL of product in a 1% agarose gel. 
Purified PCR products have been sequenced bi-directionally using standard Sanger 
sequencing. A sequencing PCR was carried out using the same forward and reverse 
primers as used during the RT-PCR except with different primer concentrations (3 ng 
of primer per reaction) in a 20 µL reaction volume. The PCR product was sequenced 
on an ABI Model 3730 automated sequencer and analyzed using DNAMAN (Lynnon 
Corporation).
1.  Carnevali P, Baccash J, Halpern AL, et al. Computational Techniques for Human Genome 
Resequencing Using Mated Gapped Reads. J Comput Biol. 2012;19:279-292
2. http://www.bx.psu.edu/~giardine/tests/tmp/DataFileFormats112.pdf
3.  Lawrence M, Gentleman R, Carey V. rtracklayer: an R package for interfacing with genome 
browsers. Bioinformatics. 2009;25:1841-1842
4.  Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC. Genome Research. 
2002;12:996-1006
5.  Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies 
chromothripsis and defects in neuritogenesis genes. Nature. 2012;483:589-593
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General Discussion
Prostate cancer (PCa) represents a major burden in our society. It is a disease of the 
elderly, a disease of the westernized world and a disease that affects different races 
differently. Since the first PCa case was described by the surgeon J. Adams in 1853, 
great advances were achieved in the detection and treatment of PCa (1). Metastatic PCa 
was found to respond to androgen ablation therapy by C. Huggins (40s), the Gleason 
pathological grading system was developed (60s) and prostate specific antigen (PSA) 
was found to be elevated in the serum of PCa patients (80s). Although much progress 
has been made during the last 20 years, the molecular mechanisms underlying PCa 
development and progression are still not entirely understood. 
In order to expand the understanding of the molecular events responsible for the 
initiation and progression of PCa, we used and combined genotyping, sequencing and 
gene expression data of several PCa samples. Our main objective was identifying novel 
genetic alterations that could provide mechanistic insight into these processes.  Initially, 
we focused on the discovery of novel DNA and RNA fusions that would be frequently 
observed across our set of PCa patient samples. In this process, we also attempted to 
determine common gene mutations as a result of mismatch repair (MMR) deficiency in 
PCa. 
Novel genetic alterations in PCa:
– the era of rare genetic events
Like all cancers, prostate cancer is a genetic disease defined by genomic alterations 
ranging from point mutations to microsatellite variations and chromosomal alterations 
(translocations, insertions, duplications, deletions) (2). Already in the early days of 
Cellular Biology, the process leading to abnormal cell division and ‘cancer’ intrigued 
scientists. One of the greatest biologists of the twentieth-century, Theodor Boveri, 
proposed much ahead of its time, that chromosomal aberrations were the cause of 
cancer and predicted the existence of tumour suppressors and oncogenes (3, 4). His 
concept of genetic (chromosomal) instability has been further developed by several 
investigators in the past decades. In 2000, Hanahan and Weinberg proposed the first 
six hallmarks of cancer, consisting of features that most, if not all cancers require, to 
develop and progress (5). Later, following the broader progress in the cancer research 
field, the hallmarks were expanded to a total of ten (6). 
In PCa, the discovery of recurrent gene fusion events contradicted the assumption 
at that time, that gene fusions were genetic alterations common in haematological 
malignancies and sarcomas. Gene fusions involving TMPRSS2 and the ETS gene family 
of transcription factors were detected at high frequency in PCa (7). Following the 
identification of the TMPRSS2-ERG gene fusion, which is present in approximately 50% 
of all PCa cases (8), other less frequent gene fusions were identified involving members 
of the RAF family or other members of the ETS family (9). Therefore, we aimed at 
analysing both the genome and transcriptome of PCa samples in order to identify novel 
common gene fusions in PCa.
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We identified two novel in-frame gene fusions involving members of the subfamily of 
membrane palmitoylated proteins (MPP), MPP2 and MPP5. MPP2 was found to be fused 
to GPS2 (chapter 2). MPP5 is fused to FAM71D and both genes are located in chromosome 
14, adjacent to each other (chapter 3). Much like most gene fusions identified so far, 
with the exception of TMPRSS2-ERG itself, these particular gene fusions are rare. MPP2 
and MPP5 are members of the MPP subfamily of the Membrane-Associated Guanylate 
Kinase (MAGUK) family of proteins to which the Disc large (Dlg) tumour suppressor 
gene also belongs (10). GPS2 is a suppressor of G protein-activated MAPK signalling 
and is a stable component of the SMRT co-repressor complex (11). FAM71D is a largely 
unknown gene encoding a protein with unidentified protein domains. Whereas GPS2 
and MPP2 have been, in some way, associated with cancer, nothing is known so far 
regarding MPP5 and FAM71D (12, 13).
In contrast to most gene fusions identified in PCa, we did not find any evidence of 
androgen regulation of the upstream regulatory partner genes GPS2 and MPP5. In any 
case, androgen regulation of gene fusions in PCa is not a requirement for functional 
relevance as shown for fusions involving HNRPA2B1, DDX5 and ESRP1 (fused to RAF1). 
GPS2-MPP2 and the MPP5-FAM71D gene fusions were shown to increase proliferation 
and in the case of GPS2-MPP2 also decrease apoptosis. As both evading apoptotic 
signals and increased proliferation capacity are acquired characteristics of tumour 
cells, GPS2-MPP2 and also MPP5-FAM71D may provide a positive selective advantage 
towards malignant transformation.
The observation that several members of the MPP subfamily are affected by gene 
rearrangements supports a role of these proteins in PCa as has been shown for MPP3 
in hepatocellular carcinoma (14).  Since MPP members are shown to regulate both 
the trafficking and processing of nectins, important cell-cell adhesion molecules, they 
might play a role in PCa invasion (15). Nectins are expressed in various tumours and are 
currently being explored not only as potential targets for antibody therapy (16), but also 
prognostic markers like PVRL1 (Nectin-1) in PCa (17). So far, both MPP3 and MPP5 were 
shown to directly interact with nectins in an isoform-specific manner. This association 
between MPP members and nectins might be an important mechanism mediating PCa 
progression. 
Interestingly, MPP proteins have also been shown to function as specific phospho-
protein-binding modules (18). This translates into phosphorylation-dependent 
interactions between MPP and other proteins. Such proteins might include known 
tyrosine kinases such as protein kinase A (PKA), aPKC, PKB, and AKT that potentially 
regulate the assembly of large protein complexes by MAGUKs (18). Future research 
into the MPP subfamily of proteins and their role in PCa might identify novel signalling 
pathways or substantiate the importance of signalling pathways already known to be 
predominant in PCa.  
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Not only for PCa but also in several other cancer types, the use of next generation 
sequencing (NGS) technologies increased the number of somatic alterations detected. 
For the most part, this encompasses the identification of passenger events that do 
not contribute, as far as we know, to the biology of cancer. Determining which of the 
alterations detected are relevant, requires experimental validation and is currently 
a challenge due to the massive amounts of data generated by NGS. In addition, the 
majority of alterations identified by NGS are rare events with some specific to just one 
patient sample. This also represents a challenge for developing novel PCa biomarkers 
and novel effective therapies that can be used in a broad spectrum of patients. In the 
future, determining which pathways are commonly affected due to different mutations 
will contribute to solving the problem.
Gene mutations in prostate cancer
– PRRT2 as a target of mismatch repair deficiency
 
The DNA mismatch repair system (MMR) is critical for preserving genomic stability 
through the recognition and repair of mismatch base-pairs that occur during DNA 
replication (19). MMR deficiency is a common characteristic of many tumour types since 
failure to repair the replication-associated errors results in a hypermutated phenotype 
with abnormally high mutation rates (20). This hypermutated phenotype has been 
described particularly for colorectal (CRC) and endometrial cancer (EC) (21, 22). Most 
of the hypermutated samples exhibited high microsatellite instability (MSI-H) caused by 
mutations in MMR genes or hypermethylation of MLH1 (23).
In PCa, a hypermutated phenotype has also been observed (24). Subsequent exome 
sequencing of advanced PCa found this phenotype in 12% of the cases, all with loss 
of MMR and MSI-H (25). The MMR deficiency observed in PCa is caused essentially 
by mutations and complex structural rearrangements involving the MSH2 and MSH6 
genes (25). So far, very few studies have focused on the prevalence of the hypermutated 
phenotype in PCa and the underlying mechanism. To further investigate the importance 
of MMR in PCa we have analysed whole genome sequencing data of the MMR-deficient 
PC346C cell line to determine the gene mutations resulting from the lack of MMR 
(chapter 4). 
We identified PRRT2 as homozygously affected in PC346C cells and frequently mutated 
in CRC and EC MSI-H patients. PRRT2 is a poorly characterized protein that has been 
associated with several paroxysmal disorders (26). The mutation detected occurs in a 9C 
repeat in the second exon of PRRT2 causing a frameshift that creates a premature stop 
codon. This 9C repeat is also known as the main mutation site for paroxysmal disorders 
(27). The low prevalence of paroxysmal disorders hampers a direct association between 
the PRRT2 mutation and cancer. We determined that this PRRT2 mutation generates 
a truncated protein that promotes cellular proliferation and migration. This gain of 
function might explain the high mutation frequency observed in CRC and EC patients.
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The identification of PRRT2 as being frequently mutated in MSI-H CRC and EC represents 
the first step in determining whether there are benefits from detecting this mutation. 
Although we have observed consistently and across different tumour types that 
the expression of PRRT2 is lower in the tumour sample as compared to normal, the 
significance behind this fact remains undetermined. On one hand, such a differential 
expression pattern provides an ideal opportunity to explore PRRT2 as a biomarker. On 
the other hand, we do not know whether having low expression of PRRT2 is correlated 
to having the mutation in the 9C repeat or whether it associates with a poorer clinical 
outcome.
Although MSI-H has been associated with a slightly better prognosis in CRC, this area is 
still subject to great debate, especially since several study designs did not have sufficient 
power to infer such associations. Whether there is value in determining the PRRT2 
status independently of MSI-H is unclear. It is known for CRC that MMR deficiency can 
cause mutations in important tumour suppressor genes like TGFβR2 (28). Depending 
on whether these MMR secondary gene mutations can be therapeutically targetable, it 
might be interesting to determine the mutation status of such genes (29).
The genomic landscape of prostate cancer
– is there a role for chromothripsis?
As genome sequencing technologies become readily available and affordable, also the 
number of novel somatic mutations identified in cancer grows. However, identifying 
novel gene mutations is not the only end result of such informative data. Another 
advantage of large-scale high resolution genome studies is the possibility to identify 
mechanisms driving the mutation signatures seen in cancer. 
One major leap in the field of molecular biology made possible by NGS technologies 
was the discovery of ‘kataegis’ (mutation storms) and ‘chromothripsis’ (chromosomal 
crisis) (30, 31). Kataegis represents a pattern of localized hypermutation. 
Chromothripsis is the process by which a genome shatters into hundreds of 
fragments from one or several chromosomes in a single cellular event and further 
recombines these fragments in a highly erroneous order. Both kataegis and 
chromothripsis represent new oncogenic mechanisms that challenge the classic model 
of a gradual and stepwise carcinogenesis process. 
The sequencing of the VCaP cell line showed that this rather peculiar phenomenon 
of chromothripsis is also present in PCa. The premise that, by such a mechanism, 
multiple gene amplifications/deletions and rearrangements can activate oncogenes 
and/or inactivate tumor suppressors, prompted us to identify gene fusions caused by 
this phenomenon. We detected a very limited number of same-direction gene fusions 
(15 events) in comparison to the total number of 573 rearrangements and only two 
were predicted to be in-frame. Clearly, the formation of gene fusions as a consequence 
of chromothripsis is not preferential over rearrangements occurring outside genes, 
neither is there a positive selection for in-frame transcripts.
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Chromosomal crises have been observed in 2 to 3% of the most common cancer types 
and are particularly frequent in bone cancer (35). The definition of chromothripsis 
presents a challenge as to how cells, undergoing such dramatic genetic catastrophes, 
can survive. So far, it has been linked to poor prognosis in acute myeloid leukaemia, 
neuroblastoma and multiple myeloma (36). If more reports are to substantiate this link 
between chromothripsis and prognosis, there might be potential for its use in aiding 
prognosis and possibly patient stratification. 
A collection of 22,347 cancer genome screens has been used to catalogue the 
occurrence of chromothripsis-like patterns (CTLP) (32). From this study, there seems 
to be a suggestive poorer overall survival for cancer patients with CTLP as compared to 
non-CTLP. In a large study of 8000 cancer genomes, there was evidence that from all 
the epithelial tumors analyzed, PCa shows the highest frequency of CTLP (21 affected 
samples out of a total number of 372) (33). A later study by Baca et al. suggests 
‘chromoplexy’ instead of chromothripsis to be much more common in PCa (34). 
Chromoplexy is essentially a smaller version of chromothripsis (less rearrangements) 
in sequential order as opposed to a single event. Clearly, further research in this field 
is required to clarify the definitions of both novel mechanisms and the mechanistic 
differences between chromoplexy and chromothripsis.
In the near future, the number of sequenced cancer genomes will certainly multiply. 
This will be especially important to accurately define how frequent all these new 
phenomena such as kataegis, chromothripsis and chromoplexy really are. Regarding 
PCa, it is essential to determine whether chromothripsis is correlated to a more initial or 
later stage of the disease. If indeed as recently suggested, chromothripsis is somehow 
associated with chronic prostatitis (35) it might be interesting to study this further in the 
context of PCa development. Also, with the potential role of the AR in promoting gene 
rearrangements, there might be an underlying link between AR and chromothripsis in 
PCa (36).
Advances in DNA sequencing technologies
– what does the future hold?
As described above, over the past years an extraordinary development of molecular 
profiling techniques was achieved, up to the most recent boost of next generation 
sequencing. Initially, the study of the genetic basis of Mendelian disorders was carried 
out through linkage mapping and cytogenetic analysis. But these techniques have a low 
resolution and therefore, a fine description of genetic alterations is virtually impossible. 
With the development of DNA microarray technology, genetic alterations could be 
observed at a relatively higher resolution (15-35 kb) through array comparative genomic 
hybridization (aCGH). Progressively, the use of aCGH was replaced by single nucleotide 
polymorphisms-based platforms (SNPs) that allowed both the estimation of genome-
wide variations in copy number changes and allelic contents at an average resolution 
of 3 kb (37, 38). This increased resolution allowed uncovering whether DNA breaks 
occurred inside genes.
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On the RNA level, microarrays revolutionized gene expression analysis from a single 
gene to all genes in a single experiment. This technology allowed for the monitoring 
of mRNA abundance which in turn provides complete information about the cell’s 
‘transcriptome’. Due to the dynamic characteristics of the cell’s transcriptome, 
microarrays are very powerful in creating multi-gene patterns of expression for different 
cancer types, contexts, treatments, etc. One such example was the distinction between 
acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) solely based 
on microarray transcript data (39). Also regarding the RNA level, the ‘next-generation’ 
revolution has arrived. Currently, NGS technologies are used to sequence cDNA enabling 
the discovery of novel genes and detection of alternative splicing and gene fusions (40). 
Since the publication of the first draft of the human genome (41, 42), tremendous 
advances were achieved regarding sequencing technologies and by now, NGS has 
mostly replaced the use of DNA microarrays. In the past few years, the sequencing 
of the first cancer genome in 2008 by Ley TJ et al. (43) was expanded  to more than 
800 fully sequenced genomes of at least 25 different cancer types (44). Up to 2014, 
the total estimated number of human genomes sequenced was approximately 228,000 
according to Francis de Souza, the president of Illumina Inc.
Despite the growing number of novel somatic mutations identified and some proven 
driver mutations, few have been translated into new treatment discovery and 
development. One of the most successful examples is the identification of frequent 
EZH2 mutations in lymphoma with promising treatment results in pre-clinical studies 
(33).  Nonetheless, one of the most important contributions of NGS to the cancer 
field has been the challenging of old concepts. The high resolution of NGS allowed the 
characterization of clonal evolution in the tumorigenesis process (45). 
In PCa, it was shown earlier this year, that morphologically ‘normal’ cells, already contain 
mutations that are present in distant tumour tissue (46). This is in agreement with the 
idea of carcinogenesis as a multistep process with separate clonal cell expansions as 
described by Vogelstein for colorectal cancer (47). Also, a recent study by Gundem et 
al. described the evolution process of metastatic PCa and showed that overall, there 
is a common shared heritage between both primary tumour and metastasis and that 
metastasis occurs as a spread of multiple tumour clones at the same time across the 
whole body (48).  
We can expect that in the next years more and more NGS studies will reveal how 
tumorigenesis actually develops in a temporal and spatial manner. This will shed 
light into the true complexity that lies within rather straightforward phenotypes and/
or genetic alterations. Especially considering heterogeneous tumours like PCa where 
different primary tumour foci harbour different genetic alterations, it is important to 
understand what changes confer an aggressive phenotype and require further attention 
concerning the clinical outcome. 
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In the future, sequencing costs will probably decrease further from the current $3,000 
per genome. The drop will likely not be as sharp as it has been until now but it will 
surely make the use of DNA studies more affordable for use in the clinic as general 
practice. DNA sequencing might become routine in medicine with the approval of 
diagnostic tests that combine sequencing of the most relevant cancer genes. So far, the 
major bottleneck in widening NGS technologies to common practice is the storing and 
analysis of such massive amounts of data. Deciphering what really matters from what 
does not, depends not only on which question is being asked but also on the extend of 
our knowledge in the subject. 
Prostate cancer treatment and diagnosis 
– are we getting close to personalized medicine?
The concept of precision and personalized medicine has always been an intrinsic part 
of the regular physician’s practice. Medical doctors have always tried to find the best 
match between patient and treatment, much like the search for suitable blood, bone 
marrow and organ donors. It is important to consider not only the environment, health 
and behaviour of the patient, but also his genomic background, hopefully achieving 
higher accuracy in personalized treatments. In the prostate cancer field, the discovery 
of androgen dependence in 1941 by Huggins and colleagues, represented a major 
milestone in developing treatment for this disease. Throughout the years, the AR 
remained the backbone in treatment of metastatic PCa but there is a clear need for 
more therapy targets and treatment options. 
The challenge in developing novel therapies has mostly to do with the druggability of 
the genetic alteration. So far, the majority of successful cancer targeted therapies are 
small-molecule kinase inhibitors. In PCa, drugs targeting relevant signalling pathways 
other than the AR  such as PI3K/Akt, HDAC and Src have failed in showing a significant 
improvement in disease outcome (49). Surely, continuing the search for alternative 
signaling pathways that drive prostate cancer progression will provide an alternative 
landscape for therapeutic treatment. Also, using different treatment combinations or 
known treatments but in a different order might improve the disease outcome. 
In PCa, most of the biomarker research is based on the diagnosis and prognosis of 
the disease. This is based on a great need for biomarkers that help distinguish BPH 
from PCa, indolent from aggressive disease and identify metastatic PCa (50). Due to 
the heterogeneity of PCa and the presence of different genetic abnormalities between 
different foci in the same patient, it will remain hard to determine the true stage of the 
disease 
Until now, several gene fusions have been observed in PCa patients and, although 
these are mostly patient-specific, some do involve important cancer-related genes like 
MAPK1, BRAF and RB1 (51). The identification of these novel genetic alterations can be 
useful in detection, monitoring or treatment of PCa patients. The presence of cancer-
specific markers like TMPRSS2-ERG gives a clear answer to whether a patient has PCa. 
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But even if a novel marker can be validated, it will be its proven added-value that will 
determine, for most part, whether it will be implemented in the clinic or not. We have 
come a long way regarding the discovery of novel candidate markers and now the focus 
should be on creating better validation and clinical implementation approaches. 
The future of PCa patient diagnosis and treatment will most likely rely on a ‘personalized 
oncology – precision medicine’ approach where each patient’s tumour DNA will be 
screened to determine the individual treatment strategy. This inter-vention method will 
include the use of early diagnostic biomarkers that will, in the first instance, serve as 
a screening tool to decide which patients should undergo tissue sampling and further 
DNA sequencing (10). Is there cancer? Should it be treated? And if so, which treatment, 
order and/or combination should be implemented? The generation of large scale 
sequencing maps of PCa patients provides a first attempt to answer these questions. 
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AATK apoptosis-associated tyrosine kinase
aCGH  array comparative genomic hybridization
AR  androgen receptor 
ARHGEF3   rho guanine nucleotide exchange factor (GEF) 3
BRAF   B-Raf proto-oncogene, serine/threonine kinase
C8ORF38   chromosome 8 open reading frame 83
CEP164  centrosomal protein 164kDa
CHD1   chromodomain helicase DNA binding protein 1
CNOT1  CCR4-NOT transcription complex, sub 1
CNVs   copy number variations
COSMIC  catalogue of somatic mutations in cancer
CRC  colorectal cancer
CRPC   castration-resistant prostate cancer
CTLP  chromothripsis-like patterns
DAB2IP  DAB2 interacting protein 
DLG   discs large homolog
DNR  dinucleotide repeat
DuCaP  dura mater-Cancer of the Prostate (cell line)
EC  endometrial cancer
ERG  v-ets erythroblastosis virus E26 oncogene homolog (avian)
ETS  E26 transforming sequence
FAM71D  family with sequence similarity 71, member D
FISH   fluorescent in situ hybridization
GPS2  G protein pathway suppressor 2
GWAS   genome-wide association studies
HGPIN  high grade prostatic intraepithelial neoplasia
LNCaP   lymph node-Cancer of the Prostate (cell line)
MAGUK   membrane-associated guanylate kinase
MAPK   mitogen-activated protein kinase
MAST4  microtubule associated serine/threonine kinase family member 4
MMR  mismatch repair
MNR  mononucleotide repeat
MPP   membrane palmitoylated protein
MPP2  membrane palmitoylated protein 2
MPP5  membrane palmitoylated protein 5
MSI   microsatellite instability
NCOA2   nuclear receptor coactivator 2
N-COR   nuclear receptor corepressor
NGS  next generation sequencing
NRXN3   neurexin 3
PCa   prostate cancer
PCA3   prostate cancer gene 3
PI3K   phosphoinositol-3-kinase
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PKD  paroxysmal kinesigenic dyskinesia 
PRRT2  proline-rich transmembrane protein 2 
PSA  prostate specific antigen
PTEN   phosphatase and tensin homolog
SMRT   silencing mediator for retinoid and thyroid hormone receptors
SNPs   single nucleotide polymorphisms
SVs   structural variations
TMPRSS2   transmembrane protease, serine 2
TNR  trinucleotide repeat
TP53  tumor protein P53
TSHR   thyroid stimulating hormone receptor
TSHZ2  teashirt zinc finger homeobox 2
TURP   transurethral resections of the prostate
VCaP   vertebral-Cancer of the Prostate (cell line)
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Prostate cancer (PCa) is a common disease of the western society. The risk of developing 
PCa increases with age and most men in their 80s will have developed PCa, even if the 
disease is not clinically relevant. Contrary to indolent PCa, aggressive disease has a poor 
survival outcome. Better treatment options and better patient stratification are urgent 
needs in the PCa field. In this thesis we have focused on the identification of novel 
genetic alterations in PCa. In the long term, identification of novel abnormalities can aid 
identifying specific subsets of patients or novel targetable pathways for the treatment 
of this disease. 
In chapter 1, a general introduction is provided, with special emphasis on the major 
signaling pathways affected in prostate cancer and the developments in technology 
together with emerging markers. 
To identify novel genetic alterations in PCa we used, in chapter 2, data from DNA 
and RNA microarrays performed in a large dataset of PCa samples. The initial aim 
was to detect novel DNA and RNA gene fusions. DNA microarray data was analysed 
with the Nexus software to obtain a list of all DNA break locations in our samples to 
determine which DNA breaks were located inside genes. Using the RNA expression 
data we determined which genes had both DNA breaks and abnormal expression. 
The top 3 candidates were used to identify possible fusion partners through 5’RACE 
PCR. Following this approach we found two novel fusions in PCa, GPS2-MPP2 in the 
LNCaP cell line and TSHR-NRXN3 in the G295 PCa clinical sample. GPS2-MPP2 was 
further investigated regarding its functional consequences and shown to promote 
proliferation and suppress apoptosis in LNCaP cells. In conclusion, combining DNA 
and RNA microarray data is a powerful approach to determine novel gene fusions but 
additional validation of the findings is fastidious. 
The boost of next generation sequencing (NGS) techniques permitted the use of this 
technology to evaluate, in chapter 3, if through a whole genome sequencing approach, 
the number of gene fusions identified in prostate cancer could be increased. Overall, 
most of the 7735 breaks identified in two genomic DNA samples, cell line PC346C and 
clinical sample G089, turned out to be polymorphisms present also in a control dataset 
of 46 normal samples. The total number of cancer-related rearrangements identified 
was 674 and 387 in PC346C and G089, respectively. From these, only 14 and 33 occurred 
between two different gene locations and only 20 were predicted to generate feasible 
gene fusions. Through PCR and Sanger sequencing 17 out of the 20 could be validated. 
Most of the genes involved in these fusions had not previously been associated with 
cancer and only a small subset of these was also found to have additional breaks in other 
PCa samples that were genotyped in chapter 2. The in-frame MPP5-FAM71D gene fusion 
resulted in an upregulation of FAM71D expression, which promoted the proliferation 
of PC346C cells. Despite the finding that the MPP5-FAM71D gene fusion seemed to 
be specific for PC346C, 10 other PCa samples showed also FAM71D upregulation. In 
this way, whole genome sequencing does provide a more comprehensive catalog of 
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structural variations. However, the identification of frequent and functionally relevant 
fusions requires large datasets of patient samples and the whole genome sequencing of 
such large numbers remains costly.  
As PC346C is a mismatch repair (MMR) deficient cell line and whole genome sequencing 
data was available, we examined whether there was an association between MMR 
deficiency and mutations in nucleotide repeat sequences in PC346C. We observed a 
bias towards mutations in mononucleotide repeats (MNR) in the PC346C which was not 
present in the mismatch repair proficient PCa sample G089. To further evaluate whether 
this bias had functional relevance, we generated a list of genes mutated in MNR in the 
PC346C sample. The top candidates, with no previous association with mismatch repair 
and microsatellite instability (MSI), were validated in a large panel of MSI stable and 
unstable cell lines, namely prostate, colorectal, endometrial and ovarian cancer cell 
lines. A mutation in a 9C repeat of the PRRT2 gene was found to be frequent in several 
of the cancer cell lines tested as well as in MSI unstable colorectal and endometrial 
patients. Through overexpression of both the wildtype PRRT2 and the mutated PRRT2 
we observed an increase in the proliferation of cells in the presence of mutated 
PRRT2. Also, the migratory capacity of cells was greatly increased. The overexpression 
of the wildtype PRRT2, on the contrary, caused a mild decrease in proliferation with 
no significant effect on migration. PRRT2 expression is, in general, lower in cancer as 
compared to normal, not only in PCa but also in lung and gastric adenocarcinomas. In 
the end, we consider mutated PRRT2 to be a novel dominant oncogene, and wtPRRT2 a 
tumor suppressor candidate.
The latest developments in cancer research had identified, based on NGS data, a 
phenomenon called chromothripsis. The identification of such phenomenon, which 
consists of tens to hundreds of rearrangements during a single catastrophic event, was 
made possible through high resolution whole genome NGS. Among our set of whole 
genome sequenced PCa samples, we observed the occurrence of a massive number of 
rearrangements in chromosome 5 of the VCaP PCa cell line. Following closer examination, 
we identified 573 DNA breakpoints in the long arm of chromosome 5, of which only 4 
involved additional chromosomes. Of these 573 DNA breaks, 43 involved different genes 
on both sides of the break and only 18 of these events could generate gene fusions. By 
qPCR we were able to confirm at the DNA level, 15 gene fusions but we could only detect 
5 gene fusion transcripts. In the end, the only in frame fusion transcript identified that 
resulted from the chromothripic event was NDUFAF2-MAST4. Whether NDUFAF2-MAST4 
is of functional relevance in the initiation or progression of PCa was not tested but our 
data indicated that chromothripsis does not preferentially result in novel gene fusions. 
To conclude, through the use of several high throughput technologies, both at the 
DNA and RNA level, we were able to identify novel genetic alterations in PCa. None of 
the genetic alterations characterized in this thesis occured frequently in clinical PCa 
samples. The individual character of these alterations does not necessarily signify they 
are ineffectual; instead they might reveal the importance of common pathways, targeted 
by the neoplastic process at different levels. 
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Samenvatting
Samenvatting
Prostaat kanker (PKa) is een frequent voorkomende ziekte bij mannen in de Westerse 
wereld. Het risico om PKa te ontwikkelen wordt groter naarmate men ouder wordt 
en na hun 80e levensjaar zullen de meeste mannen PKa hebben, ook al is dit meestal 
niet klinisch relevant. In tegenstelling tot indolente PKa, geeft agressieve PKa slechts 
een kleine kans op overleving. Betere behandelingen en indeling van patiënten in 
groepen met verschillen in prognose zijn noodzakelijke ontwikkelingen in het PKa veld. 
In dit proefschrift hebben wij ons gefocust op de identificatie van nieuwe genetische 
veranderingen in PKa. Op de lange termijn kan de ontdekking van nieuwe afwijkingen 
helpen bij het identificeren van nieuwe doelwitten voor therapeutische behandeling en 
bij de selectie van patiënten die gebaat zijn bij behandeling van deze ziekte.
Het eerste hoofdstuk beschrijft een algemene introductie met specifieke nadruk op 
netwerken van signaaloverdracht die veranderd zijn in PKa en van de technologische 
ontwikkelingen bij het onderzoek naar nieuwe markers. 
Om nieuwe genetische afwijkingen in PKa te identificeren, hebben wij in hoofdstuk 2 
gegevens gebruikt van DNA en RNA microarrays van een groot aantal PKa monsters. 
Het aanvankelijke doel was om nieuwe DNA en RNA fusiegenen te detecteren. De 
DNA microarray gegevens werden geanalyseerd met Nexus software om een lijst te 
verkrijgen van alle locaties van DNA breuken in onze monsters en om te bepalen welke 
DNA breuken zich in genen bevonden. Gebruik makend van de RNA expressie data, 
hebben wij omschreven welke genen zowel breuken in het DNA als abnormale expressie 
vertoonden. De top 3 kandidaten werden gebruikt om potentiele fusiepartners te 
ontdekken met behulp van een 5’RACE PCR. Met deze aanpak hebben wij twee nieuwe 
fusie genen ontdekt in PKa, GPS2-MPP2 in de LNCaP cellijn en TSHR-NRXN3 in het klinische 
PKa monster G295. GPS2-MPP2 werd verder onderzocht op functionele consequenties. 
Het fusiegen bleek proliferatie te stimuleren en apoptose te onderdrukken in LNCaP 
cellen. Samenvattend, het combineren van DNA en RNA microarray data is een krachtige 
techniek om nieuwe fusie genen te ontdekken, maar de validatie van deze bevindingen 
komt erg nauw. 
De sterke ontwikkeling van next generation sequencing (NGS) technieken heeft ertoe 
geleid, dat wij NGS konden toepassen bij het evalueren van een lijst van fusiegenen en 
bij het uitbreiden hiervan  (hoofdstuk 3). Globaal gezien waren de meeste van de 7735 
geïdentificeerde breuken in twee onderzochte PKa samples polymorfismen, die tevens 
aanwezig waren in een controle dataset van 46 normale monsters. Het totale aantal aan 
PKa gerelateerde  breuken dat ontdekt werd was respectief 674 en 387 in PC346C en 
G089. Hiervan waren slechts 14 en 33 aanwezig tussen twee verschillende gen locaties 
en van slechts 20 kon worden voorspeld dat ze genfusies konden betreffen. Door middel 
van PCR en Sanger sequencing konden 17 van de 20 bevestigd worden. De meeste genen 
betrokken bij deze fusies waren nog niet eerder geassocieerd met kanker en slechts een 
gedeelte ervan had breuken in andere PKa monsters, gegenotypeerd in hoofdstuk 2. De 
in-frame MPP5-FAM71D genfusie veroorzaakte een verhoogde expressie van FAM71D, 
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dat leidde tot een verhoogde proliferatie van PC346C cellen. Ondanks het feit dat de 
MPP5-FAM71D fusie specifiek leek voor PC346C, vertoonden 10 andere PKa monsters 
ook verhoogde expressie van FAM71D. Op deze wijze biedt whole genome sequencing 
een uitgebreide catalogus van structurele variaties. De identificatie van frequente en 
functioneel relevante fusies, verlangt echter grotere datasets van patiënt monsters en 
whole genome sequencing van zulke grote aantallen, blijft prijzig.
Aangezien PC346C een mismatch repair (MMR) deficiënte cellijn is en whole genome 
sequencing beschikbaar was, hebben wij de associatie tussen MMR deficiëntie en 
mutaties in nucleotide repeat sequenties in PC346C onderzocht. Wij observeerden 
een voorkeur voor mutaties in mononucleotide repeats (MNR) in PC346C, die niet 
aanwezig was in het mismatch repair competente PKa monster G089. Om verder te 
onderzoeken of deze voorkeur functioneel relevant was, hebben wij een lijst gemaakt 
van genen gemuteerd in MNR in PC346. De top kandidaten, die geen eerdere associatie 
hadden met mismatch repair en microsatelliet instabiliteit (MSI), werden bevestigd in 
een uitgebreide selectie van MSI stabiele en instabiele cellijnen, namelijk: prostaat, 
colorectaal, endometrium en eierstok kanker cellijnen. Een mutatie in een 9C repeat 
van het PRRT2 gen bleek frequent voor te komen in meerdere van de geteste kanker 
cellijnen en in de MSI instabiele colorectale en endometriale patiëntensamples. Door 
middel van overexpressie van zowel wildtype PRRT2 als gemuteerde PRRT2, hebben we 
een verhoogde proliferatie geconstateerd in de aanwezigheid van het gemuteerde PRRT2 
gen. De capaciteit tot migreren van cellen was tevens sterk verhoogd. Integenstelling 
hiermee veroorzaakte overexpressie van wildtype PRRT2 een beperkte vertraging van 
proliferatie en had geen significant effect op migratie. PRRT2 expressie was over het 
algemeen lager in kanker dan in normaal weefsel, niet alleen PKa, maar ook in long- en 
maagcarcinomen. Wij beschouwen gemuteerd PRRT2 als een nieuw, dominant oncogen 
en wtPRRT2 als een mogelijke tumor suppressor. 
 
De laatste ontwikkelingen in kankeronderzoek hebben, gebaseerd op NGS data, 
een fenomeen ontdekt genaamd chromothripsis. De identificatie van een dergelijk 
fenomeen, dat tien tot honderden genomische herverdelingen omvat ontstaan bij een 
enkele gebeurtenis, is mogelijk gemaakt door hoge resolutie whole genome NGS. In onze 
set van whole genome sequenced PKa monsters hebben wij massale herverdelingen 
ontdekt in chromosoom 5 van de VCaP PKa cel lijn. Nadere inspectie liet zien dat 573 
DNA breukpunten in de lange arm van chromosoom 5 aanwezig waren, waarvan slechts 
bij 4 van deze breuken andere chromosomen waren betrokken. Van deze 573 DNA 
breuken waren er bij 43 verschillende genen betrokken aan beide zijden van de breuk 
en slechts 18 konden genfusies genereren. Met een kwantitatieve PCR konden we 15 
genfusies bevestigen op het DNA niveau, maar we konden slechts 5 transcripten van 
fusiegenen detecteren. Uiteindelijk konden we het in frame fusie transcript NDUFAF2-
MAST4 als enige identificeren, als resultaat van de chromothripsis gebeurtenis. Wij 
hebben niet getest of NDUFAF2-MAST4 functioneel relevant kan zijn bij het ontstaan 
of de progressieve groei van PKa, maar onze data suggereren dat chromothripsis niet 
noodzakelijk resulteert in genfusies. 
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Samenvatting
Samenvattend: met behulp van verschillende high throughput technieken op zowel 
DNA als RNA niveau, konden wij nieuwe genetische veranderingen identificeren in PKa. 
Geen enkele genetisch verandering in deze thesis, was veelvoorkomend in klinische PKa 
monsters. Het individuele karakter van deze veranderingen betekent niet zozeer dat 
deze irrelevant zijn, ze kunnen mogelijk cruciale componenten zijn van de vele complexe 
netwerken van signaaloverdracht betrokken bij neoplastische processen.
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